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ABSTRACT 
 
Canine Hepatic Slices as a Model for Studying Drug Toxicity and Metabolism.  (May 2005) 
Maya Millicent Scott, B.S., University of Arkansas; 
D.V.M., Oklahoma State University 
Co-Chairs of Advisory Committee:  Dr. Dawn M. Boothe 
   Dr. Stephen H. Safe 
 
     Tissue slices can be made from organs, such as liver, kidney, brain, and heart, and from 
various species including humans, dogs, non-human primates, rats and mice.  It has been 
demonstrated that human and rat liver slices are viable for up to 2 days, and liver slices have 
been extensively used as an in vitro method to study hepatic drug metabolism and toxicity in 
humans.  The objective of this study was to determine the utility of canine hepatic slices as an in 
vitro model for studying drug metabolism and hepatotoxicity in dogs.  Canine hepatic slices 
were incubated in media containing various drugs to determine the hepatotoxicity of the agents 
and the ability of the slices to metabolize the drugs.  The toxicity of phenobarbital, primidone, 
lidocaine and carprofen to canine hepatic slices was assessed by determining changes in 
supernatant concentrations of potassium ions and adenosine triphosphate (ATP); histologic 
lesions were determined as necrosis, extent of vacuolation and severity of vacuolation.  
Xenobiotic drug metabolizing enzymatic activity was investigated by determining the 
metabolism of lidocaine to monoethylglycinexylidide (MEGX), and administration of 
phenobarbital plus primidone was used as a positive control for hepatotoxicity in dogs.  The 
function of drug-metabolizing enzymes was demonstrated by the successful metabolism of 
lidocaine to MEGX.  Carprofen, a drug which causes idiosyncratic hepatic disease in dogs, did 
not show any hepatotoxicity at concentrations of 10, 50 and 100 µg/ml using potassium ion 
levels, ATP concentrations and histology as indicators of hepatotoxicity.  Slices incubated in 
media without drug showed no toxicity over 24 hours based on potassium ion and ATP 
supernatant concentrations while significant increases in histologic lesions were noted at 8, 12 
and 24 hours.  Canine hepatic slices were a useful model for examining drug metabolism and 
toxicity for up to 24 hours.  
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CHAPTER I 
INTRODUCTION 
 
Drug Metabolism 
    Drug metabolism, the process by which the body removes foreign and endogenous substances, 
is important not only for the detoxification of xenobiotics but also for the detoxification of 
endogenous substances. The study of the metabolism of compounds involves not only the 
reactions or pathways of their biotransformation but also their absorption, distribution, excretion, 
protein binding and membrane transport, all of which may vary with species (Williams, 1974).  
Drug metabolism is commonly called biotransformation, but biotransformation usually includes 
only the enzymatic transformation of endogenous and exogenous substrates.  Watkins and 
Klaassen (1986) term biotransformation “as the sum of all chemical reactions that alter the 
structure, aqueous solubility and eventual disposition of non-nutritive [generally foreign] 
compounds.”  Meyer (1996) has a slightly different definition offering that biotransformation 
means “a lipid-soluble xenobiotic or endobiotic compound is enzymatically transformed into 
polar, water-soluble, and excretable metabolites.”  Although drug metabolism and 
biotransformation are similar, the other processes involved in metabolism—absorption, 
distribution and excretion—can influence biotransformation.   Since metabolism encompasses 
more than just biotransformation of substances, it is important to note the difference between 
these terms when describing the enzymatic processes that occur within the body concerning 
foreign and endogenous compounds. 
     The processes by which substances enter the bloodstream, diffuse to tissues and cells and are 
removed from the body are called absorption, distribution and excretion (Rozman & Klaassen, 
2001).  Absorption is the process by which a substance crosses body membranes and enters the 
bloodstream.  This process can occur through the skin, gastrointestinal tract or respiratory tract.  
Once a substance reaches systemic circulation, it is distributed throughout the body.  The final 
amount of substance at each organ or tissue depends upon the ability of the substance to 
penetrate membranes and is also associated with its affinity for the organ or tissue (Rozman & 
Klaassen, 2001).  The removal of substances from the body, excretion, occurs via several  
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routes—biliary, renal, pulmonary or dermal.  Whether a substance is excreted directly or post- 
biotransformation depends on the physical properties, ionization and lipid solubility of the 
substance.   
     The process of drug biotransformation involves two stages—phase I and phase II.  These 
processes occur mostly in the liver but may also occur in the kidney, intestinal tract or other 
organs.  The liver is particularly adept at biotransformation because it is the main site of 
exchange for substances from the intestinal tract to the bloodstream.  Phase I biotransformation 
is typically a detoxifying process, but in the case of some xenobiotics, an active metabolite is 
formed (Nebert & Dieter, 2000).  This active metabolite may be beneficial or toxic.  In the 
former situation, the metabolite may be the agent imparting therapeutic benefit.  In the latter 
case, the metabolite may have toxic side-effects.  Phase II biotransformation involves the 
addition of polar components to xenobiotics or endogenous compounds that have gone through 
phase I biotransformation.  The addition of the polar compounds makes these substances more 
water soluble and this facilitates their removal through urinary or biliary excretion.  Some 
compounds can undergo phase II biotransformation without previous phase I transformation.  
The reverse may also occur as some products of phase I biotransformation may be eliminated 
without further processing by phase II enzymes.  Additionally, other compounds are eliminated 
from the body unchanged. 
     Phase I metabolism involves oxidation, reduction, and hydrolysis reactions.  During phase I, 
hydroxyl (-OH), carboxyl (-COOH), amino (-NH2) and, occasionally, sulfhydryl (-SH) groups 
are introduced into the molecule (Williams, 1974; Parkinson, 2001).  Phase I metabolism usually 
only produces a small increase in water solubility of the substrate (Parkinson, 2001).  The 
functional groups added in phase I are often the sites for phase II conjugation.  The enzymes 
involved in phase II metabolism, such as UDP-glucuronosyltransferases, glutathione 
transferases, and sulfotransferases, conjugate various substrates and reactive intermediates to 
form water soluble derivatives which are subsequently excreted and thereby complete the 
detoxification process (Nebert & Dieter, 2000). 
     The most common enzymes involved in biotransformation are cytochrome P450 (phase I), 
UDP-glucuronosyltransferase (phase II), glutyltransferase (phase II), sulfotransferase (phase II), 
epoxide hydrolase (phase II), and acetyltransferase (phase II).  Other enzymes that may play a 
role in phase I metabolism are dehydrogenases, oxidases, esterases, or reductases (Meyer, 1996). 
These enzymes are located either anchored in the membrane of the endoplasmic reticulum 
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(P450-dependent monooxygenases, epoxide hydrolase, glucuronosyltansferase) or located in the 
cytosol (acetyltransferase, sulfotransferase, xanthine oxidase) (Meyer, 1996; Parkinson, 2001).   
 
Enzymes of Drug Biotransformation 
Cytochrome P450 Monooxygenase 
     Cytochrome P450 monooxygenases have two parts, a hemoprotein and a flavoprotein (Meyer, 
1996).  Cytochrome P450 (CYP), the hemoprotein, is the binding site for substrates and oxygen 
(Meyer, 1996).  NADPH-cytochrome P450 reductase, the flavoprotein, carries electrons from 
NADPH to the cytochrome P450 substrate complex, thus providing the electrons required for 
microsomal P450 activity (Meyer, 1996; Waxman, 1999).  The cytochrome P450 enzymes are 
designated by “CYP” followed by an Arabic numeral representing the family.  This numeral is 
followed by a letter indicating the subfamily and a second Arabic numeral representing the gene 
within the subfamily.   
     There are 17 distinct P450 gene families in mammals (Waxman, 1999).  Four of these gene 
families (CYPs 1-4) code for liver-expressed enzymes that metabolize foreign compounds and 
endogenous lipophilic substrates (Waxman, 1999).  The remaining families are not regularly 
involved in the metabolism of foreign compounds (Waxman, 1999).  For humans, the prominent 
CYP enzymes involved in drug biotransformation are CYP3A4, CYP2D6, CYP2C9, CYP2C19, 
CYP1A2 and CYP2E1 (Meyer, 1996).  Examples of substrates for each enzyme are caffeine and 
theophylline for CYP1A2, phenytoin and warfarin for CYP2C9, omeprazole and diazepam for 
CYP2C19, dextromethorphan and metoprolol for CYP2D6, ethanol and 4-nitrophenol for 
CYP2E1 and lidocaine and cyclosporine for CYP3A4 (Meyer, 1996).  The various P450 
isozymes can be induced or inhibited by various chemicals.  Additionally, the agents capable of 
inducing or inhibiting may vary with species.  In humans, ketoconazole is a CYP3A4 inhibitor, 
and rifampin is an inducer of CYP3A4 (Meyer, 1996; Parkinson, 2001). 
     The highest concentration of P450 enzymes active in xenobiotic biotransformation are located 
in the liver (Parkinson, 2001).  When using enzyme concentration in rats as a basis of 
comparison for several species, the total cytochrome P450 concentration in the liver of cattle, 
sheep, guinea pigs and mice is approximately the same as that in rats (Watkins & Klaassen, 
1986).  The total hepatic CYP concentration in dogs, cats and rainbow trout is approximately 
35% less than that found in rat liver (Watkins & Klaassen, 1986).  Swine and quail have the 
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lowest CYP levels in the liver (approximately 50% less than in rats), and rabbits have about 41% 
more CYP than rats (Watkins & Klaassen, 1986).   
 
Uridine diphosphate (UDP)-glucuronosyltransferase  
     UDP-glucuronosyltransferases catalyze the transfer of glucuronic acid from UDP-glucuronic 
acid to acceptor substrates.  The site of glucuronidation is usually an electron-rich nucleophilic 
heteroatom (O, N or S) (Parkinson, 2001).  The activity of these enzymes varies with species and 
is dependent upon the lipid environment of the endoplasmic reticulum membrane (Watkins & 
Klaassen, 1986).   
     Glucuronidation is a major phase II biotransformation pathway of most mammals (Williams, 
1974; Parkinson, 2001).  Domestic cats, lions, lynxes and civets are deficient in glucuronidation, 
but they are not completely devoid of the ability to form glucuronides; their ability to conjugate 
glucuronides depends on the isozymes and substrates involved (Williams, 1974; Caldwell, 1980; 
Parkinson, 2001).  UDP-glucuronosyltransferases are found in the liver, kidney, spleen, intestine 
and other tissues, and glucuronide conjugates are normally eliminated in the urine and bile 
(Parkinson, 2001).  Some compounds which undergo glucuronidation are acetaminophen, 
morphine, naproxen and amitryptyline (Parkinson, 2001).     
 
N-acetyltransferase 
     N-acetylation is a major phase II biotransformation pathway for compounds which contain 
aromatic amines (R-NH2) or hydrazine groups (R-NH-NH2) (Watkins & Klaassen, 1986; 
Parkinson, 2001).  N-acetyltransferase catalyzes acetyl group transfer from the cofactor acetyl-
coenzyme A to an arylamine (Watkins & Klaassen, 1986).  There are two steps in the N-
acetylation process; first, the acetyl group is transferred from acetyl-coenzyme A to an active site 
cysteine residue within N-acetyltransferase, releasing coenzyme A (Parkinson, 2001).  Second, 
the acetyl group is transferred from the acylated enzyme to the amino group of the compound, 
regenerating the enzyme (Parkinson, 2001).   
     N-acetyltransferases are found in the liver and other tissues of most mammals (Parkinson, 
2001).  When comparing N-acetyltransferase activity in the liver of several species, rabbits have 
the highest activity while dogs have very low activity (Watkins & Klaassen, 1986).  The fox and 
guinea pig are also deficient in N-acetylation (Williams, 1974; Caldwell, 1980; Parkinson, 
2001). 
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Glutathione S-transferase 
     Glutathione conjugation involves the addition of the tripeptide glutathione to xenobiotics 
(Parkinson, 2001).  Glutathione is made of glycine, cysteine and glutamic acid (Parkinson, 
2001).  The substrates for glutathione S-transferase are hydrophobic, contain an electrophilic 
atom and react nonnenzymatically with glutathione (Parkinson, 2001).  High concentrations of 
glutathione S-transferase are found in the liver, kidneys, lung and other tissues (Parkinson, 
2001).  These enzymes are located primarily in the cytoplasm with less than 5% located in the 
endoplasmic reticulum (Parkinson, 2001).  The amount of glutathione conjugation varies among 
species; glutathione conjugation in cattle and sheep liver is approximately half of that of rats 
(Watkins & Klaassen, 1986). 
 
Sulfotransferase 
     Sulfonate conjugation of xenobiotics is catalyzed by sulfotransferases and results in highly 
water soluble sulfuric acid esters (Parkinson, 2001).  Sulfotransferases are cytosolic enzymes 
found in the liver, kidney and intestinal tract, as well as, other tissues (Parkinson, 2001).  During 
sulfonate conjugation, sulfonate is transferred from 3’-phosphoadenosine-5’-phosphosulfate 
(PAPS) to the xenobiotics; PAPS is a cofactor for the reaction (Parkinson, 2001).  Xenobiotics 
conjugated with sulfonate are usually excreted in the urine (Parkinson, 2001).  The pig and 
opossum are deficient in sulfonation, but this deficiency is highly dependent upon the substrate 
(Caldwell, 1980). 
 
Drug-induced Hepatotoxicity 
     As many drugs administered are lipophilic, their conversion to more water-soluble forms is 
necessary for their elimination (Watkins, 1990; Parkinson, 2001).  The liver is the major location 
for xenobiotic biotransformation in mammals, and it is often a site of drug-induced toxicity.  
Some drugs are inherently hepatotoxic and a reduction in the ability to detoxify or eliminate 
these compounds may predispose a patient to hepatotoxicity (Watkins, 1990).  Other drugs may 
cause hepatotoxicity as a result of formation of toxic metabolites via biotransformation.   
     Most adverse hepatic drug events (AHDEs) in companion animals are the result of direct 
hepatic injury although some reflect immunologic (allergic) responses (Bunch, 1993).  
Metabolism of xenobiotics by mixed function oxidases may lead to the formation of toxic 
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metabolites which can cause direct hepatic damage via formation of free radicals, electrophiles 
or activated oxygen species (Farber & Gerson, 1984; Kaplowitz et al., 1986).  The drug or toxic 
metabolites may cause an immune response and immune-mediated injury by binding covalently 
to or altering liver proteins (Lee, 2003; Kaplowitz, 2004).  Large adducts can serve as immune 
targets leading to formation of antibodies or cytolytic T-cell responses (Lee, 2003; Kaplowitz, 
2004). 
       Interactions between host-related factors and the chemical features of drugs contribute to the 
development of AHDEs (Bunch, 1993).  Age, hepatic blood flow, nutritional status and genetics 
are factors related to the development of AHDEs in both animals and humans (Bunch, 1993; Van 
Steenbergen et al., 1998).  As humans age, blood flow in the liver decreases; therefore, hepatic 
metabolism of drugs may be altered for those drugs whose biotransformation is highly blood-
flow dependent; hepatic elimination, first pass metabolism or hepatic clearance may decrease for 
some drugs in elderly patients (Bunch, 1993).  Differences in hepatic biotransformation also 
exist among immature, adult and geriatric dogs; the changes in metabolic activity, however, vary 
with the compound (e.g. felbamate) (Tibbitts, 2003).  Women have a higher incidence of drug-
induced hepatotoxicity, but the reasons for the gender difference are not clear (Lee, 2003).  
Hepatic enzyme polymorphisms exist for humans and dogs; differing metabolism among breeds 
has been noted with propofol for beagles and greyhounds (Hay Kraus et al., 2000; Nebert & 
Dieter, 2000; Tibbitts, 2003).  Poor nutrition can affect the quantity or quality of drug 
detoxifying enzymes which may alter xenobiotic metabolism (Bidlack et al., 1986).  Certain 
foods and drugs can induce or inhibit hepatic enzymes.  Hepatic enzyme induction or inhibition 
may contribute to the potential for a drug to cause hepatotoxicity by increasing formation of 
toxic metabolites or increasing exposure to the parent compound (Bunch, 1993; Lee, 2003).   
     Drug-induced liver damage can vary from hepatocyte swelling and rupture to cholestatsis 
without cell injury to mixed forms involving both the hepatocytes and bile canaliculi (Kaplowitz 
et al., 1986; Lee, 2003).  The injury to the liver cells is specific to the intracellular organelles 
affected (Lee, 2003).  The usual clinical expression of hepatic injury in animals is a 
hepatocellular or a mixed hepatocellular and cholestatic pattern of biochemical abnormalities 
and histopathologic findings (Bunch, 1993).   
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In Vivo Model 
     Several methods are used to study drug-induced hepatotoxicity.  The goal of these models is 
to mimic or re-create the toxicity so that the cause can be elucidated.  In vivo and in vitro models 
are used to examine toxicity at the molecular, cellular or organ level (Groneberg et al., 2002). 
     Dogs are common animal models for study of agents that cause toxicity in humans (Tibbitts, 
2003).  Dogs have many comparable physiologic processes as man, but there are also some 
differences which may not provide the best representation for all human situations (Tibbitts, 
2003).  Because of their similarity with humans, dogs are a valuable model for characterizing 
and predicting toxicity (Tibbitts, 2003). 
     The whole animal model is used to study toxicity as it occurs in nature.  Because the whole 
animal is exposed to the xenobiotic, the organ of interest can be examined along with other 
system interactions.  Only in vivo studies can be used to assess the effects of a substance on the 
whole animal.  It is often difficult to replicate complex interactions in vitro since in vitro 
techniques only examine one cell type, tissue or organ.   
     Whole animal studies are limited by animal welfare and ethical concerns (Groneberg et al., 
2002).  The expense of maintaining numerous animals in a colony along with increased federal 
requirements for housing, exercise and socialization is a major limitation of in vivo studies (Azri 
et al., 1990; Groneberg et al., 2002).  As with all models, gaps between the data collected from 
the species studied and the target population exist and can be an issue when interpreting the 
effects for comparison.  With in vivo studies, it is difficult to delineate the mechanism of 
toxicity, and it is hard to distinguish primary and secondary toxic effects (Azri et al., 1990; 
Groneberg et al., 2002). 
 
In Vitro Models 
     In vitro models can help alleviate some of the limitations of in vivo studies.  With in vitro 
techniques, the number of experiments that could be done is increased while decreasing the 
number of animals used.  Microsomes, cell suspensions, cell culture, tissue slices and ex vivo 
isolated perfused organs are methods used to study hepatic metabolism and toxicity. 
 
Microsomes 
     Microsomes are vesicles derived from the endoplasmic reticulum.  They are the most widely 
used subcellular fraction in the in vitro study of drug metabolism (Ekins et al., 2000).  They are 
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prepared by differential centrifugation of homogenized tissue, have a reproducible nature, can be 
stored for long periods of time and have well-characterized incubation conditions (Ekins et al., 
2000).   
     Microsomes contain cytochrome P450 enzymes, as well as, other enzymes involved in drug 
biotransformation, allowing for the study of phase I and phase II biotransformation (Cervenkova 
et al., 2001).  They are also useful in studying drug-drug interactions (Ekins et al., 2000).  
Microsomes have limitations as the addition of cofactors is needed to maintain enzyme activity 
and some enzymes may be labile and be lost in preparation (Ekins et al., 2000; Cervenkova et 
al., 2001).  Additionally, they only represent one organelle and cannot provide information about 
the entire intracellular compartment (Cervenkova et al., 2001).  This is particularly true for phase 
I and some phase II enzymes which are cytosolic.   
   
Isolated Cells and Cell Suspensions 
     Isolated cells and cell suspensions are used during development of new drugs and in 
metabolism and toxicity studies of xenobiotics (Cervenkova et al., 2001).  They are used to 
predict in vivo drug clearance and represent a more physiological model than microsomes 
(Griffin & Houston, 2005).  They are employed to assess cellular metabolism, cytotoxicity and 
genotoxicity (Groneberg et al., 2002).   
     Hepatocytes are prepared through a two-step collagenase process.  The process disrupts the 
intracellular contacts and alters the transport capabilities of the cells (Azri et al., 1990; 
Cervenkova et al., 2001).  The lack of cell-to-cell interactions is a major disadvantage to 
hepatocytes (Groneberg et al., 2002).  The cells maintain phase I and II drug-metabolizing 
enzymes, have cell membrane receptors and do not need artificially high concentrations of 
cofactors (Groneberg et al., 2002; Griffin & Houston, 2005).  Cells in suspension allow for rapid 
dispersal of the agent being tested aiding distribution and sampling (Griffin & Houston, 2005).  
Use of hepatocyte suspensions is limited as they only remain viable for four to six hours 
(Cervenkova et al., 2001; Griffin & Houston, 2005).   
 
Primary Cell Culture 
     Primary cell culture is a frequently used in vitro cell model, which can be maintained for 
weeks.  This in vitro model only represents selected (or specific) cell types (Bach et al., 1996; 
Cervenkova et al., 2001).  Isolation is time consuming, and cells must be protected from 
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overgrowth, infection and contamination (Cervenkova et al., 2001).  Cultured cells have cell-to-
cell interactions, but the monolayers have a larger contact area with surroundings than cells have 
in vivo or in tissue slices (Cervenkova et al., 2001).  This model is useful for assessing 
metabolism and cellular cytotoxicity. 
     Similar to isolated cells and cell suspensions, hepatocytes used for cell culture are obtained 
from a collagenase liver perfusion (Cervenkova et al., 2001).  Hepatocytes are separated from 
other cells by differential centrifugation, and the viable cells are seeded onto collagen-coated 
culture dishes (Cervenkova et al., 2001).  To maintain the health of cells, culture media must be 
changed every twenty-four hours (Cervenkova et al., 2001). 
     Cells in culture simplify the experimental system, and because cultured cells can be 
maintained for extended periods of time, experiments requiring long time periods can be 
performed (Cervenkova et al., 2001).  As cells in culture dedifferentiate, this is not a reliable 
method for comparison of interspecies differences of metabolism (Azri et al., 1990; Bach et al., 
1996; Cervenkova et al., 2001).  For hepatocytes, there is usually only basal cytochrome P450 
activity as a rapid decrease in cytochrome P450 activity occurs within 24 hours after formation 
of a monolayer (Cervenkova et al., 2001).  The range of cytochrome P450 enzymes is often 
different in cell culture compared to fresh tissue (Cervenkova et al., 2001). 
 
Isolated Perfused Organs 
     Isolated perfused organs are used to investigate drug and chemical-induced hepatotoxicity 
and are the closest model to in vivo conditions (Groneberg et al., 2002).  Perfused organs are a 
transition between tissue slices and whole organisms (Cervenkova et al., 2001).  Because they 
maintain organ physiology and morphology, they can be used to assess gross organ function, bile 
production and tissue histology (Groneberg et al., 2002).   
     The organ is excised from the donor animal and perfused with blood-free or autologous blood 
perfusates (Groneberg et al., 2002).  With the isolated perfused organ model three-dimensional 
organ structure and all cell-to-cell interactions are preserved (Groneberg et al., 2002).  Real-time 
bile collection and analysis can be performed, and hemodynamic parameters can be studied if 
blood is used as the perfusate (Groneberg et al., 2002).  Isolated perfused livers can be used for 
in vitro toxicity testing, studying induction or inhibition of drug metabolizing enzymes of 
various xenobiotics, exploring biotransformation and generating metabolites (Kurihara et al., 
1993). 
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     Preservation of function and viability within physiological ranges is difficult with perfused 
organ models (Groneberg et al., 2002).  Additionally, functional integrity is not maintained over 
a prolonged period (Groneberg et al., 2002).  When using perfused livers, liver cells are subject 
to ischemia-reperfusion injury and hemolysis; this effect may alter the results of an experiment 
and is of concern when using this model (Groneberg et al., 2002).  With the rat model, there are 
significant differences in organ size, function and geometry compared to humans, so porcine, 
canine or bovine livers are usually used to better simulate human in vivo conditions (Groneberg 
et al., 2002).  Establishment of the isolated perfused organ model is expensive and ethical 
concerns about animal welfare have limited its use (Groneberg et al., 2002). 
 
Tissue Slice Model 
Early Development 
     Tissue slices can be made from various organs—e.g., liver, kidney, brain, lung, heart—and 
various species—e.g., man, dog, non-human primates, rat, mice (Bach et al., 1996).  They are 
one of the oldest in vitro methods used to study metabolism (Bach et al, 1996).  Use of tissue 
slices was initially reported in the 1920s (Warburg, 1923; Bach et al., 1996; Groneberg et al., 
2002).  Slices were prepared using “free-hand” techniques, and as time progressed, simple 
“slicers” were developed (Azri et al., 1990; Bach et al., 1996).   
     The early slicers made it difficult to obtain reproducible slices, and the quality of the slices 
restricted use to a few hours (Azri et al., 1990; Bach et al., 1996).  The techniques were also 
complex making it difficult for a beginner to get replicable data (Bach et al., 1996).  
Inconsistency in slicing and poor incubation techniques also contributed to inconsistent results 
(Bach et al., 1996; Gandolfi et al., 1996).  Because of the problems associated with tissue slices, 
their use declined in favor of other in vitro models. 
     In the mid 1980s changes in slicing instrumentation allowed for the production of thin, 
reproducible slices (Bach et al., 1996; Ekins et al., 2000).  Precision-cut tissue slicer and 
improved incubation conditions brought about a resurgence in the use of liver slices in the late 
1980s and early 1990s (Gandolfi et al., 1996; Ekins et al., 2000).   
     With precision-cut tissue slicers, slices are formed under physiological conditions and are of 
uniform thickness and diameter (Gandolfi et al., 1996).  Eight millimeter diameter disks of tissue 
can be created with the optimal thickness of 200-250 microns (Bach et al., 1996; Gandolfi et al., 
1996).  The precision-cut slicing apparatuses used are either Krumdieck or Brendel-Vitron tissue 
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slicers.  The basic slicing technique involves using a sharp coring tool to take a cylindrical core 
of tissue and placing it in the tissue holder of the slicer.  A razor or microtome blade is moved 
across the core to produce the slices, and the slices are collected in a collecting device.  During 
the process of slicing, the slices are kept in cold, oxygenated buffer or media. 
     With the use of surface culture techniques, tissue slices could be incubated for longer periods 
of time (Bach et al., 1996).  Dynamic organ culture was developed to provide adequate gas and 
nutrient delivery to the slices during incubation (Azri et al., 1990; Gandolfi et al., 1996).  A 
rotating incubator is used so that the slices are dipped in and out of the media to facilitate gas 
exchange to both sides of the slice (Gandolfi et al., 1996).   
     The changes made to the early liver slice techniques, producing slices of reliable quality with 
minimal trauma, have allowed slices to be used with increasing frequency in pharmaceutical, 
university and government laboratories (Fisher et al., 2001; Olinga et al., 2001).  Slices are used 
as an in vitro method of examining organ toxicity and biotransformation.  In this system, the 
cellular aspects of liver toxicology in a tissue-specific background can be studied (Groneberg et 
al., 2002).   
 
Advantages  
     Liver slices are an intermediate between liver cells and isolated organs (Bach et al., 1996). 
A major advantage of hepatic slices compared to isolated hepatocytes is the lack of disruption of 
cell-to-cell contacts as occurs during the hepatocyte isolation procedure (Olinga et al., 2001).  
With liver slices the normal tissue architecture, cell heterogeneity and cell-cell interactions are 
maintained; the native cell types and integrity of the organ remain intact (Azri et al., 1990; Bach 
et al., 1996; Cervenkova et al., 2001; Lupp et al., 2001).   
     Liver slices are useful in the study of cytotoxicity, genotoxicity and xenobiotic 
biotransformation (Bach et al., 1996).  Liver slices perform phase I and II biotransformations as 
are seen in vivo (Gandolfi et al., 1996).  Liver slices exposed to xenobiotics appear to take up 
drugs as they would in an intact body; the rate of xenobiotic uptake, however, is influenced not 
only by the uptake rate of the cells but also the rate of penetration into the slice (Olinga et al., 
2001).  Freshly prepared rat liver slices retain high viability for up to 48 hours of incubation; 
phase I and II xenobiotic metabolizing enzyme activities are stable and functional, and 
cytochrome P450 expression is similar to that of normal liver (Lupp et al., 2001).  Phase I 
hepatic enzymes can also be induced in fresh slices (Lupp et al., 2001).  In humans, the tissue 
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slice system can be used for two to three days for studying hepatotoxicity (Groneberg et al., 
2002).   
     Slices can be collected and prepared from several organs using the same type of media; 
several organs from same animal or human can be used, as well as, organs from treated or 
untreated subjects (Bach et al., 1996; Cervenkova et al., 2001).  Because the methodology is 
comparable for all species and organs, comparison among species and organs is facilitated (Bach 
et al., 1996; Cervenkova et al., 2001).  Collected slices can be stored in cold, oxygenated media 
for over one hour after slicing, and incubation and experimental conditions are easier compared 
to perfused organs (Gandolfi et al., 1996; Cervenkova et al., 2001). 
     Tissue slices are a viable alternative to in vivo studies as fewer animals are needed (Azri et 
al., 1990).  This system maximizes the use of available tissue while allowing for the study of 
biotransformation, cell biology and toxicology (Bach et al., 1996).  The biotransformation rates 
of various drugs using liver slices is more similar to that of perfused organs and in vivo than rates 
obtained with isolated hepatocytes (Cervenkova et al., 2001).  Slices can be prepared from 
treated animals and humans or from organs with lesions (Bach et al., 1996).  They are a valuable 
tool when whole cell metabolism is desired over short periods up to 4 hours and metabolite 
identification across species is desired (Ekins et al., 2000).   
 
Limitations 
     In spite of the many advantages associated with tissue slices, this system also has its 
limitations.  Generally, uptake or metabolism of xenobiotics is lower in liver slices than in 
isolated hepatocytes or hepatocyte suspensions (Ekins et al., 2000; Cervenkova et al., 2001).  
Slices have a shorter viability than cultured cells, and there are difficulties in maintaining the 
viability of slices for long-term culture (Ekins et al., 2000; Groneberg et al., 2002).   
     Although rat slices can be incubated for up to three to five days, the cytochrome P450 activity 
of the slices decreases during incubation (Cervenkova et al., 2001).  Not only is cytochrome 
P450 enzyme activity decreased over time but cytochrome P450 content declines as well 
(Gandolfi et al., 1996; Ekins et al., 2000).  Since slices are not whole organs, they cannot be 
used to analyze bile or portal flow (Groneberg et al., 2002).   
     During preparation and incubation, slices must be handled carefully as they are susceptible to 
compression and mechanical damage (Bach et al., 1996).  Antifungal agents added to media to 
prevent contamination may affect cell membranes, and antimicrobials added to media may 
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interact with the chemical being studied (Bach et al., 1996).  The availability of tissue and 
expense of the equipment and supplies needed for slicing and incubation are also potential 
drawbacks. 
     Long-term storage of unused prepared slices is an issue.  Cryopreservation techniques have 
not been confirmed or standardized for all species, and viability can vary from 60 to 90% of the 
values of fresh slices depending on conditions and organs used (Bach et al., 1996).  Additionally, 
not all cell types freeze the same (Bach et al., 1996).  Recent studies have shown that 
cryopreserved liver slices retain phase I and II biotransformation ability but have decreased 
viability compared to fresh slices (Martignoni et al., 2004).   
 
Results in Animal Models 
     Initial studies with precision-cut rat liver slices examined the culture conditions for 
maintenance of the slices, and it was determined that rat liver slices could be maintained for up 
to 20 hours with little loss in viability (Smith et al., 1986).  It was noted that potassium (K+) and 
ATP levels reached a plateau following a two to four hour recovery period (Smith et al., 1986).  
In the 1980s both precision-cut liver slices and other older slicing techniques were used. Using 
0.4 millimeter thick liver slices prepared from a hand-held slicer, Powis et al. (1989) used liver 
slices and isolated hepatocytes of humans, dogs and rats to investigate the metabolism of 
biphenyl.  This study was used to compare the metabolizing ability of isolated hepatocytes to 
liver slices, and it was concluded that liver slices were better than hepatocytes for comparing in 
vitro human metabolism among species (Powis et al., 1989).   
     By the early 1990s, techniques for cryopreservation of liver slices were being tested.  As 
human tissue is difficult to obtain, Fisher et al. (1991) evaluated the effects of several 
cryopreservation methods on pig and human liver slices.  They found that cryopreserved pig 
liver slices maintained 80 to 85% of the intracellular K+ compared to fresh slices while  
cryopreserved human liver slices maintained 29 to 90% compared to fresh tissue.  Fisher et al. 
(1996a) determined that dog kidney slices could be maintained in cold-storage for up to 10 days 
using intracellular K+ content and protein synthesis as viability assays, but dog liver slices could 
only be cold-stored for 7 days based on intracellular K+ concentrations and 4 days based on 
protein synthesis.  Cryopreserved kidney slices and liver slices retained 60 to 70% viability 
following a four hour incubation (Fisher et al., 1996a).  Martignoni et al. (2004) compared the 
phase I and II biotransformation capacity in cryopreserved liver slices among mice, rats, dogs, 
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monkeys and humans.  They found that biotransformation ability was maintained but that 
viability was decreased (Martignoni et al., 2004).  Vanhulle et al. (2003) noted that not only was 
viability in rat liver slices decreased following cryopreservation, but protein synthesis, lipid 
synthesis and drug conjugation were also rapidly lost following incubation after cryopresevation.  
Similar results were noted for human cryopreserved slices (Glockner et al., 1999). 
     Fresh liver slices are useful for evaluating xenobiotic biotransformation in humans and rats 
(Vickers, 1994; Oddy et al., 1997).  Fresh rat liver slices have cytochrome P450 subtypes similar 
to that of normal liver though the expression is generally lower (Lupp et al., 2001).  Lupp et al. 
(2001) noted that in vitro induction of phase I hepatic enzymes could be seen 
immunohistochemically in rat liver slices twenty-four hours after incubation with ß–
naphthoflavone, phenobarbital and dexamethasone.  Lupp et al. (2002) performed a similar study 
using cryopreserved rat liver slices; they reported similar results although the number of viable 
cells in the cryopreserved slices was lower.  Ekins et al. (1996) compared the metabolism of 
several substances among rat, human and dog freshly isolated hepatocytes and 16 millimeter 
diameter liver slices.  They found lower metabolism of substrates in rat liver slices compared to 
isolated hepatocytes and showed similar results with dog and human samples. 
     Liver slices are used in investigational pathology to assess hepatotoxic effects of substances 
(Gandolfi et al., 1995; Groneberg et al., 2002).  The toxicity of several compounds was tested 
using rainbow trout liver slices (Fisher et al., 1996b).  Liver slices can also be used to study drug 
uptake mechanisms; Olinga et al. (2001) studied the maintenance of uptake processes in rat and 
human liver slices.  Liver slices exposed to xenobiotics appear to take up drugs as they would in 
an intact body; the rate of xenobiotic uptake, however, is influenced not only by the uptake rate 
of the cells but also the rate of penetration into the slice (Olinga et al., 2001). 
 
Development of Dog Model 
     Studies using canine liver slices are limited and are related to using the dog as an in vitro 
model for humans or in comparison studies to determine whether the rat or dog better predict 
what occurs in human tissue (Fisher et al., 2001).  As the availability of human tissue is often 
scarce, dog tissue slices are often used to develop and perfect techniques for use with human 
tissue slices.   
     The use of dog tissue slices for the purpose of studying drugs known to be toxic to dogs has 
not been reported.  The aim of this study is to determine whether dog liver slices can be used as a 
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model for studying drug toxicity and metabolism.  To determine the capacity of canine liver 
slices for the study of metabolism and toxicity, tissue slices were assessed for 1) viability and 
toxicity using potassium ion levels, ATP levels and histopathology, 2) metabolic and functional 
capacity by examining appearance of parent drug or metabolites in slice supernatant or the 
appearance of metabolites in slice media and 3) ability of compounds to induce or inhibit 
cytochrome P450 enzymes.    
     Liver slices should prove to be an effective mechanism for investigating hepatotoxicity and 
metabolism in dogs.  The information gathered may be of further use to identify factors, such as 
gender, breed characteristics or drug interactions, which may increase a dog’s risk of developing 
drug-induced hepatotoxicity. 
 
Assessment of Slice Viability 
     Potassium (K+) ion levels, adenosine triphosphate (ATP) cellular levels and histopathology 
are used as indicators of hepatotoxicity and tissue viability (Bach et al., 1996).  Hepatic slice 
viability can be assessed via measurement of hepatic enzymes, intracellular ions (potassium), 
cellular energy content (ATP) and xenobiotic metabolism (Azri et al., 1990).  The use of several 
viability parameters provides a better picture of tissue health than just one parameter.   
 
Potassium 
     Intracellular potassium ion content is a sensitive indicator of cell membrane damage.  
Potassium ion concentrations are measured in the hepatic slice supernatant.  Damaged cell 
membranes will cause potassium ions to leak out of the cell leading to decreased tissue 
concentrations.  Intracellular potassium ion content reflects the function of Na+-K+-ATPase; the 
constant concentration of potassium ions in the cell is an indication that the plasma membrane is 
intact (Cervenkova et al., 2001).  Alterations in intracellular ion content are indicative of cell 
death or injury and are used as a general index of viability (Azri et al., 1990).   
     Potassium ions are the primary and universal measure of slice viability; it is sensitive assay to 
monitor overall health of slices (Azri et al., 1990).  The content of potassium ions in control 
slices should remain constant; changes in potassium ion concentrations in treated slices are an 
indication of cellular injury (Azri et al., 1990).  Potassium ions are the most commonly used 
biochemical indicator of viability and toxicity; it is one of the first alterations observed and is 
often the most sensitive indicator (Gandolfi et al., 1996). 
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ATP 
     ATP content is measured in the hepatic slice supernatant and is an indication of the function 
of the ATP production chain.  ATP provides the energy necessary for cellular processes, so a 
decrease in ATP content can indicate impairment in the production chain.  ATP depletion is an 
indication of mitochondrial damage or impairment of mitochondrial function.  Measurement of 
ATP concentration can be used as indication of slice viability (Azri et al., 1990; Cervenkova et 
al., 2001).  Because of the high metabolic activity of the liver, it requires high-energy 
intermediates (ATP), functional mitochondria and oxygen (Gandolfi et al., 1996).  Alterations in  
ATP can be used an indication of toxic insult (Gandolfi et al., 1996).  
 
Histopathology 
     Histological examination is the method of choice for determining slice viability (Cervenkova 
et al., 2001).  Correlation of biochemical and functional changes with histopathological changes 
provides a picture of overall slice health (Bach et al., 1996; Gandolfi et al., 1996).  Because 
cellular architecture of liver is maintained in slices, changes in centrilobular or periportal 
hepatocytes can be monitored and cell-specific lesions can be seen (Bach et al., 1996; Gandolfi 
et al., 1996).   
     Histologically, the liver’s response to toxic injury from xenobiotics can vary from lipid 
accumulation to cell death (Treinen-Moslen, 2001).  Lipid accumulation in paraffin-embedded 
and solvent-extracted sections is noted as the presence of vacuoles displacing the nucleus to the 
periphery of the cell (Treinen-Moslen, 2001).  Although fat accumulation is a common response 
of the liver to some hepatotoxins, frozen sections and special stains are needed to determine 
whether the vesicles are fat (Treinen-Moslen, 2001).  Cell death may occur via necrosis or 
apoptosis.  The features of necrosis are cell swelling, leakage, nuclear disintegration and 
presence of inflammatory cells (Treinen-Moslen, 2001).  For apoptosis the features are cell 
shrinkage, nuclear fragmentation, apoptotic bodies and lack of inflammation (Treinen-Moslen, 
2001).  Liver cells may die in a focal, zonal or panacinar pattern.  Focal cell death is represented 
by death of single or clusters of hepatocytes while zonal necrosis occurs in periportal or 
centrolobular areas (Treinen-Moslen, 2001).  Panacinar necrosis is widespread hepatocyte death 
with a few or no surviving cells (Treinen-Moslen, 2001).  Another necrotic pattern which can be 
seen following a hepatotoxic insult is bridging necrosis (Treinen-Moslen, 2001).  This is a less 
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extensive form of necrosis than panacinar and is signified by zones of confluent cell lysis 
(Treinen-Moslen, 2001). 
     Maintenance of morphological integrity is one of the most important indicators of the 
viability of tissue slices; histology is a way of detecting target cell injury (Bach et al., 1996).  
Histological assessment is more difficult and resource-intensive than use of biochemical markers 
for determining toxicity (Bach et al., 1996).  Fisher et al. (2001) noted that histological 
evaluation was a more sensitive indicator of slice viability than biochemical evaluation. 
 
Determination of Slice Function and Metabolic Capacity 
     Several substances, such as cyclosporine A, carbamazepine, styrene and testosterone, have 
been used to determine the metabolic capacity and function of liver slices (Vickers et al., 1992; 
Vickers, 1994; Ekins et al., 1996; Martignoni et al., 2004).  In this study, lidocaine, 
phenobarbital and primidone were used as marker drugs with drug disappearance in media or 
metabolic appearance in liver supernatant or incubation media serving as indicators of 
metabolism.  Carprofen was used to assess the ability of a non-steroidal anti-inflammatory drug 
to cause toxicity to liver slices alone or following phenobarbital or cimetidine incubations.  (The 
structures of drugs studied are in appendix II.) 
 
Phenobarbital 
     Phenobarbital is an anticonvulsant used in the medical management of seizures in dogs.  
Phenobarbital is known to cause hepatotoxicity in dogs (Bunch, 1993; Dayrell-Hart et al., 1991; 
Podell, 1998; Müller et al., 2000), and the hepatotoxicity is usually associated with increased 
plasma concentrations of phenobarbital (Podell, 1998).   
     Phenobarbital was applied to slices to determine if it would cause dose-dependent changes in 
viability parameters indicating toxicity.  Indications of toxicity at higher drug concentrations 
would mimic the in vivo toxicity.  The presence of phenobarbital in the supernatant would also 
indicate that the drug was penetrating the hepatocytes. 
 
Primidone 
     Primidone is an anticonvulsant used in the medical management of epilepsy in dogs.  The use 
of primidone has fallen out of favor as it is associated with hepatotoxicity in dogs (Schwartz-
Porsche et al., 1985; Podell, 1998).  Primidone is metabolized to phenobarbital and 
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phenylethylmalonamide (Yeary, 1980).  The measurement of phenobarbital concentrations in 
liver slices exposed to primidone was used to determine the metabolic ability of the slices and to 
determine if dose-dependent toxicity could be detected.  Since both phenobarbital and primidone 
are associated with hepatotoxicity, and primidone is metabolized to phenobarbital, the results of 
the studies could be compared to determine any differential effects of the drugs.   
 
Lidocaine  
     Lidocaine is a local anesthetic and is used in the treatment of ventricular arrhythmias in dogs.  
Lidocaine is metabolized to monoethylglycinexylidide (MEGX) and glycinexylidide (GX) in 
dogs (Keenaghan & Boyes, 1972; Wilcke et al., 1983).  In humans, lidocaine is metabolized to 
MEGX by CYP3A4, and measurement of MEGX in blood following intravenous administration 
of lidocaine has been used as a sensitive indicator of oxidative drug metabolizing hepatic 
function (Tanaka & Breimer, 1997).   
     Slices exposed to lidocaine were used to determine the metabolic function of the slices.  The 
measurement of lidocaine disappearance and appearance of MEGX and/or GX is an indication of 
the metabolic capacity. 
 
Carprofen 
     Carprofen is a propionic acid non-steroidal anti-inflammatory drug (NSAID) approved for 
use in the medical management of canine osteoarthritis.  Carprofen can cause a hepatocellular 
toxicosis in dogs which is believed to be idiosyncratic  (MacPhail et al., 1998).  The hepatic 
localization and hematologic changes from this toxicity are similar to those associated with other 
NSAIDs known to cause hepatic disease.  The hepatocellular damage associated with carprofen 
varies from mild to severe, and the hepatic pathological changes can vary as well (MacPhail et 
al., 1998).  Hepatocellular necrosis ranges from multifocal to extensive and is characterized by 
ballooning degeneration, lytic necrosis and apoptosis (MacPhail et al., 1998).  Bridging necrosis, 
zones of confluent cell lysis, with parenchymal collapse is most common (MacPhail et al., 1998; 
Treinen-Moslen, 2001).   
     Since carprofen can cause a hepatotoxicity in dogs, it was used to determine if similar 
changes could be seen in canine liver slices exposed to the drug.   
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Inducers and Inhibitors 
     Cytochrome P450 (CYP) enzyme inducers and inhibitors were used to determine if they 
could alter the ability of carprofen to cause hepatotoxicity in canine liver slices.  To induce and 
inhibit cytochrome P40 isoforms in hepatic slices, phenobarbital and cimetidine were used, 
respectively.   
     The cytochrome P450 2B subfamily is the most inducible by phenobarbital (Hojo et al., 
2002).  In dog liver microsomes, the phenobarbital inducible cytochrome P450 enzyme is 
CYP2B11 (Graham et al., 2002).  Phenobarbital also induces CYP3A12 and CYP2C21 in dog 
liver hepatocytes and microsomes (Nishibe & Hirata, 1993; Eguchi et al., 1996).  Phenobarbital 
has been used to induce cytochrome P450 isoforms in rat liver slices in vitro (Lupp et al., 2001; 
Lupp et al., 2002).   
     In microsomes of male rats, cimetidine inhibits CYP2C11 (Levine et al., 1998).  In humans, 
substrates for the CYP2C subfamily include ibuprofen and flubiprofen, which are propionic 
acids like carprofen (Boelsterli et al., 1995).     
     The CYPs involved in carprofen metabolism in dogs are not known.  Phenobarbital was 
selected as the inducer because it has been shown to induce CYP expression in rat liver slices in 
vitro (Lupp et al., 2001).  Additionally, hepatic enzyme induction can lead to the formation of 
toxic metabolites that may cause hepatotoxicity (Nebert & Dieter, 2000).  Cimetidine was 
selected as it inhibits isoforms of the CYP2C subfamily, and in humans the CYP2C subfamily 
has been shown to have a key role in the metabolism of NSAIDs (Leemann et al., 1993; Levine 
and Bellward, 1995; Levine et al., 1998; Boelsterli et al., 1995).  Since inhibition studies using 
cimetidine have not been performed in liver slices, extrapolations from other in vitro models 
were made.  The mechanism of carprofen-induced hepatotoxicity is unknown, and therefore, 
alterations in toxicity following induction or inhibition of drug metabolizing enzymes would 
support the role of metabolism in mediating hepatotoxicity by a metabolite.   
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CHAPTER II 
MATERIALS AND METHODS 
 
Tissue Collection, Incubation and Handling 
Liver 
     The right liver lobe was harvested from euthanized dogs (n=10; male, hound cross) within 
fifteen minutes of death to maintain hepatic viability.  Following removal, the liver was cut into 
quarters, placed in V-7, a cold preservation solution (Vitron, Inc., Tucson, AZ) (Fisher et al., 
1996a), and kept cold in a refrigerator (4ºC) until slice preparation (10 to 12 hours after 
collection).  One dog was used for each day’s experiment (Table 1). 
 
 
Table 1.  Study dates.  Day one of each study performed is shown with the item(s) of interest tested for in the media 
or supernatant listed.  The numbers in the dog column represent the identification number assigned to each liver.   
Drug  Supernatant Media Date 
(Day 1) 
Dog 
Carprofen (repetition (rep.) 1) 
Carprofen (rep. 2) 
Carprofen C (rep. 3) 
drug appearance drug disappearance  2/25/03 
10/14/03 
10/14/03 
1 
4 
4 
Phenobarbital drug appearance drug disappearance 5/1/03 2 
Lidocaine drug or metabolite 
appearance 
drug disappearance 5/1/03 2 
Primidone metabolite appearance metabolite appearance 7/3/03 3 
Diazepam (rep. 2) drug or metabolite 
appearance 
metabolite appearance or 
drug disappearance 
10/14/03 4 
Diazepam (rep. 1) drug or metabolite 
appearance 
metabolite appearance or 
drug disappearance 
10/15/03 5 
Diazepam and phenobarbital drug or metabolite 
appearance 
metabolite appearance or 
drug disappearance 
10/15/03 5 
Diazepam and cimetidine drug or metabolite 
appearance 
metabolite appearance or 
drug disappearance 
10/15/03 5 
Carprofen and phenobarbital 
(rep. 1, 2 & 3) 
drug appearance drug disappearance  11/10/03 6 
Carprofen and cimetidine (rep. 
1, 2 & 3) 
drug appearance drug disappearance  11/12/03 7 
Carprofen and phenobarbital drug appearance drug disappearance  1/28/04 8 
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Slicing 
     Several cylindrical cores of tissue were made from each liver section using an 8 mm diameter 
coring tool (Vitron, Inc., Tucson, AZ).  The cores were placed in a Brendel/Vitron Tissue Slicer 
(Figure 1) (Vitron, Inc., Tucson, AZ) and sliced to make disks of tissue 200 –250 µm thick.  
Throughout coring and slicing, a 95% oxygen and 5% carbon dioxide gas mixture was used to 
propel cold V-7 solution through the slicer to help maintain liver and slice integrity.  Cores and 
slices were kept cold prior to, during and post-slicing.  Following slicing, the tissue slices were 
loaded onto roller inserts (Type A) (Figure 1) (Vitron, Inc., Tucson, AZ) with a slice handling 
tool.  One slice was loaded per roller insert.  The roller inserts consisted of a Teflon cradle with a 
titanium wire mesh and Viton O-rings.   
 
 
B 
A C 
 
Fig. 1.  Slicing and incubation instruments.  A. Type A Roller Insert; B. Dynamic Organ Culture Incubator;  
C.  Brendel/Vitron Tissue Slicer. 
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Tissue Incubation Media 
     Waymouth’s MB 752/1 liquid media with L-glutamine was purchased from Gibco Invitrogen 
Corporation (Carlsbud, CA; catalog no. 11220).  One liter of the final media preparation 
contained 10% fetal bovine serum (BioWhittaker, Inc, Walkersville, MD; catalog no. 14501E), 
50 mg of gentamicin (BioWhittaker, Inc, Walkersville, MD) and 10 ml antibiotic antimycotic 
solution (Sigma-Aldrich, St. Louis, MO; catalog no. A5955).  The media was sterile filtered 
using a Millipore Stericup filtration system (Millipore Corporation, Bedford, MA; catalog no. 
SCGPU05RE).  The media was kept protected from light at 2 to 8ºC.  Media for the study was 
prepared one to two days prior to use and was kept refrigerated and protected from light for up to 
one week.  Unprepared Waymouth’s media was stored until the labeled expiration date. 
 
Incubation 
     Slices on roller inserts were placed into 20 ml scintillation vials (VWR Scientific Products, 
Willard, OH; catalog no. 66022-004) containing 1.7 ml media.  The vials were allowed to reach 
room temperature before loading roller inserts.  A cap, with a 1-2 mm hole to allow for gas 
exchange, was placed on each vial.  Slices were incubated at 37°C in a Dynamic Organ Culture 
Incubator (Figure 1) (Vitron, Inc., Tucson, AZ).  A gas atmosphere of 95% oxygen and 5% 
carbon dioxide was supplied to the incubator at a flow rate of 1 L/ min. 
 
Slice and Media Handling Post-incubation 
     All slices were weighed (blotted weight recorded for potassium and ATP normalization), 
placed in a microcentrifuge tube containing one milliliter purified water and homogenized 
(Tissue-Tearor®, Spectrum Chemicals, Gardena, CA) for approximately five seconds.  
Homogenized slices were frozen then thawed and centrifuged at 16,110 g for 15 minutes.  The 
supernatant was aliquoted and frozen until analysis.  Media samples were frozen until assayed.    
 
Tissue Viability 
Potassium Analysis 
     A VITROS 250 Analyzer and VITROS K+ Slides (Ortho-Clinical Diagnostics, Inc, 
Rochester, NY) were used to assay potassium content in hepatic slice supernatant by ion-
selective electrodes.  Samples were analyzed by the Clinical Pathology Lab at the Texas 
Veterinary Medical Center at Texas A&M University (College Station, TX). 
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ATP Analysis 
     An ATP determination kit from Molecular Probes (Eugene, OR; catalog no. A-22066) was 
used to measure ATP content in hepatic slice supernatant.  The samples were analyzed according 
to kit directions on a FLUOstar Optima (BMG Labtechnologies, Inc, Durham, NC). 
 
Histopathologic Analysis 
     Slices for histopathological analysis were fixed in five ml of 10% formalin for at least 24 
hours.  Tissues were embedded in paraffin, sectioned at 5 µm and stained with hematoxylin and 
eosin (H&E).  The entire section of each tissue (approximately 50 mm2) was examined by light 
microscopy.  The extent and severity of microscopic changes were semiquantitatively graded as:  
score 0, normal; 1, minimal change; 2, mild change; 3, moderate change; 4, marked change; 5, 
severe change (Herbert et al., 2002).  Grading of the extent of necrosis (including apoptosis) and 
the extent of vacuolation was based on the approximate percentage of hepatocytes affected 
(Table 2).  Grading of the severity of vacuolation was based on visual assessment of the ratio of 
clear space to pink cytoplasm in the parenchyma.  The slide observer was unaware of slice 
treatment. 
 
 
Table 2.  Lesion score scale.  Histologic criteria for grading extent of necrosis and extent of vacuolation. 
Lesion score % hepatocytes affected 
0 (normal) <1 
1 (minimal change) 1-10 
2 (mild change) 11-20 
3 (moderate change) 21-40 
4 (marked change) 41-90 
5 (severe change) >90 
 
 
Tissue Treatments 
     Incubation conditions were optimized for the hepatic slices, and the impact of the drug on 
slice viability was determined.  Normal activity was assessed by the ability of slices to take up 
and metabolize drugs.  Lidocaine, phenobarbital and primidone were used as marker drugs with 
drug disappearance or metabolic appearance in liver supernatant or incubation media serving as 
indicators of metabolism.  Diazepam was used as an additional drug to measure hepatic slice 
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metabolism and to determine the ability to induce and inhibit cytochrome P450 drug 
metabolizing enzymes in slices.  Carprofen was used to assess the ability of a non-steroidal anti-
inflammatory drug to cause toxicity in the slices in normal, induced and inhibited conditions.   
     To induce and inhibit cytochrome P450 drug metabolizing enzymes in hepatic slices, 
phenobarbital and cimetidine were used, respectively.  The cytochrome P450 2B subfamily is the 
most inducible by phenobarbital (Hojo et al., 2002).  In dog liver microsomes, the phenobarbital 
inducible cytochrome P450 enzyme is CYP2B11 (Graham et al., 2002).  Phenobarbital also 
induces CYP3A12 and CYP2C21 in dog liver hepatocytes and microsomes (Nishibe & Hirata, 
1993; Eguchi et al., 1996).  In male rats, cimetidine inhibits CYP2C11 (Levine et al., 1998).  In 
humans, substrates for the CYP2C subfamily include ibuprofen and flubiprofen, which are 
propionic acids like carprofen (Boelsterli et al., 1995).  To determine if phenobarbital induced 
CYP2B11, an enzyme-linked immunoassay (ELISA) was used to measure the concentration of 
the enzyme in the hepatic supernatant.  An ELISA for CYP2C21 was used to determine 
cimetidine inhibition.  The kits used specific antisera developed for dog liver microsomes.  
 
Lidocaine 
     Slices were incubated in media containing 0, 3, 10 and 20 µg/ml of lidocaine.  Following 
incubation for 1, 3, 6, 8, 12 and 24 hours, slices were removed and prepared for ATP, K+ and 
high pressure liquid chromatography (HPLC) analysis for the presence of parent compound and 
metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX).  The media was also 
analyzed for parent compound and metabolites.  Incubation media concentrations were 
approximately 0, 1, 3.3 and 6.5 times canine plasma concentrations measured following a 
therapeutic dose.  A liquid-liquid extraction was used to extract the parent compound and 
metabolites for HPLC analysis. 
 
Phenobarbital 
     Slices were incubated in media containing 0, 20, 45 and 75 µg/ml of phenobarbital.  
Incubation media concentrations were approximately 0, 1, 2.25 and 3.75 times canine plasma 
concentrations measured following a therapeutic dose.  Following incubation for 1, 3, 6, 8, 12 
and 24 hours, slices were removed and prepared for ATP, K+ and fluorescence polarization 
immunoassay for the parent compound.  The media was also analyzed for parent compound.     
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Primidone 
     Slices were incubated in media containing 0, 20, 45 and 75 µg/ml of primidone.  Incubation 
media concentrations matched those of the phenobarbital experiment.  Following incubation for 
1, 3, 6, 8, 12 and 24 hours, slices were removed and prepared for ATP, K+ and fluorescence 
polarization immunoassay for phenobarbital, an active metabolite of primidone.  The media was 
also analyzed for the presence of phenobarbital. 
 
Diazepam 
     Diazepam was applied to the slices at 0, 100, 250 and 500 ng/ml.  The slices were incubated 
in the media for 0, 1, 4, 8, 12 and 24 hours.  Incubation media concentrations were 
approximately 0, 1, 2.5 and 5 times canine plasma concentrations measured following a 
therapeutic dose.  To determine the effects of hepatic drug metabolizing enzyme induction or 
inhibition on drug concentrations, the induction and inhibition methods described under 
cytochrome P450 induction and inhibition were used with diazepam as the drug of interest.   
(See Appendix IV for diazepam results.) 
 
Carprofen 
     Slices were incubated in media containing increasing concentrations (0, 10, 25, 50, 75 or 100 
µg/ml) of carprofen as the racemic mixture or its enantiomers.  Incubation media concentrations 
were approximately 0, 1, 2.5, 5, 7.5 and 10 times canine plasma concentrations measured 
following a therapeutic dose.  At 1, 6, 8, 12 and 24 hours or 0, 1, 4, 8, 12 and 24 hours 
incubation, the slices were removed from incubation and prepared for ATP, K+, drug and 
histopathologic analysis.  The drug concentrations in the media and the slice were determined by 
HPLC analysis.   
     Using the method described under cytochrome P450 induction, the ability of carprofen to 
induce toxicity was evaluated in the presence of a cytochrome P450 induced slice.  The slice was 
exposed to the inducer in media, and the media was replaced by media containing the racemic 
mixture or enantiomers of carprofen.  The method described under cytochrome P450 inhibition 
was used for determining the effect of a cytochrome P450 inhibitor on the ability of carprofen to 
cause toxicity.      
 
 26
Carprofen Enantiomers 
     An unsuccessful attempt was made to separate enantiomers by chiral derivatization.  As 
separation did not occur, the same protocol that was used for the racemic mixture was repeated 
as would have been done with the individual enantiomers.   
 
Additional Carprofen and Phenobarbital Incubation 
     Slices were incubated for 48 hours in 75 µg/ml phenobarbital or for 24 or 48 hours in 150 
µg/ml phenobarbital.  Following the 24 or 48 hour incubation, rollers were removed from the 
induction vials, blotted to remove excess media and placed in new vials containing media with 
100 µg/ml carprofen.  Slices were then incubated for an additional 4, 12 or 24 hours.  At the end 
of the second incubation, slices and media were examined for concentration of carprofen. 
 
Cytochrome P450 Induction 
     Slices were incubated for 24 hours in 75 µg/ml of phenobarbital.  This concentration was 
chosen as it is the high end of the acceptable plasma concentrations for phenobarbital in dogs.  
Additionally, hepatic slices showed decreases in potassium and ATP content at this 
concentration.  Concentrations used for in vitro induction studies with dog hepatocytes used 1 
mM (233.24 µg/ml) or 2 mM (466.48 µg/ml) phenobarbital (Nishibe & Hirata, 1993).   
     Following the 24 hour incubation, rollers were removed from the induction vials, blotted to 
remove excess media and placed in new vials containing media with desired drug.  Slices were 
then incubated for an additional 1, 4, 8, 12 or 24 hours.  At the end of the second incubation, 
slices and media were handled as stated previously.  Supernatant was evaluated for induction of 
cytochrome P450 2B11 by ELISA. 
Cytochrome P450 Inhibition 
     Slices were incubated for 24 hours in 1000 µM of cimetidine.  This concentration was based 
on in vitro studies using rat and human microsomes (Levine & Bellward, 1995; Furuta et al., 
2001).  Following the 24 hour incubation, rollers were removed from the inhibition vials blotted 
to remove excess media and placed in new vials containing media with desired drug.  Slices 
were then incubated for an additional 1, 4, 8, 12 or 24 hours.  At the end of the second 
incubation, slices and media were handled as stated previously.  The supernatant was evaluated 
for inhibition of cytochrome P450 2C21 by enzyme-linked immunoassay (ELISA).  
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Tissue Analysis 
Drug Analysis 
    For all high pressure liquid chromatography (HPLC) analyses, the following components, 
provided by Waters, Inc (Milford, MA), were used:  Waters Millenium® software, Waters 474 
Scanning Fluorescence Detector, Waters 2487 Dual Wavelength Absorbance Detector, Waters 
996 Photodiode Array Detector, Waters 717plus Autosampler, and Waters 600 Controller. 
 
Phenobarbital and Primidone Slice Analysis 
     A TDxFLx System with phenobarbital kit by Abbott Laboratories (Abbott Park, IL) was used 
to measure the amount of phenobarbital in the media and slices for the phenobarbital and 
primidone studies.  The TDxFLx System uses fluorescence polarization immunoassay 
technology.  The lower limit of quantification (LOQ) was 1.1 µg/ml.  The upper LOQ was 80 
µg/ml.  The kit controls predicted in the acceptable range, and media controls were within 10% 
of expected concentrations. 
 
Lidocaine Assay 
     Each 250 µl sample was combined with 300 µl of 2 M sodium hydroxide and 5 ml of methyl 
tert-butyl ether and vortexed for 10 seconds.  The mixed samples were centrifuged at 1600 g at 
5°C for 15 minutes.  After centrifugation, the samples were placed in a freezer at -80° C for 15 
minutes.  The organic phase was transferred to another tube, combined with 250 µl of 17 mM 
phosphoric acid and vortexed for 30 seconds.  Following centrifugation at 1600 g at 5°C for 15 
minutes, the supernatant was removed and the remaining solution was analyzed by HPLC.  A 
Luna 3 µ C-18(2) 150x4.6 mm column (Phenomenex, Torrance, CA) with Luna 4x3 mm guard 
column (Phenomenex, Torrance, CA).  Lidocaine and its metabolites, MEGX and GX, were 
detected by photodiode array (210 nm-263 nm).  The mobile phase contained 1800 ml of water, 
400 µl of triethylamine, 2.4 ml of 85% phosphoric acid and 200 ml acetonitrile.  For a flow rate 
of 0.7 ml/min, the retention times were 8.5 minutes, 9.8 minutes and 12.5 minutes for lidocaine, 
GX and MEGX, respectively.  The lower and upper LOQs for lidocaine were 50 and 25000 
ng/ml.  For MEGX and GX, the lower and upper LOQs were 50 and 1000 ng/ml.  Three media 
controls and three supernatant controls were used for each compound measured.  The controls 
predicted within 10% of expected concentrations. 
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Diazepam Assay 
     Each 500 µl sample was prepared for HPLC analysis by adding 0.5 ml of distilled water and 
20 µl of 5% acetic acid and vortexing the mixture.  This mixture was applied to a BondElut C-
18, 200 mg solid-phase extraction column (Varian, Inc., Harbor City, CA).  The column was 
conditioned with one ml each acetonitrile and water.  Following conditioning, the sample was 
applied to the cartridge, washed with one ml of water and eluted with one ml of methanol.  The 
eluent was placed in the HPLC vial and analyzed.  The HPLC system used consisted of a Prevail 
C-18 5 µm 250x4.6 mm column (Alltech Associates, Inc.) with a mobile phase of 
methanol:acetonitrile:water (10:40:50).  The pH of the mobile phase was adjusted to 3.2 using 
acetic acid.  The flow rate was 1 ml/min with an injection volume of 100 µl.  The compounds 
were detected by UV at a wavelength of 232 nm.  The retention times were 6.1 minutes for 
diazepam, 9.8 minutes for oxazepam, 14.3 minutes for temazepam and 17.2 minutes for 
nordiazepam.  The lower and upper LOQs for diazepam were 40 and 500 ng/ml.  For oxazepam 
and temazepam the lower and upper LOQs were 80 and 250 ng/ml.  The lower and upper LOQs 
for nordiazepam were 40 and 250 ng/ml.  Three supernatant and three media controls were used 
for each compound measured.  The controls predicted within 10% except for the low control for 
temazepam which was within 15% of expected concentrations.  (See Appendix IV for diazepam 
results.) 
 
Carprofen Assay 
     Each 500 µl sample was prepared for HPLC analysis by mixing it with 500 µl of 1% 
phosphoric acid.  This mixture was applied to a Strata C18E, 100 mg solid phase extraction 
cartridge (Phenomenex, Torrance, CA), which had been conditioned with 1 ml methanol and 1 
ml 1% phosphoric acid.  The cartridge was washed with 1 ml 1% phosphoric acid and eluted 
with 1 ml of ethanol. The eluent was placed in an HPLC vial and analyzed.  The HPLC system 
used consisted of a CHIRALCEL® OD (4.6 x 250 mm) column (Chiral Technologies, Inc., 
Exton, PA) and OD guard column or cartridge (0.4 x 1 cm) with a mobile phase of 
hexane:ethanol:trifluoroacetic acid (90:10:0.15).  The flow rate was 1 ml/min with an injection 
volume of 20 µl.  The compound was detected by UV at a wavelength of 254 nm.  The retention 
time was 12 –13 minutes.  The lower and upper LOQs were 3 and 300 µg/ml.  Three supernatant 
and three media controls predicted within 10% of expected concentrations. 
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Enantiomer Separation 
     An attempt was made to separate the enantiomers by chiral derivatization to form the 
diastereoisomers.  The method used was based on Spahn et al. (1988) using R(+) and S(-)-α-
methylbenzylamine (Spectrum Chemicals, Gardena, CA) as the derivatizing agent.  Each α -
methylbenzylamine (0.8g) was dissolved in 4 ml of acetone, and 1.8 g of racemic carprofen was 
dissolved in 36 ml acetone.  The α -methylbenzylamine mixture was mixed with the carprofen 
mixture and allowed to stand at room temperature, protected from light, for three days.  Four 
crystallizations were performed.  The enantiomers were hydrolyzed with 0.1 M hydrochloric 
acid according to the article procedure.  The enantiomers were analyzed by HPLC using a chiral 
column by the method described above under carprofen assay. 
 
Cytochrome P450 Analysis 
     A BD Gentest Products canine-specific enzyme-linked immunoassay (ELISA) (BD 
Biosciences, Bedford, MA) was used to measure the amount of cytochromes P450 2B11 (catalog 
no. 458937) or 2C21 (catalog no. 458020) in the samples.  Samples were analyzed at 450 nm.  
The antibodies and method were provided with the kit. 
 
Statistical Analysis 
     Changes in potassium content, ATP content, drug concentrations and AUC were assessed as 
significant differences among treatments and across time using analysis of variance (ANOVA).  
Histopathologic changes indicative of hepatic damage (necrosis, vacuolation) were also assessed 
across time and among treatments by ANOVA.  Cytochrome P450 concentration comparisons 
were made using paired t-tests.  Statistical analyses were performed using SYSTAT®, Microsoft 
Excel® and GraphPad Prism®.  A p-value (α) < 0.05 was considered statistically significant.  
Differences among ANOVA groups were determined using Tukey’s test for multiple 
comparisons. 
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CHAPTER III 
CANINE HEPATIC SLICE BEHAVIOR AND ASSESSMENT 
 
Potassium, ATP and Histology 
     The behavior of canine hepatic slices, incubated in media without drug, was assessed across 
time, for up to twenty-four hours, and across experiment dates for potassium content (µmol/g-L), 
ATP content (nmol/g) and histologic lesion scores (necrosis, vacuolation extent and vacuolation 
severity).  Mean potassium concentrations (Figure 2, Table 3) were compared using one-way 
ANOVA for time or experiment date. Significant differences were noted across time (df=7, F-
ratio=28.51, p-value<0.0001) and among experiment dates (df=11, F-ratio=4.806, p-
value<0.0001).   
     For time, mean zero hour concentrations of potassium were higher than those for all other 
time points (Figure 2A, Table 3).  One, three and eight hour potassium concentrations were 
lower than those at 24 hours (Figure 2A, Table 3).  For experiment date, mean potassium 
concentrations on 5/1/2003 were lower than those for 10/15/2003 (repetition (rep.) 1 and 2), 
11/10/2003 (rep. 1 and 2) and 11/12/2003 (rep. 1 and 2) (Figure 2B, Table 3).  Mean potassium 
concentrations on 7/3/2003 were lower than those on 10/15/2003 (rep. 2), 11/10/2003 (rep. 2) 
and 11/12/2003 (rep.1 and 2) (Figure 2B, Table 3).   
     Mean ATP concentrations across time and among experiment dates (Figure 3, Table 4) were 
compared using one-way ANOVA.  Across time no significant differences were noted in the 
ATP concentrations (Figure 3A).  Among experiment dates, however, differences were noted 
(df=11, F-ratio=5.561, p-value<0.0001) (Figure 3B).  Mean ATP concentrations for 7/3/2003 
were higher than those of 2/25/2003, 5/1/2003, 10/15/2003 (rep. 1), 11/10/2003 (rep. 2) and 
11/12/2003 (rep. 1) (Figure 3B, Table 4).  Additionally, ATP concentrations on 10/15/2003 (rep. 
1) were lower than those of 10/14/2003 (rep. 1) and 11/12/2003 (rep. 2) (Figure 3B, Table 4). 
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Fig. 2.  Mean potassium concentrations for slices exposed to media with no drug.  Pot
concentrations (mean±SE, µmol/g-L) of slices exposed to media without drug across 2
among experiment dates (B).  Different repetitions on the same date are represented as
Homogeneous groups by Tukey’s test for multiple comparisons (p<0.05) are shown a
dates with the same letter are not significantly different. For time n=12, except hour 0
hour 4 and 6, n=6; hour 24, n=24.  For dates, n=4, except 2/25/2003, n=10; 5/1/2003, 
10/14/2003 (rep.1 and 2) and 10/15/2003 (rep. 1), n=12.  
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 Table 3.  Potassium concentrations (µmol/g-L) for slices exposed to media with no drug.  Means with standard deviations (std dev) represent variability across time, 
among day and between day.  The mean values for time and date are plotted in Fig. 2.   
Time 
(hour) 2/25/2003 5/1/2003 7/3/2003 10/14/2003 10/14/2003 10/15/2003 10/15/2003 10/15/2003       11/10/2003 11/10/2003 11/12/2003 11/12/2003 Mean std dev
0            83623.69 125506.07 122676.58 122605.36 107279.69 97222.22 109890.11 126530.61 150537.63 118221.81 16260.00
               116104.87 123287.67 129870.13 101214.57 116363.64 102739.73 117241.38 139639.64 135658.91
1            QNS 48076.92 56224.90 89494.16 70796.46 61855.67 63517.83 14746.84
             60200.67 60606.06 40293.04 87649.40 63348.42 60150.38
3            45454.55 46931.41 57035.88 12573.83
              69090.91 66666.67
4              82706.77 72072.07 83333.33 82375.89 7427.95
               85470.09 76923.08 93750.00
6 88888.89 53763.44 64516.13          71739.84 14021.01
 85271.32 76595.74 61403.51            
8            68852.46 57692.31 64171.12 68273.09 68085.11 76530.61 66705.17 6885.96
             68840.58 62500.00 54347.83 70038.91 63063.06 78066.91
12           99264.71 54474.71 63218.39 81180.81 80952.38 87155.96 75795.47 13929.12
             72727.27 55319.15 81871.35 75000.00 67010.31 91370.56
24           83720.93 71713.15 76502.73 74380.17 84821.43 102766.80 90909.09 69869.00 92896.17 92682.93 62015.50 61728.40 81216.38 12029.37
             76305.22 74235.81 75000.00 95454.55 77586.21 74074.07 87719.30 81218.27 101604.28 97297.30 82191.78 62500.00
               
Mean 78230.23 60793.56 62595.59            84114.71 81121.02 88466.75 100612.1 93682.65 98615.6 104277.9 102594.4 102606.2
std 
dev 11406.34 10213.05 12040.72            12908.73 21301.69 21576.93 15752.66 21769.68 4494.216 11294.85 36552.27 47150.14
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Fig. 3.  Mean ATP concentrations for slices exposed to media with no drug.  ATP con
(mean±SE , nmol/g) of slices exposed to media without drug across 24 hours (A) or a
dates (B).  Different repetitions on the same date are represented as rep. 1, 2 or 3.  Hom
by Tukey’s test for multiple comparisons (p<0.05) are shown as letters.  Times or date
letter are not significantly different. For time n=12, except hour 0, n=18; hour 3, n=4; 
hour 24, n=24.  For dates, n=4, except 2/25/2003, n=10; 5/1/2003, 7/3/2003, 10/14/20
10/15/2003 (rep. 1), n=12. 
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Table 4.  ATP concentrations (nmol/g) for slices exposed to media with no drug.  Means with standard deviations (std dev) represent variability across 
time, among days and between days.  The mean values for time and date are plotted in Fig. 3. 
Time 
(hour) 2/25/2003 5/1/2003 7/3/2003 10/14/2003 10/14/2003 10/15/2003 10/15/2003 10/15/2003 11/10/2003 11/10/2003 11/12/2003 11/12/2003 Mean std dev
0             0.133563 0.082182 0.145604 0.127799 0.136371 0.209470 0.131331 0.108560 0.005837 0.115053 0.054142
               0.181772 0.094588 0.178024 0.149639 0.128633 0.070663 0.091572 0.091792 0.003558
1 0.261167 0.161748 0.249336 0.388308 0.225251 0.051878       0.209271 0.121163
 0.023148 0.226146 0.237635 0.402588 0.230626 0.053424         
3            0.108910 0.238568 0.190976 0.106252
              0.098044 0.318382
4           0.245519 0.252395 0.081670 0.201385 0.097244
             0.272121 0.283970 0.072635
6 0.180345 0.188467 0.355537          0.244718 0.068725
 0.229858 0.215210 0.298894            
8 0.076692 0.120283 0.343441 0.427561 0.268529 0.101800       0.234136 0.130948
 0.171040 0.137252 0.332160 0.440005 0.280467 0.110401         
12 0.107492 0.137374 0.387272 0.252609 0.319044 0.137500       0.226771 0.109897
 0.122515 0.150300 0.390205 0.250094 0.342187 0.124659         
24           0.103992 0.158579 0.372342 0.131331 0.231777 0.093177 0.147107 0.139069 0.126450 0.120664 0.151701 0.713034 0.191397 0.161758
             0.097525 0.167968 0.348597 0.137486 0.069946 0.111598 0.110923 0.163441 0.143757 0.082875 0.073220 0.596978
               
Mean 0.137378 0.155857 0.322697            0.271913 0.223414 0.105198 0.133867 0.141878 0.137585 0.106610 0.106318 0.329851
std dev 0.072575 0.039596 0.055384            0.116678 0.092082 0.037803 0.018141 0.015040 0.057178 0.023080 0.033522 0.378435
 
 
 
 
 
 
 
 35
     Histologic lesion scores for necrosis, vacuolation extent and vacuolation severity were 
examined by one-way ANOVA across time and among experiment dates (Figures 4-6).  No 
significant group differences were noted among experiment dates for necrosis (Figure 4B, Table 
5), vacuolation extent (Figure 5B, Table 6) and vacuolation severity (Figure 6B, Table 7).  
     Across time, however, significant differences were noted for all lesion score categories.  
Mean necrosis histologic lesion scores (df=5, F-ratio=23.07, p-value<0.0001) at 0 hour were 
lower than those at 8, 12 and 24 hours (Figure 4A, Table 5).  At 1 hour, necrosis scores were 
lower than those at 8 and 24 hours, and scores at 4 and 12 hours were lower than those at 24 
hours (Figure 4A, Table 5).  Mean vacuolation extent histologic scores (df=5, F-ratio=4.956, p-
value=0.0014) at 0 hour were lower than those at 8, 12 and 24 hours (Figure 5A, Table 6).  Mean 
vacuolation severity histologic lesion scores (df=5, F-ratio=8.972, p-value<0.0001) at 0 hour 
were lower than those at 8, 12 and 24 hours (Figure 6A, Table 7).  Scores at 24 hours were 
higher than those at 1 and 4 hours (Figure 6A, Table 7). 
 
Potassium, ATP and Histology Summary 
     Mean potassium concentrations had little variability after an initial decrease after zero hour.  
The differences in mean potassium concentrations among experiments may be related to the 
differing number of samples comprising the mean.  For 5/1/2003 and 7/3/203, twelve samples 
were averaged across twenty-four hours while for 10/15/2003 and 11/12/2003 only four samples 
per date were averaged.  The higher potassium concentrations at 24 hours compared to one, three 
and eight hours may also be related to the number of samples averaged.  Additionally, the 
presence of zero hour potassium values may have increased the mean values as zero hour 
potassium concentrations were higher than those for other times.  
     The average ATP concentrations across time were not statistically different from each other. 
The differences in ATP concentrations across dates may be related to the variability in health of 
the liver samples or inter-dog differences.   
     For all histologic lesion categories, no statistical differences were noted among experiment 
dates.  Across time all lesion score categories had lower mean scores at zero hour compared to 
mean scores at 8, 12 and 24 hours.  Differences in mean histologic lesion scores appear to be an 
effect of length of incubation and may indicate that hepatic slice histology is a more sensitive 
indicator of slice health than either potassium or ATP content.    
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Fig. 4.  Mean necrosis lesion scores for slices exposed to media with no drug.  Necrosis lesion scores (mean±SE) of 
slices exposed to media without drug across 24 hours (A) or among experiment dates (B).  Different repetitions on the 
same date are represented as rep. 1, 2 or 3.  Homogeneous groups by Tukey’s test for multiple comparisons (p<0.05) 
are shown as letters.  Times or dates with the same letter are not significantly different. For time n=5, except hour 0, 
n=12; hour 4, n=4; hour 24, n=13.  For dates, n=6, except 2/25/2003, n=4; 10/15/2003 (rep. 2 and 3), 11/10/2003 (rep. 
1-3) and 11/12/2003 (rep. 1-3), n=2. 
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Table 5.  Necrosis lesion scores for slices exposed to media with no drug.  Necrosis lesion score means with standard 
deviations (std dev) represent variability across time, among days and between days.  The mean values for time and 
date are plotted in Fig. 4. 
Necrosis Lesion Scores 
Time 
(hour) 2/25 10/14 10/14 10/14 10/15 10/15 10/15 11/10 11/10 11/10 11/12 11/12 11/12 Mean
std 
dev
0  0 0 0 0 0 0 0 0 0 0 0 0 0.00 0.00
1 0 0 0 0 0         0.00 0.00
4  1 1 0 1         0.75 0.50
8 1 2 2 1 1         1.40 0.55
12 1 1 1 1 1         1.00 0.00
24 4 2 2 1 2 2 3 2 1 2 3 3 1 2.15 0.90
                
Mean 1.50 1.00 1.00 0.50 0.83 1.00 1.50 1.00 0.50 1.00 1.50 1.50 0.50   
std dev 1.73 0.89 0.89 0.55 0.75 1.41 2.12 1.41 0.71 1.41 2.12 2.12 0.71   
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Fig. 5.  Mean vacuolation extent lesion scores for slices exposed to media with no drug.  Vacuolation extent lesion 
scores (mean±SE) of slices exposed to media without drug across 24 hours (A) or among experiment dates (B).  
Different repetitions on the same date are represented as rep. 1, 2 or 3.  Homogeneous groups by Tukey’s test for 
multiple comparisons (p<0.05) are shown as letters.  Times or dates with the same letter are not significantly different. 
For time n=5, except hour 0, n=12; hour 4, n=4; hour 24, n=13.  For dates, n=6, except 2/25/2003, n=4; 10/15/2003 
(rep. 2 and 3), 11/10/2003 (rep. 1-3) and 11/12/2003 (rep. 1-3), n=2. 
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Table 6.  Vacuolation extent lesion scores for slices exposed to media with no drug.  Vacuolation extent lesion score 
means with standard deviations (std dev) represent variability across time, among days and between days.  The mean 
values for time and date are plotted in Fig. 5. 
Vacuolation Extent Lesion Scores 
Time 
(hour) 2/25 10/14 10/14 10/14 10/15 10/15 10/15 11/10 11/10 11/10 11/12 11/12 11/12 Mean std dev
0  1 1 4 0 0 0 0 2 0 0 0 1 0.75 1.22 
1 3 0 0 4 0         1.40 1.95 
4  2 2 3 2         2.25 0.50 
8 3 3 3 4 3         3.20 0.45 
12 4 4 4 4 1         3.40 1.34 
24 3 4 4 4 2 0 1 1 4 1 4 4 4 2.77 1.54 
                
Mean 3.25 2.33 2.33 3.83 1.33 0.00 0.50 0.50 3.00 0.50 2.00 2.00 2.50   
std dev 0.50 1.63 1.63 0.41 1.21 0.00 0.71 0.71 1.41 0.71 2.83 2.83 2.12   
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Fig. 6.  Mean vacuolation severity lesion scores for slices exposed to media with no drug.  Vacuolation severity lesion 
scores (mean±SE) of slices exposed to media without drug across 24 hours (A) or among experiment dates (B).  
Different repetitions on the same date are represented as rep. 1, 2 or 3.  Homogeneous groups by Tukey’s test for 
multiple comparisons (p<0.05) are shown as letters.  Times or dates with the same letter are not significantly different. 
For time n=5, except hour 0, n=12; hour 4, n=4; hour 24, n=13.  For dates, n=6, except 2/25/2003, n=4; 10/15/2003 
(rep. 2 and 3), 11/10/2003 (rep. 1-3) and 11/12/2003 (rep. 1-3), n=2. 
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Table 7.  Vacuolation severity lesion scores for slices exposed to media with no drug.  Vacuolation severity lesion 
score means with standard deviations (std dev) represent variability across time, among days and between days.  The 
mean values for time and date are plotted in Fig. 6. 
Vacuolation Severity Lesion Scores 
Time 
(hour) 2/25 10/14 10/14 10/14 10/15 10/15 10/15 11/10 11/10 11/10 11/12 11/12 11/12 Mean
std 
dev
0  1 1 2 0 0 0 0 1 0 0 0 1 0.50 0.67
1 3 0 0 2 0         1.00 1.41
4  1 1 1 1         1.00 0.00
8 3 2 2 3 1         2.20 0.84
12 4 4 4 2 1         3.00 1.41
24 3 4 4 4 2 0 2 2 4 2 4 4 3 2.92 1.26
                
Mean 3.25 2.00 2.00 2.33 0.83 0.00 1.00 1.00 2.50 1.00 2.00 2.00 2.00   
std dev 0.50 1.67 1.67 1.03 0.75 0.00 1.41 1.41 2.12 1.41 2.83 2.83 1.41   
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CHAPTER IV 
CANINE HEPATIC SLICE RESPONSE TO  
PHENOBARBITAL, PRIMIDONE AND LIDOCAINE 
 
Phenobarbital 
Media and Supernatant Drug Concentrations 
     Hepatic slices were exposed to phenobarbital to determine the ability of slices to survive in 
the media and incubator conditions and to determine the hepatotoxic potential of phenobarbital 
in the liver slice system.  Phenobarbital media and supernatant concentrations of slices incubated 
in media with no drug were below the limit of quantification.  For media containing drug, the 
concentration of phenobarbital was consistent over 24 hours of incubation (Figure 7).  Media 
concentrations of phenobarbital remained within ten percent of the original concentrations 
during incubation, and no significant changes in media phenobarbital concentrations were seen 
across time.  All prepared media was within ten percent of expected concentrations.  The area 
under the curve (AUC) (hour*µg/ml) of phenobarbital in media was calculated for each 
concentration (Table 8).   
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Fig. 7.  Phenob al medi trations.  Phenobarbital media concentrations (µg/ml±SE, average) during 24 
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Table 8.  AUC of phenobarbital media.  The AUC (hour*µg/ml) of phenobarbital in media following 24 hour hepatic 
slice incubation with media containing 0, 20, 45 or 75 µg/ml phenobarbital. 
 
Phenobarbital Media 
Concentration 
(µg/ml) 
AUC 
(hour*µg/ml) 
0 below LOQ 
20 445.90 
45 989.50 
75 1735.00 
 
 
 
 
 
     Quantifiable concentrations of phenobarbital were noted in the hepatic slice supernatant of 
slices incubated up to 24 hours in media containing 45 and 75 µg/ml phenobarbital (Figure 8).  
No statistically significant changes in hepatic slice supernatant concentrations (µg/ml) across 
time were noted.  The AUC (hour*µg/ml) of phenobarbital in hepatic slice supernatant was 
calculated for each media concentration (Table 9).   
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Fig. 8.  Phenoba  super trations.  Phenobarbital concentrations (µg/ml±SE, average) in hepatic slice 
supernatant during 24 hours of incubation.  No statistically significant differences were noted across time for slices 
incubated in eith r 75 µg/m   Supernatant concentrations are an average of two samples per time point for 
ch phenobarbital concentration. 
 
rbital natant concen
er 45 o l media.
ea
 
 44
Table 9.  AUC of phenobarbital in hepatic slice supernatant.  The AUC (hour*µg/ml) of phenobarbital in hepatic slice 
llowing 24 incubation in media containing 0, 20, 45 and 75 µg/ml phenobarbital.   supernatant fo
Phenobarbital Supernatant 
Concentration 
(µg/ml) 
AUC 
(hour*µg/ml) 
0 below LOQ 
20 below LOQ 
45 32.22 
75 62.35 
 
 
 
Potassium 
     Potassium concentrations were measured in the hepatic slice supernatant to determine the 
viability of the slices during incubation.  Figure 9 shows the concentrations of potassium 
(µmol/g-L) in hepatic slice supernatant following twenty-four hours of incubation with 0, 20, 45 
and 75 µg/ml phenobarbital.     
     Two-way analysis of variance (ANOVA) was performed using time and concentration as 
factors.  The interaction of the factors determined whether the main effects (time and 
concentration) were independent of each other.  The time-concentration interaction (df=15, F-
ratio=1.054, p-value =0.441) was not significant indicating that the factors were independent.  
NOVA groups were based on the means of all samples at each time point (n=8) or the means of 
all times for each concentration (n=12).  The two-way ANOVA results for potassium by time 
han 
t 1 hour.  No other times were significantly different. The two-way ANOVA results for 
oncentration (df=3, F-ratio=3.538, p-value =0.030) revealed that mean potassium values for 75 
g/ml phenobarbital media were significantly lower than for media containing no phenobarbital 
 
A
(Table 10, Figure 10) showed that there were two homogeneous groups (df = 5, F-ratio =4.021, 
p-value=0.009).  Mean potassium concentrations at 6 and 24 hours were significantly higher t
a
c
µ
(Table 11, Figure 11).  The potassium content AUC (hour*µmol/g-L) was also determined for 
each concentration of phenobarbital (Table 12).   
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Fig. 9.  Potassium supernatant levels after incubation of slices with phenobarbital.  Potassium concentrations (µmol/g-
L±SE, average) in hepatic slice supernatant during 24 hours of incubation in media containing phenobarbital at 0, 20, 
5 and 75 µg/ml.  Potassium concentrations are an average of two samples per time point for each concentration. 
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Table 10.  Time analysis of potassium concentrations for slices incubated with phenobarbital.  Means (µmol/g-L) of 
all potassium samples (n=8) at each time point.  Homogeneous groups for potassium two-way ANOVA for time are 
represented as letters.  Times with the same letter are not significantly different.   
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Table 12.  Potassium content AUC for slices incubated with phenobarbital.  The AUC (hour*µmol/g-L) of potassium 
content for slices incubated in media containing 0, 20, 45 and 75 µg/ml phenobarbital.   
 
Concentration 
(µg/ml) 
AUC 
(hour*µmol/g-L) 
0 1.418E+06 
20 1.284E+06 
45 1.310E+06 
75 1.226E+06 
 
 
 
ATP 
  As another measure of hepatic slice viability, ATP concentrations were measured in hepatic 
slice supernatant.  Concentrations of ATP (nmol/g) were measured following incubation in 
media containing varying concentrations of phenobarbital (Figure 12).  The two-way ANOVA 
for ATP content revealed a significant interaction between the factors time and concentration 
(df=15, F-ratio=2.671, p-value =0.015).  The effects of the two factors were not independent.  
ANOVA groups were based on the means of all samples at each time point (n=8) or the means of  
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Fig. 12.  ATP supernatant concentrations of slices incubated with phenobarbital.  ATP concentrations (nmol/g±SE, 
average) in hepatic slice supernatant during 24 hours of incubation in media containing phenobarbital (0, 20, 45, 75 
µg/ml).  ATP concentrations are an average of two samples per time point per media concentration.    
 
 
 
all times for each concentration (n=12).  The two-way ANOVA of ATP content for time (Table 
13, Figure 13) showed that there were three homogeneous groups (df = 5, F-rati 41, p-
Tab aly centrations for slices incubated with phenobarbital.  Means (nmol/g) of all ATP 
sam ch mogeneous groups for ATP two-way ANOVA for time are represented as letters.  
Tim e le cantly different.   
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value=0.000).  Mean ATP concentrations at 1 and 24 hours were significantly higher than at 3 
hours.  Mean ATP values at 6 hours were significantly higher than at 1, 3, 8 and 12 hours.   
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Fig. 13.  A ons f s incubated with phenobarbital.  Means (nmol/g±SE) of 
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The two-way ANO sults for concentration (Table 14, Figure 14) revealed that a significant 
d renc sted g the ps (d F atio=167.701, p-value =0.000).  The mean ATP 
values for 75 µg/m noba  med ere significantly lower than for media containing 0, 
20 or 45 l phenobarbital.  The ATP content AUC (hour*nmol/g) was also determined for 
each concentration eno al (T 15).
 
 
able 14.  Concentration analysis of ATP concentrations for slices incubated with phenobarbital.  Means (nmol/g) of 
l ATP samples (n=12) at all times for each phenobarbital media concentration.  Homogeneous groups for ATP two-
 ANOVA for concentration are represented as letters.  Concentrations with the same letter are not significantly 
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Fig. 14.  ATP analysis among media concentrations of slices incubated with phenobarbital.   Means (nmol/g±SE) of 
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Table 15.  ATP content AUC for slices incubated with phenobarbital.  The AUC (hour*nmol/g) of ATP content for 
slices incubated in media containing 0, 20, 45 and 75 µg/ml phenobarbital.   
Concentration 
(µg/ml) 
AUC 
(hour*nmol/g) 
0 3.47 
20 3.40 
45 3.52 
75 3.47 
 
 
 
Primidone 
Media and Supernatant Drug Concentrations 
     Primidone was applied to the slices to determine their drug-metabolizing ability and to 
determine the hepatotoxic potential of primidone in the liver slice system.  As phenobarbital i
an active metabolite of pri
s 
midone, phenobarbital was measured as an indication of the slices’ 
ability to metabolize primidone in the media to phenobarbital (Yeary, 1980; Schwartz-Porsche et 
al., 1982).  At the applied concentrations of primidone (0, 20, 45 and 75 µg/ml) and incubation 
for up to 24 hours, no quantifiable concentrations of phenobarbital were noted in either the 
media or supernatant.  As shown in Tables 16 and 17, phenobarbital concentrations in the media 
and hepatic slice supernatant were detectable but below the limit of quantification, 1.1 µg/ml. 
 a
a
b
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Table 16.  Primidone metabolism in media.  Phenobarbital concentrations in media of slices incubated in primidone 
media.  The limit of quantification was 1.1 µg/ml.  All values are shown as printed on the automated printout.  Low 
indicates values were below lowest calibrator. 
 
 entration  M Time Conc  of Primidone in edia 
  µ l hour 0 µg/ml 20 g/ml 45 µg/m 75 µg/ml 
0.06 0.2  0.40 5 0.50 1 
0.11 .2 0.30 0 1 0.40   
0.23 .2 0.43 0 8 0.52 3 
0.05 0.24 0.31 0.48   
0.23 0.30 Low Low 6 
0.06 0.24 Low Low   
Low Low Low Low 8 
Low Low Low Low   
Low Low Low Low 12 
Low Low Low Low   
Low 0.22 0.16 0.50 24 
C
on
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nt
ra
tio
n 
of
 P
he
no
ba
rb
ita
l i
n 
M
ed
ia
 (µ
g/
m
l) 
0.08 0.19 0.23 0.36   
 
 
 
Table 17.  Primidone metabolism in supernatant.  Phenobarbital concentrations in hepatic slice supernatant of slices 
incubated in primidone media.  The limit of quantification was 1.1 µg/ml.  All values are shown as printed on the 
automated printout.  Low indicates values were below lowest calibrator. 
 Concentration of Primidone in Media Time 
 0 µg/ml 20 µg/ml 45 µg/ml 75 µg/ml hour 
0.17 0.03 0.05 0.11 1 
0.15 0.1 0.07 0.1   
0.08 0.13 0.1 0.18 3 
0.11 0.16 0.14 0.05   
0.09 0.04 Low 0.06 6 
Low Low 0 0.04   
0.02 0.02 Low Low 8 
Low 0.09 Low 0.02   
0.08 0 0.09 0.06 12 
Low 0.07 0.03 0.01   
Low 0.1 0.02 Low 24 
C
on
ce
nt
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tio
n
(µ
g/
m
l) 
Low Low Low Low   
 o
f P
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l i
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Potassium 
 
    Figure 15 shows the concentrations of potassium in hepatic supernatant across time following 
incubation in primidone.  Two-way ANOVA performed on the data showed that the factors time 
 
 
0
10000
20000
30000
1 3 6 8 12 24
C
on
ce
nt
40000
50000
80000
90000
ra
tio
n 
(µ
m
o 60000
70000
l/g
-L
)
0 µg/ml
20  µg/ml
45  µg/ml
75  µg/ml
Time (hour)
 
Fig. 15.  Potassium supernatant concentrations for slices incubated with primidone.  Potassium concentrations 
(µmo E tic s rnatant during 24 hours of incubation in media containing 0, 20, 45 and 
75 µ mid  co s are an average of two samples per time point per media concentration. 
 
 
 
and concentration were indepe =15, F-ratio=1.443, p-value =0.205).  ANOVA groups 
ere based on the means of all samples at each time point (n=8) or the means of all times for 
ach concentration (n=12).  The two-way ANOVA results for time showed that no means were 
ignificantly different (df = 5, F-ratio =1.371, p-value=0.270).  The two-way ANOVA results for 
concentration (df=3, F-ratio=7.506, p-value =0.001) showed that two homogeneous groups were 
present (Table 18, Figure 16).  The mean potassium values for media containing 20, 45 and 75 
µg/ml primidone were significantly lower than for media without primidone (0 µg/ml).  The 
potassium content AUC (hour*µmol/g-L) was also determined for each concentration of 
primidone (Table 19).     
l/g-L±S
g/ml pri
, average) in hepa
one.  Potassium
lice supe
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ndent (df
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Table 18.  Concentration analysis of potassium concentrations for slices incubated with primidone.  Means (µmol/g-
L) of all potassium samples (n=12) at all times for each primidone concentration.  Homogeneous groups for potassium 
two-way ANOVA for concentration are represented as letters.  Concentrations with the same letter are not 
significantly different. 
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Table 19.  assium t AUC for slices wi  primidone.  The AUC (hour*µmol/g-L) of potassium 
content for es incu e n media contain 5 and 75 µg/ml primidone.   
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Fig. 16.  Potassium analysis among media concentrations for slices incubated with primidone.  Means (µmol/g-L±SE)
of potassium samples for all times (n=12) for each primidone media concentration.  Homogeneous groups for 
potassium two-way ANOVA for concentration are represented as letters.  Concentrations with the same letter a
significant
Pot conten  incubated th
 slic bat d i ing 0, 20, 4
Concentration 
(µg/ml) 
AUC 
(hour*µmol/g-L) 
0 1.560E+06 
20 6.366E+05 
45 5.583E+05 
75 3.831E+05 
Media 
Concentration 
(µg/ml) 
Homogeneous 
groups 
Means 
 (µmol/g-L) 
0 a  62595.59 
20  b 44371.76 
45  b 43093.91 
75  b 35028.63 
a 
b
bb
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ATP 
  Figure 17 depicts the ATP concentrations in hepatic slice supernatant following incubation in  
edia containing primidone (0, 20, 45, 75 µg/ml).  The two-way ANOVA for the interaction of 
e factors were independent of each other.  ANOVA groups were based on the means of all 
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time and concentration was not significant (df=15, F-ratio=1.684, p-value=0.123) indicating that 
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Fig. 17.  ATP supernatant concentrations of slices incubated with primidone.  ATP concentrations (nmol/g±SE, 
average) in hepatic slice supernatant during 24 hours of incubation in media containing primidone (0, 20, 45, 75 
µg/ml).  ATP concentrations are an average of two samples per time point per media concentration. 
 
 
 
samples at each time point (n=8) or the means of all times for each concentration (n=12).  Table 
20 shows the homogeneous groups for the two-way ANOVA of ATP concentrations for time 
(df=5, F-ratio=12.353, p-value=0.000).  The analysis revealed that at 12 hours mean ATP values 
were significantly higher than for 1, 3, 6 and 24 hours and that mean values at 8 hours were more 
than those for 1 hour (Table 20, Figure 18).  For primidone media concentrations, the two-way  
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Table 20.  Time analysis of ATP concentrations for slices incubated with primidone.  Means (nmol/g) of all ATP 
 ANOVA for time are represented as letters.  
 
samples (n=8) at each time point.  Homogeneous groups for ATP two-way
Times with the same letter are not significantly different. 
 
 
 
 
 
 
Time 
(hour) 
Homogeneous 
groups 
Means 
(nmol/g) 
1  a   0.250162 
3  a b  0.284632 
6  a b  0.286840 
8   b c 0.318584 
12    c 0.359611 
24  a b  0.281255 
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Fig. 18.  Analysis across time of ATP concentrations for slices incubated with primidone.  Means (nmol/g±SE) of all 
ATP samples (n=8) at each time point.  Homogeneous groups for ATP
letters.  Times with the same letter are not significantly different. 
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ab 
c
bc
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ANOVA showed that differences in the concentrations existed (df=3, F-ratio=6.330, p-
value=0.003).  Table 21 illustrates that ATP values in media containing no primidone were 
significantly higher than those for 75 µg/ml  media (Figure 19).  The ATP content AUC 
(hour*nmol/g) was also determined for each concentration of primidone (Table 22).     
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Table 21.  Concentration analysis of ATP concentrations for slices incubated with primidone.  Means (nmol/g) of all 
ATP samples (n=12) at all times for each primidone media concentration.  Homogeneous groups for ATP two-way 
ANOVA for concentration are represented as letters.  Concentrations with the same letter are not significantly 
different. 
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Fig. 19.  ATP analysis among media concentrations of slices incubated with primidone.   Means (nmol/g±SE) of ATP 
samples for all times (n=12) for each primidone media concentration.  Homogeneous groups for ATP two-way 
ANOVA for concentration are represented as letters.  Concentrations with the same letter are not significantly 
different. 
 
 
 
Table 22.  ATP content AUC for slices incubated with primidone.  The AUC (hour*nmol/g) of ATP content for slices 
incubated in media containing 0, 20, 45 and 75 µg/ml primidone.   
 
Primidone ATP Content 
Concentration 
(µg/ml) 
AUC 
(hour*nmol/g) 
0 8.04 
20 7.10 
45 7.12 
75 6.53 
Media 
Concentration 
(µg/ml) 
Homogeneous 
groups 
Means 
 (nmol/g) 
0 a  0.322697 
20 a b 0.295795 
45 a b 0.299865 
75  b 0.269032 
a 
b
abab
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Lidocaine 
edia and Supernatant Drug Concentrations 
   As another measure of hepatic slice drug-metabolizing ability, slices were incubated with 
edia containing lidocaine.  Two active metabolites of lidocaine are produced in dogs, 
onoethylglycinexylidide (MEGX) and glycinexylidide (GX) (Wilcke et al., 1983).  Lidocaine 
nd the metabolites, MEGX and GX, were measured over 24 hours incubation.  Figures 20 
rough 22 illustrate the concentrations of lidocaine and MEGX in media.  No quantifiable 
oncentrations of GX were found in the media or hepatic slice supernatant.   
   For media containing 3 µg/ml lidocaine (Figure 20), the concentrations for lidocaine 
ecreased over 24 hours while MEGX concentrations hovered around the lower limit of 
-
ure 20B).   
  Figure 21 shows the concentrations of lidocaine and MEGX in media with a beginning 
oncentration of 10 µg/ml lidocaine.  As with the 3 µg/ml media, the concentration of lidocaine 
creases over time while the concentration of MEGX increases.  One-way ANOVA for 10 
µg/ml media revealed significant differences across time (p-value=0.0003).  The lidocaine 
concentrations at one hour were higher than those at 6, 8, 12 and 24 hours (Figure 21B).  Three 
hour concentrations were higher than 12 and 24 hour concentrations.  Six and eight hour 
lidocaine concentrations were higher than those at 24 hours.  Time differences were also noted 
for the one-way ANOVA of MEGX concentrations (p-value=0.0093).  One hour concentrations 
were lower than those at 6, 8 and 12 hours (Figure 21C). 
M
  
m
m
a
th
c
  
d
quantification (50 ng/ml).  MEGX concentrations were above the LOQ at only 1 and 6 hours.  
Lidocaine concentrations at twelve hours were significantly lower than those at one hour (one
way ANOVA for time, p-value=0.0441) (Fig
  
c
de
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Fig. 20.  Lidocaine (3µg/ml) and MEGX media concentrations.  Lidocaine and MEGX concentrations (ng/ml±SE) in
media following 24 hours of incubation in media containing 3 µg/ml lidocaine (A).  Media concentrations are an 
average of two samples per time point.  Homogenous groups (one-way ANOVA) across time for lidocaine 
concentrations (ng/ml±SE) are represented as letters (B).  Times with the same letter 
 
are not significantly different.  
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media following 24 hours of incubation in media containing 10µg/ml lidocaine (A).  Media concentrations are an 
average of two samples per time point.  Homogenous groups (one-way ANOVA) across time for lidocaine (B) or 
MEGX (C) concentrations (ng/ml±SE) are represented as letters.  Times with the same letter are not significantly 
different.  LOQ for lidocaine and MEGX is 50 ng/ml. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21.  Lidocaine (10 µg/ml) and MEGX media concentrations.  Lidocaine and MEGX concentrations (ng/ml±SE) in 
0.00
2000.00
4000.00
6000.00
8000.00
10000.00
12000.00
tio
n 
(n
g/
m
l
1 3 6 8 12 24
Time (hour)
C
on
ce
nt
ra
)
Lidocaine
0.00
20.00
40.00
60.00
80.00
1 3 6 8 12 24
Time (hour)
C
on
ce
nt
ra
t
100.00
120.00
io
n 
(n
g/
m
l)
MEGX
a 
ab 
bc bc
AB
B B 
AB
B 
B C
cd
d
A
A
 60
Lidocaine (20 µg/ml) - 2 Axes
0
5000
10000
15000
20000
25000
0 5 10 15 20 25
Time (hour)
C
on
ce
nt
ra
tio
n 
(n
g/
m
l)
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
160.00
180.00
Lidocaine
MEGX
 
 
 
 
 
 
 
Fig. 22  a  MEG ce .  Lidocaine and MEGX concentrations (ng/ml±SE) in 
media owin  24 hours of nc  i ai g 20µg/ml lidocaine (A).  Media concentrations are an 
average of two mp  p oint.  H groups (one-way ANOVA) across time for lidocaine (B) or 
MEGX (C) concentrations (ng/m SE) ar d a letters.  Times with the same letter are not significantly 
differe c EGX  
ifferences across time were noted for both lidocaine (p-value=0.0027) and MEGX (p-
alue=0.0039) by one-way ANOVA.  For lidocaine one and three hour concentrations were 
higher than those at 12 and 24 hours (Figure 22B).  For MEGX one hour concentrations were 
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     A similar pattern of lidocaine concentrations decreasing over time while MEGX 
concentrations increased existed for 20 µg/ml lidocaine media (Figure 22).  Significant 
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lower than those at 8 and 12 hours (Figure 22C).  Additionally, eight hour concentrations were 
igher than 3 and 24 hour concentrations.  The AUC (hour*ng/ml) of lidocaine in media was 
calcu ach 0, 3, 10 or 20 µg/ml) (Table 23). 
     Lidocaine concentrations in the hepatic supernatant were not quantifiable at any of the media 
concentrations.  MEGX concentrations in the supernatant were quantifiable for one time point 
for 20 µg/ml med  (1 ho e time point for 10 µg/ml media (3 hour). 
 
able 23.  AUC of lidocaine and MEGX in media.  The AUC (hour*ng/ml) of lidocaine and MEGX in media 
llowing 24 hour hepatic slice incubation in media containing 0, 3, 10 or 20 µg/ml lidocaine. 
 
Lidocaine Media 
h
lated for e  concentration (
ia ur) and on
 
T
fo
Concentration 
(µg/ml) 
Lidocaine AUC 
(hour*ng/ml) 
MEGX AUC 
(hour*ng/ml) 
0 below LOQ below LOQ
3 32947.00 283.98
10 102606.00 1946.10
20 199158.00 2554.80
 
 
Potassium 
     Figure 23 shows the potassium concentrations in hepatic slice supernatant following 24 hours 
incubation with lidocaine  (0, 3, 10, 20 µg/ml).  The two-way ANOVA of the interaction of time 
and concentration showed no significant differences (df=15, F-ratio=0.883, p-value=0.590).   
ANOVA groups were based on the means of all samples at each time point (n=8) or the means of 
all times for each concentration (n=12).  For the analysis of concentration, no significant 
difference was noted (df=3, F-ratio=1.313, p-value=0.294).  The two-way ANOVA for 
potassium values across time showed a significant difference (df=5, F-ratio=2.967, p-
value=0.033).  The homogeneous groups for time are displayed in Table 24.  The mean 
potassium values for 1 hour were significantly lower than those for 24 hours (Figure 24).  The 
potassium content AUC (hour*µmol/g-L) was also determined for each concentration of 
lidocaine (Table 25).     
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Fig. 23. otas   f slices incubated with lidocaine.  Potassium concentrations (µmol/g-
L±SE, e  h c slice s  du ng 24 hours of incubation in media containing 0, 3, 10 and 20 µg/ml 
lidoca ota ium centrat average of two samples per time point per media concentration. 
 
 
 
 
ium h
p
T ly different. 
 
 
 
 
 
Time 
(hour) 
Homogeneous 
groups 
Means 
(µmol/g-L) 
1  a    51006.225 
  P sium supernatant concentrations o
averag ) in
s
epati upernatant ri
ine.  P s  con ions are an 
Table 24.  Time analysis of  potass  concentrations for slices incubated wit  lidocaine.  Means (µmol/g-L) of all 
potassium samples (n=8) at each time point.  Homogeneous grou s for potassium two-way ANOVA for time are 
represented as letters.  imes with the same letter are not significant
 
 
 
3  a b   55351.079 
6  a b   58950.573 
8  a b   60018.558 
12  a b   57257.081 
24   b   65153.067 
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Fig. 24.  Analysis across time of potassium concentrations for slices incubated with lidocaine.  Means (µmol/g-L±S
of all potassium samples (n=8) at each time point.  Homogeneous groups for potassium two-way ANOVA for time are
represented as letters.  Times with the same letter are not significantly different. 
 
E) 
 
able 25.  Potassium content AUC for slices incubated with lidocaine.  The AUC (hour*µmol/g-L) of potassium 
Lidocaine Potassium Content
 
T
content for slices incubated in media containing 0, 3, 10 and 20 µg/ml lidocaine.   
 
Concentration
 
 
-L) (µg/ml)
AUC 
(hour*µmol/g
0 1.418E+06
3 1.364E+06
10 1 06.356E+
20 1 06.326E+
 
 
 
ATP 
     Figure 25 depicts the concentrations of ATP in hepatic slice supernatant following exposure 
to media containing lidocaine.  The two-way ANOVA for supernatant ATP values following 
incubation with lidocaine showed a significant interaction for the time and concentration factors 
(df=15, F-ratio=11.778, p-value=0.000).  For the main effects of time (df=5, F-ratio=13.397, p-
value=0.000) and concentration (df=3, F-ratio=5.672, p-value=0.004), a significant difference  
a 
b 
ababab
ab 
 64
0
0.25
0.2
ol
/g
)
0.15
on
 (n
m 0 µg/ml
3 µg/ml
0.05
0.1
1 3 6 8 12 24
Time (hour)
C
on
ce
nt
ra
ti 10 µg/ml
20 µg/ml
Fig. 25.  ATP supernatant concentrations of slices incubated with lidocaine.  ATP concentrations (nmol/g±SE
average) in hepatic slice supernatant during 24 hours of incubation in media containing 0, 3, 10 and 20 µg/ml 
lidocaine.  ATP concentrations are an average of two samples per time point per media concentration. 
 
 
 
 
 
, 
as noted.  ANOVA groups were based on the means of all samples at each time point (n=8) or 
e means of all times for each concentration (n=12).  Table 26 depicts the homogeneous groups 
for time.  The mean ATP values for 24 hours were significantly higher than those for 1, 6, 8 and 
urs.  Table 27 
t 
able 26.  Time analysis of ATP concentrations for slices incubated with lidocaine.  Means (nmol/g) of all ATP 
mples (n=8) at each time point.  Homogeneous groups for ATP two-way ANOVA for time are represented as letters.  
imes with the same letter are not significantly different.  
 
 
1 a   0.126838 
w
th
12 hours (Figure 26).  Additionally, mean values for 12 hours were significantly higher than for 
 hour, and mean concentrations at 3 hours were higher than those at 1 and 6 ho1
shows the homogeneous groups for concentration.  The mean ATP concentrations for 3 µg/ml 
lidocaine media were lower than those for all other concentrations (Figure 27).  The ATP conten
AUC (hour*nmol/g) was also determined for each concentration of lidocaine (Table 28).   
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 Time 
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groups 
Means 
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3  b c 0.160602 
 32 
8 a b  0.146688 
712 
  
6 a  0.1369
12  b  
 c 
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24 0.181700
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Fig. 26.  Analysis across time of ATP concentrations for slices incubated with lidocaine.  Means (nmol/g±SE) of all 
ATP samples (n=8) at each time point.  Homogeneous groups for ATP two-way ANOVA for time are represented as 
letters.  Times with the same letter are not significantly different. 
 
 
 
Table 27.  Concentration analysis of ATP concentrations for slices incubated with lidocaine.  Means (nmol/g) of all 
ATP samples (n=12) at all times for each lidocaine media concentration.  Homogeneous groups for ATP two-way 
ANOVA for concentration are represented as letters.  Concentrations with the same letter are not significantly 
different.   
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0 a  0.155857 
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Fig. 27.  Analysis among media concentrations of ATP concentrations for slices incubated with lidocaine.   Means 
(nmol/g±SE) of ATP samples for all times (n=12) for each lidocaine media concentration.  Homogeneous groups for 
ATP two-way ANOVA for concentration are represented as letters.  Concentrations with the same letter are not 
significantly different. 
 
 
 
Table 28.  ATP content AUC for slices incubated with lidocaine.  The AUC (hour*nmol/g) of ATP content for slices 
incubated in media containing 0, 3, 10 and 20 µg/ml lidocaine. 
 
Lidocaine ATP Content 
Concentration 
(µg/ml) 
AUC 
(hour*nmol/g) 
0 3.47 
3 3.41 
10 3.68 
20 3.86 
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CHAPTER V 
C NINE H PATIC SLICE RESPONSE TO CARPROFEN, CARPROFEN WITH 
PHENOBARBITAL AND CARPROFEN WITH CIMETIDINE 
 
Carprofen Media and S nt D g Concen ions 
patic slices bated n media con 50 µg/ml carprofen.  
rior to incubation, media concentrations were within ten percent of expected concentrations.  A 
chiral column was used to separate the carprofen enantiomers, but the R or S enantiomer 
designation corresponding to each peak could not be determined.  As such, the peak with the 
shorter retention time was designated peak A, and the one with the longer retention time was 
designated peak B.  Three replications of each experiment were performed using the racemic 
mixture.  For all experiments, the carprofen concentrations in media containing 0 µg/ml 
carprofen were below the lower limit of quantification; the supernatant concentrations of 
carprofen for slices incubated in 0 µg/ml media were also below the lower limit of 
quantification.   
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Fig. 28.  Mean media concentrations of carprofen.  Concentrations (µg/ml±SE, mean) of carprofen enantiomers (A or 
B) in media following incubation for 0, 1, 4, 8, 12 and 24 hours.  Values are means of six (0 and 4 hour) or ei
12 and 24 hour) samples.  Carprofen concentrations of 0 µg/ml media were below the LOQ. 
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     The mean values of carprofen enantiomers (µg/ml) in media (Figure 28) were measured ove
twenty-four hours of incubation.  The area under the curve (AUC) (hour*µg/ml) for each pea
(A or B) was determined.  AUC values for peaks were compared using paired t-tests.  For 10, 
and 100 µg/ml media, no differences were noted between the AUC for peak A or peak B (Tab
29, Figure 29). 
r 
k 
50 
le 
 
/ml) 
Carprofen   Media 
 Carprofen 
(without 0 hour)   Media 
 
Table 29.  AUC of carprofen in media.  Mean AUC (hour*µg/ml, n=3) of carprofen in media (0, 10, 50 or 100 µg
following 24 hour hepatic slice incubation. 
 
Concentration 
(µg/ml) Peak 
AUC 
(hour*µg/ml)
 Concentration 
(µg/ml) Peak 
AUC 
(hour*µg/ml) 
0 A below LOQ 0 A below LOQ 
 B below LOQ  B below LOQ 
10 A 202.43 10 A 197.33 
 B 195.97  B 190.43 
50 A 988.4 A 956.80 0 50 
 B 909  B 879.83 .73
100 1931.6 A 1871.67 A 7 100 
  1764.67  B 1707.00 B 
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ig. 29. AUC of carprofen in media.  The AUC (hour*µg/ml, mean, n=3) of carprofen in media (10, 50 or 100 µg/ml) 
llowing 24 hour hepatic slice incubation. For each media concentration, peaks were compared for significant 
differences. Within each carprofen media concentration, peaks with the same letter are not significantly different. 
l) (Figure 30), 
upernatant concentrations for slices incubated in 0 and 10 µg/ml carprofen were below the 
 
) and 100 
µg/ml media (p-val ; with ut 0 ho =0.00 e 30, Figure 31). 
 
F
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   For the mean carprofen concentrations in hepatic slice supernatant (ng/m  
s
lower limit of quantification.  The carprofen supernatant AUC (hour*ng/ml) of peak B was
igher than that of peak A for 50 (p-value=0.004; without 0 hour p-value=0.0041h
ue=0.0028 o ur p-value 27) (Tabl
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Fig. 30.  Mean supernatant concentrations of carprofen.  Concentrations (ng/ml±SE, mean) of carprofen enantiomers 
(A or B) in hepatic slice supernatant following incubation for 0, 1, 4, 8, 12 and 24 hours.  The values are means of four 
(0 and 4 hour) or  six (1, 8, 12 and 24 hour) samples.  Carprofen supernatant concentrations for slices incubated in 0 
and 10 µg/ml media were below the LOQ. 
 
 
 
 
Table 30.  AUC of carprofen in hepatic slice supernatant.  Mean AUC (hour*ng/ml, n=3) of carprofen in supernatant 
of hepatic slices incubated for 24 hours in carprofen media (0, 10, 50 or 100 µg/ml). 
 
Carprofen   Supernatant 
 
Carprofen 
(without 0 hour)  Supernatant 
Concentration 
(µg/ml) Peak 
AUC 
(hour*ng/ml)
 Concentration 
(µg/ml) Peak 
AUC 
(hour*ng/ml) 
0 A below LOQ  0 A below LOQ
 B below LOQ   B below LOQ
10 A below LOQ  10 A below LOQ
 B below LOQ   B below LOQ
50 A 65307.33  50 A 65252.33
 B 96043.33   B 95928.67
100 A 206537.00  100 A 205801.33
  B 250988.67   B 250131.33
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arprofen media concentration, peaks with the same letter are not 
gnificantly different.  For both media concentrations, Peak B AUC is greater than that of Peak A (p<0.005). 
otassium 
     Potassium concentrations (µmol/g- i natant were used as an 
ind icit n potassium s we ermined for hepatic slices 
exposed to carprofen m er twenty-f rs (F ignificant differences were 
noted across time (df=5, F-ratio=29.751, p-value=0.000) and g media concentrations (df=3, 
F-ratio=2.730, p-value=0.048).  ANOVA groups were based on the means of all samples at each 
me point (n=24 except for 0 and 4 hour where n=16) or the means of all times for each 
oncentration (n=32).  For time, mean potassium concentrations at 0 hour were higher than those 
t all other time points.  The mean potassium concentrations at 1 hour were lower than those at 4 
he media concentrations, potassium concentrations for 0 µg/ml media 
).  
 (Table 33).   
a
 
Fig. 31.  AUC of carprofen in supernatant.  The AUC (hour*ng/ml, mean, n=3) of carprofen in supernatant of hepatic 
slices incubated in carprofen media (50 or 100 µg/ml) for 24 hours.  For each media concentration, peaks were 
compared for significant differences. Within each c
si
 
 
 
Carprofen P
L) in the hepat c slice super
ication of tox y; mea concentration re det
edia ov ou our h igure 32).  S
amon
ti
c
a
and 24 hours.  Among t
were higher than those for 50 µg/ml media.  There were three homogeneous groups for time 
(Table 31, Figure 33) and two homogeneous groups for concentration (Table 32, Figure 34
The potassium content AUC (hour*µmol/g-L) was also determined for each concentration of 
carprofen
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Fig. um conc ation  s s ubated with carprofen.  Potassium concentrations (µmol/g-L±SE, 
mean  slice supernatant ri f in ba edi ont ing 0, 10, 50 and 100 µg/ml 
carprofen sium concentrations are a mean o  an our) or six (1, 8, 12 and 24 hour) samples per time 
point oncentration. 
 
 
 
Tabl  analysi centrat s for slic  in ate it rprofen.  Comparison of mean 
potas ntration ol/g  o ll as  s ples (n=24 except fo  and 4 hour where n=16) at each 
time poin  all carprofen concentrations.  Homogeneous groups for potassium two-way ANOVA for time are 
repr tters.  Ti s with e e ter e not sig cant  di nt
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Fig. 33.  Analysis across time of potassium levels after treatment of slices with carprofen.  Comparison of mean 
potassium concentrations (µmol/g-L±SE) of all potassium samples (n=24 except for 0 and 4 hour where n=16) at each 
time point for all carprofen concentrations.  Homogeneous groups for potassium two-way ANOVA for time are 
represented as letters.  Times with the same letter are not significantly different. 
able 32.  Concentration analysis of potassium levels after treatment of slices with carprofen.  Comparison of mean 
otassium concentrations (µmol/g-L, n=32) at all times for each carprofen media concentration.  Homogeneous groups 
o-way ANOVA for concentration are represented as letters.  Concentrations with the same letter are 
not significantly different. 
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Concentration 
(µg/ml) 
Homogeneous 
groups 
Means 
(µmol/g-L) 
0 a    82496.8218 
10 a b   76914.2584 
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Fig. 34.  Analysis among media concentrations of potassium levels after treatment of slices with carprofen.  
Comparison of mean potassium concentrations (µmol/g-L±SE, n=32) at all times for each carprofen media 
concentration.  Homogeneous groups for potassium two-way ANOVA for concentration are represented as letters.  
Concentrations with the same letter are not significantly different. 
 
Carprofen Potassium Content 
 
Carprofen 
(without 0 hour) 
Potassium 
Content 
 
Table 33.  Potassium content AUC for slices incubated with carprofen.  Mean AUC (hour*µmol/g-L, n=3) of 
otassium content for slices incubated in media containing 0, 10, 50 and 100 µg/ml carprofen.    p
 
Concentration 
(µg/ml) 
AUC 
(hour*µmol/g-L) 
 Concentration 
(µg/ml) 
AUC 
(hour*µmol/g-L)
0 1.881E+06 0 1.788E+06
10 1.779E+06 10 1.699E+06
50 1.644E+06 50 1.560E+06
100 1.714E+06 100 1.630E+06
 
 
 
Carprofen ATP 
     ATP was used as another measure of slice viability.  The mean ATP supernatant 
concentrations (nmol/g) for slices exposed to carprofen media were determined over twenty
hours of incubation (Figure 35).  Significant differences across time were noted in the two-wa
ANOVA of time and carprofen concentration.  ANOVA groups were based on the m
-four 
y 
eans of all 
amples at each time point (n=24 except for 0 and 4 hour where n=16) or the means of all times 
r each concentration (n=32).  For time (df=5, F-ratio=20.682, p-value=0.000), mean ATP 
s
fo
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concentrations at 0 hour were less than those at 1, 4, 8, and 12 hours.  ATP concentrations at 4
and 8 hours were higher than those at 12 and 24 hours.  Twenty-four hour concentrations were 
 
less than those at 1and 12 hours.  There were three homogeneous groups for time (Table 34, 
Figure 36).  T ent *nmol/g) was also determined for each concentration 
of carprofen (Table 35). 
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Fig.  af fe   ATP concentrations (nmol/g±SE, mean) in hepatic slice 
superna g 24 hou bation in  0, 10, 50 and 100 µg/ml carprofen.  ATP concentrations 
are a mean ur (0 a  r) r six (1, 8  24 hour) samples per time point for each concentration. 
 
 
able 34.  Time analysis of ATP concentrations for slices incubated with carprofen.  Comparison of mean ATP 
concentrations (nmol/g) of all ATP samples (n=24 except for 0 and 4 hour where n=16) at each time point for all 
carprofen concentrations.  Homogeneous groups for ATP two-way ANOVA for time are represented as letters.  Times 
with the same letter are not significantly different. 
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Fig. 36.  Analysis across time of ATP levels after treatment of slices with carprofen.  Comparison of mean ATP 
concentrations (nmol/g±SE) of all ATP samples (n=24 except for 0 and 4 hour where n=16) at each time point for all 
carprofen concentrations.  Homogeneous groups for ATP two-way ANOVA for time are represented as letters.  
ith the same letter are not significantly different. 
Times 
Carprofen ATP Content (without 0 hour) ATP Content
w
 
 
 
Table 35.  ATP content AUC for slices incubated with carprofen.  Mean AUC (hour*nmol/g, n=3) of ATP content for 
slices incubated in media containing 0, 10, 50 and 100 µg/ml carprofen.    
 
 
Carprofen 
Concentration C ncentration 
(µg/ml) 
AUC 
(hour*nmol/g)(µg/ml) 
AU
(hour*nmol/g) 
 Co
0 5.23 0 5.05
10 5.38 10 5.22
50 4.41 50 4.25
100 4.33 100 4.16
 
Carprofen Histology 
igure 37), vacuolation extent (Figure 38) and vacuolation severity (Figure 39) on a scale from 
 to 5.   
 
 
 
     Hepatic slices were examined for extent of necrosis and extent and severity of vacuolation as 
indicators of toxicity (Table 36).  Slices exposed to carprofen were evaluated for necrosis 
(F
0
 
 77
Table 36.  Hepatic slice lesion scores for slices incubated with
carprofen for up to twenty-four hours.   
 carprofen.  Lesion scores of hepatic slices incubated in 
    Lesion scores*
Media 
Concentration 
Time 
(hour) 
Necrosis 
: extent 
Vacuolation 
: extent 
Vacuolation 
: severity 
           
0 µg/ml 0  0 0  1 4  1 2 
0 µg/ml 1 0 0 0 3 0 4 3 0 2 
0 µg/ml 4  1 0  2 3  1 1 
0 µg/ml 6 1   3   3   
0 µg/ml 8 1 2 1 3 3 4 3 2 3 
0 µg/ml 12 1 1 1 4 4 4 4 4 2 
0 µg/ml 24 4 2 1 3 4 4 3 4 4 
           
10 µg/ml 0  0 0  2 2  2 2 
10 µg/ml 1 0 1 0 3 1 1 3 1 1 
10 µg/ml 4  4 1  2 1  1 1 
10 µg/ml 6 2   3   3   
10 µg/ml 8 2 2 1 3 3 3 3 2 2 
10 µg/ml 12 3 2 2 3 2 3 3 1 3 
10 µg/ml 24 3 3 3 4 4 4 4 4 4 
           
50 µg/ml 0  0 0  4 4  2 2 
50 µg/ml 1 0 0 0 4 3 4 3 2 2 
50 µg/ml 4  0 0  3 3  1 1 
50 µg/ml 6 2   4   3   
50 µg/ml 8 2 2 1 3 3 3 2 2 2 
50 µg/ml 12 3a 1 2a 3a 4 3a 2a 3 2a
50 µg/ml 24 2 2 1 3 3 4 3 2 4 
           
100 µg/ml 0  0 0  4 3  2 2 
100 µg/ml 1 0 0 0 4 3 3 3 2 2 
100 µg/ml 4  0 0  3 3  1 1 
100 µg/ml 6 2   4   4   
100 µg/ml 8 2 2a 3 2 3a 3 1 2a 2 
100 µg/ml 12 4a 1 2a 2a 3 4a 2a 2 2a
100 µg/ml 24 2 3a 2a 1 4a 1a 2 3a 1a
* Lesion scoring: (outermost zone ~10 hepatocytes wide was disregarded) 
 0 < 1% hepatocytes affected 3 21-40% 
1 1-10% 4 41-90% 
 2 11-20% 5 >90% 
a Slides showing marked difference in lesion extent and/or severity as move across the slide 
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Fig. 37.  Necrosis hepatic slice lesion score for slices incubated with carprofen.  Necrosis lesion scores (±SE) for 
average of slices incubated for up to 24 hours in 0, 10, 50 or 100 µg/ml carprofen media.  Scores are one (6 hour), an 
two (0 and 4 hour) or a mean of three (1, 8, 12 and 24 hours) samples per time point. 
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Fig. 38.  Vacuolation extent hepatic slice lesion score for slices incubated with carprofen.  Vacuolation extent lesion 
scores (±SE) for slices incubated for up to 24 hours in 0, 10, 50 or 100 µg/ml carprofen media.  Scores are one (6 
hour), an average of two (0 and 4 hour) or a mean of three (1, 8, 12 and 24 hours) samples per time point. 
 79
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 1 4 6 8 12 24
Time (hour)
Va
cu
ol
at
io
n 
Se
ve
rit
y 
Le
si
on
 S
co
re
0 µg/ml
10 µg/ml
50 µg/ml
100 µg/ml
 
Fig. 39.  Vacuolation severity hepatic slice lesion score for slices incubated with carprofen.  Vacuolation severity 
lesion scores for slices incubated for up to 24 hours in 0, 10, 50 or 100 µg/ml carprofen media.  Scores are one (6 
hour), an average of two (0 and 4 hour) or a mean of three (1, 8, 12 and 24 hours) samples per time point. 
 
 
 
     When the lesion scores for carprofen media were analyzed for time and concentration in a 
two-way ANOVA for necrosis, vacuolation extent or vacuolation severity, some significant 
differences were noted.  ANOVA groups were based on the means of all samples at each time 
point (n=12 except for 0 and 4 hour whe  n=8) o f all times for each concentration 
(n= ro , tw OVA reveale cha e ac df=5, F-
rat v 0.0 ecrosis ores a 12 
and 24 (Table 37, Fi  Vacuolation ext owed a significant difference 
across media concentrations (df=3, F-ratio=2.904, p-va e=0.046) ean scores 0 µg/ml 
media w  higher an those f  µg/ml media (Tab  38, Figur 1).  Two-w NOVA of 
vacuolation severi ss time (df=5, F-ratio .216, p .000) 
(Table 39, Figure 42); me  at 0 8 hours.  
V uolation sever urs were lower th n those at nd 12
re r the means o
16).  For nec sis o-way AN d a significant ng ross time (
io=28.801, p- alue= 00).  N  sc t 0, 1 and 4 hours were less than those at 8, 
hours gure 40). ent scores sh
lu ; m  for 5
ere  th or 10 le e 4 ay A
ty denoted differences acro =9 -value=0
an scores at 24 hours were higher than those , 1, 4 and 
ac ity scores at four ho a  8 a  hours.   
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Table 37.  Time analysis of mean necrosis lesion scores for slices incubated with carprofen.  Comparison of mean 
 
 
 
 
necrosis lesion scores (n=12 except for 0 and 4 hour where n=8) across time for slices incubated in all concentrations 
of carprofen.  Homogeneous groups for necrosis two-way ANOVA for time are represented as letters.  Times with the 
same letter are not significantly different.   
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Fig. 40.  Time analysis for mean necrosis lesion scores for slices incubated with carprofen.  Comparison of mean 
necrosis lesion scores (±SE, n=12 except for 0 and 4 hour where n=8) across time for slices incubated in all 
concentrations of carprofen.  Homogeneous groups for necrosis two-way ANOVA for time are represented as letters.  
Times with the same letter are not significantly different.   
 
 
 
Table 38.  Concentration analysis of mean vacuolation extent lesion scores for slices incubated with carprofen.  
Comparison of mean vacuolation extent lesion scores (n=16) among carprofen concentrations for all time points.  
Homogeneous groups for vacuolation extent two-way ANOVA for concentration are represented as letters.  
Concentrations with the same letter are not significantly different.   
 
groups Score 
0 a   0.00 
Time 
(hour) 
Homogeneous  Mean Lesion 
1 a   0.08 
4 a   0.75 
8  b  1.75 
b  1.92 
 b  2.33 
12  
24 
 
 
 
Concentration 
(µg/ml) 
Homogeneous 
 groups 
Mean Lesion 
Score 
0 a b   3.125 
10 a    2.563 
50  b   3.375 
100 a b   2.875 
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Fig. 41.  Concentration analysis for mean vacuolation extent lesion scores for slices incubated with carprofen.  
omparison of mean vacuolation extent lesion scores (±SE, n=16) among carprofen concentrations for all time points.  
 extent two-way ANOVA for concentration are represented as letters.  
Concentrations with the same letter are not significantly different. 
.  Time analysis of mean vacuolation severity lesion scores for slices incubated with carprofen.  Comparison 
f mean vacuolation severity lesion scores (n=12 except for 0 and 4 hour where n=8) across time for slices incubated 
 all concentrations of carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for time are 
presented as letters.  Times with the same letter are not significantly different.  
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Time 
(hour) 
Homogeneous  
groups 
Mean 
Lesion 
Score 
1 a 
4 a 
8  
b 2.00 
 1.00 
b 2.17 
b 2.50 
 3.17 
  
 
 
12  c 
24  c 
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Fig. 42.  Time analysis of mean vacuolation severity lesion scores for slices incubated with carprofen.  Comparison of 
mean vacuolation severity lesion scores (±SE, n=12 except for 0 and 4 hour where n=8) across time for slices 
incubated in all concentrations of carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for 
time are represented as letters.  Times with the same letter are not significantly different.  
 
 
 
Carprofen and Phenobarbital Incubation 
Media and Supernatant Drug Concentrations 
     Hepatic slices were incubated for 24 hours in media containing phenobarbital (75 µg/ml) 
followed by incubation with carprofen.  Media concentrations for 0 µg/ml carprofen media were 
below the lower limit of quantification.  Supernatant concentrations measured for carprofen were 
etermined; for 0, 10, 50 and 100 µg/ml media, 0 and 24 hour concentrations were below the 
wer limit of quantification (Figure 43).  For 10 µg/ml media, the AUC (hour*µg/ml) for peak 
or either 50 or 100 µg/ml media (Figure 
44).   
 
below the lower limit of quantification for 0 and 10 µg/ml media.   
     The mean carprofen media concentrations (µg/ml), post-phenobarbital incubation were 
d
lo
B was higher than that of peak A (p-value=0.0057; without 0 hour p-value>0.05) (Table 40, 
Figure 44).  No differences were noted between peaks f
 83
-20
0
20
100
0 24 25 28 32 36 48
T
C
on
ce
n
0 µg/ml - Peak A
0 µg/ml - Peak B
10 µg/ml - Peak A
40
60
80
tr
at
io
n 
(µ
g/
m
l)
10 µg/ml - Peak B
50 µg/ml - Peak A
50 µg/ml - Peak B
100 µg/ml - Peak A
100 µg/ml - Peak B
ime (hour)
 
Fig. 43.  Mean carprofen edia co en tions following incubatio enobarbital and carprofen.  Mean 
conce µg/ml±SE) of carp en antiomers (A  B) media af  in  for 24 hours with 
phenobarbital (75µg/ml) owed th  a tio l in at  in n f , 4, 8, 12 and 24 hours.  Values are 
means of nine samples pe edia c nce ation pe time oin  Carprofen oncentrations of 0 µg/ml media were 
be
 
 
 
Table  of carp  in media following n with phenobarbital and carprofen.  Mean AUC 
(hour*µg/ml, n=3) of carprofen in ed 0 , r 1  µg/ml) slic  incubated for 24 hours in phenobarbital 
(75µg/ml) followed by an additional 24 ou n carprofen. 
  
Carprofen and 
phenobarbital   M a 
 rp n  
en rbi
 hour) 
  Media 
m nc tra n with ph
ntration ( rof  en or  in ter cubation
 foll  wi  an ddi na cub ion  carprofe or 1
r m o ntr r  p t.  c
low the LOQ. 
 40.  AUC rofen  incubatio
 m ia ( , 10 50 o 00 for es
 h r incubation i
edi
Ca rofe and
ph oba tal 
(without 0
C on Peak AUC hour /m
 Concentration 
(µg/ml) eak 
AUC oncentrati
(µg/ml)  ( *µg l) P (hour*µg/ml) 
0 A A 11.56 23.12 0 
 B B 33.24 66.48  
10 A 9  A 178.20 18 .77 10
 B 08 B 175.37 2 .60  
50 A A 843.07 854.67 50 
 B 4 B 811.37 84 .60  
100 A 0  A 1678.00 169 .00 100
  B 1662.00 B 1629.00 
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Fig. 44.  AUC of carprofen in media following incubation with phenobarbital and carprofen.  Mean AUC 
(hour*µg/ml, n=3) of carprofen in media (10, 50 or 100 µg/ml) for slices incubated for 24 hours in phenobarbital 
(75µg/ml) followed by an additional 24 hour incubation in carprofen.  For each media concentration, peaks were 
compared for significant differences. Within each carprofen media concentration, peaks with the same letter are not 
significantly different.  For 10 µg/ml media, no statistical difference was noted (a1*) when 0 hour carprofen 
concentrations were excluded. 
 
 
 
ean carprofen supernatant concentrations (ng/ml) following phenobarbital incubation 
ion (Figure 45).  The AUC (hour*ng/ml) of carprofen supernatant for peak B was 
higher than the AUC of peak A for both 50 µg/ml (p-value=0.0066; without 0 hour p-
value=0.0069) and 100 µg/ml media (p-value=0.0078; without 0 hour p-value=0.0078) (Table 
     The m
were determined, and mean concentrations at 0 and 24 hours were below lower limit of 
quantificat
41, Figure 46). 
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Fig. 45.  Mean hepatic slice supernatant concentrations of carprofen following incubation with phenobarbital and 
carprofen.  Mean concentrations (ng/ml±SE) of carprofen enantiomers (A or B) in hepatic slice supernatant after 
incubation for 24 hours with phenobarbital (75 µg/ml) followed with an additional incubation in carprofen for 1, 4, 8, 
12 and 24 hours.  The values are an average of six samples per media concentration per time point.  Carprofen 
supernatant concentrations for slices incubated in 0 and 10 µg/ml media were below the LOQ. 
 
 
 
 
Table 41.  AUC of carprofen in hepatic slice supernatant following incubation with phenobarbital and carprofen.  
Mean AUC (hour*ng/ml, n=3) of carprofen in supernatant of hepatic slices incubated for 24 hours in phenobarbital 
(75µg/ml) followed by an additional 24 hour incubation in carprofen media (0, 10, 50 and 100 µg/ml). 
 
Carprofen and 
phenobarbital   Supernatant 
 Carprofen and 
phenobarbital 
(without 0 hour) 
 Supernatant 
Concentration 
(µg/ml) Peak 
AUC 
(hour*ng/ml)
 Concentration 
(µg/ml) Peak 
AUC 
(hour*ng/ml) 
0 A 0.00 0 A 0.00
 B 0.00  B 0.00
10 A 0.00 10 A 0.00
 B 0.00  B 0.00
50 A 57822.00 50 A 57881.67
 B 82576.33  B 82577.67
100 A 166514.67 100 A 166518.67
  B 205865.00  B 205865.00
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ig. 46.  AUC of carprofen in hepatic slice supernatant following incubation with phenobarbital and carprofen.  Mean 
 of carprofen in supernatant of hepatic slices incubated for 24 hours in phenobarbital 
(75µg/ml) followed by an additional 24 hour incubation in carprofen media (50 and 100 µg/ml). For each media 
concentration, peaks were compared for significant differences. Within each carprofen media concentration, peaks 
with the same letter are not significantly different.  For both media concentrations, Peak B AUC is greater than that of 
Peak A (p<0.01). 
 
 
 
Potassium 
     The mean potassium concentrations (µmol/g-L) for slices incubated in phenobarbital 
followed by carprofen are displayed in Figure 47.  Two-way ANOVA showed a significant 
difference across time (df=6, F-ratio=30.046, p-value=0.000).  ANOVA groups were based on 
the means of all samples at each time point (n=24) or the means of all times for each 
r 
oncentration of carprofen (Table 43). 
a
F
AUC (hour*ng/ml, n=3)
concentration (n=42).  Potassium concentrations at 0 hour were higher than those at all othe
time points, and 24 hour concentrations were higher than 48 hour concentrations (Table 42, 
Figure 48).  The potassium content AUC (hour*µmol/g-L) was also determined for each 
c
 
 87
0
20000
40000
60000
80000
100000
120000
140000
C
on
ce
nt
ra
tio
n 
(µ
m
ol
/g
-L
)
0 µg/ml
10 µg/ml
50 µg/ml
0 24 25 28 32 36 48
Time (hour)
100 µg/ml
/ml).  Potassium 
ncentrations are a mean of six samples per time point for each concentration. 
 
as 
 
 
 
 
 
rou  
M
(µmol/g-
118678.73 
 
Fig. 47.  Potassium concentrations of slices after incubation with carprofen and phenobarbital.  Potassium 
concentrations (µmol/g-L±SE, mean) in hepatic slice supernatant during 24 hours of incubation phenobarbital 
(75µg/ml) followed by an additional 24 hour incubation in carprofen (0, 10, 50 and 100 µg
co
 
 
Table 42.  Time analysis of potassium concentrations for slices incubated with carprofen and phenobarbital.  
Comparison of mean potassium concentrations (µmol/g-L) of all potassium samples (n=24) at each time point for all 
carprofen concentrations.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additional 24 
hour incubation in carprofen.  Homogeneous groups for potassium two-way ANOVA for time are represented 
letters.  Times with the same letter are not significantly different.  
 eans 
L
Time 
(hour) 
Homogeneous  
g ps ) 
0 a    
24  b   92757.17 
 84466.99 
85598.34 
89251.99 
85623.27 
  c  80661.32 
25 b c  
28  b c  
32  
 
b c  
 36 
48 
b c 
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Fig. 48.  Time analysis of potassium concentrations for slices incubated with carprofen and phenobarbital.  
Comparison of mean potassium concentrations (µmol/g-L±SE) of all potassium samples (n=24) at each time point for 
all carprofen concentrations.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additional 
24 hour incubation in carprofen.  Homogeneous groups for potassium two-way ANOVA for time are represent
letters.  Times with the same letter are not significantly different. 
ed as 
Table 43.  Potassium content AUC for slices incubated with carprofen and phenobarbital.  Mean AUC (hour*µmol/g-
L, n=3) of potassium content for slices incubated for 24 hours in phenobarbital (75 µg/ml) followed by an additional 
24 hour incubation in media containing 0, 10, 50 and 100 µg/ml carprofen.  
 
Carprofen and 
phenobarbital 
Potassium 
Content 
 Carprofen and 
phenobarbital 
(without 0 hour)
Potassium 
Content 
 
 
Concentration 
(µg/ml) 
AUC 
(hour*µmol/g-L) 
 Concentration AUC 
0 4.627E+06 0 2.192E+06
10 4.494E+06 10 2.059E+06
50 4.414E+06 50 1.980E+06
100 4.375E+06 100 1.940E+06
 
 
 
ATP 
     Figure 49 illustrates the mean ATP concentrations (nmol/g) for slices incubated in 
phenobarbital followed by carprofen incubation.  Two-way ANOVA indicated that a significant 
time-concentration (factor) interaction (df=18, F-ratio=1.761, p-value=0.039) and a significant 
time-related difference (df=6, F-ratio=3.243, p-value=0.006) in mean ATP concentrations.  
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ANOVA groups were based on the means of all samples at each time point (n=24) or the means 
of all times for each concentration (n=42).  When compared across time, ATP concentration
25 hours were higher than those at 32 hours.  With the disorderly factor int
s at 
eraction, the time 
effe fi t co tent AUC (hour*nmol/g) was also determined 
for each concentration of c
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Table 44.  ATP content AUC for lices incubated with carprofen and phenobarbital.  Mean AUC (hour*nmol/g, n=3) 
of ATP content for slices cubated for 24 ho  phenob ital (75 µg/ml) followed by an additional 24 hour 
incubation in media containing 0, 10, 50 and 100 µg/ml carprofen. 
 
Carprofen and 
phenobarbital ATP Content 
 Carprofen and 
phenobarbital 
(without 0 hour)
ATP Content
 
Fig. 49.  ATP concentrations for slices incubated with carprofen and phenobarbital.  ATP concentrations (nmol/
mean) in hepatic slice supernatant during 24 hours of incubation phenobarbital (75µ
a
ch con
 µg/ml). 
ntration. 
 s
 in urs in arb
Concentration 
(µg/ml) 
AUC 
(hour*nmol/g) 
 Concentration 
(µg/ml) 
AUC 
(hour*nmol/g)
0 4.03 0 1.43
10 3.63 10 1.55
50 3.80 50 1.72
100 4.18 100 2.10
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Histology 
         Slices incubated in phenobarbital followed by incubation with carprofen were evaluated for 
the extent of necrosis (Table 45, Figure 50), extent of vacuolation (Table 45, Figure 51) and 
severity of vacuolation (Table 45, Figure 52).  Two-way ANOVA was performed on mean lesion 
scores for necrosis, vacuolation extent and vacuolation severity for slices.  Significant 
 
 
 
Table 45.  Hepatic slice lesion scores for slices incubated with carprofen and phenobarbital.  Lesion scores of hepatic 
slices incubated in phenobarbital for 24 hours followed with incubation with carprofen for and additional 1, 4, 8, 12 
and 24 hours. 
 
    Lesion scores*
Media 
Concentration 
Time 
(hour) 
Necrosis 
: extent 
Vacuolation 
: extent 
Vacuolation 
: severity 
           
0 µg/ml 0 0 0 0 0 2 0 0 1 0 
0 µg/ml 24 2 1 2 1 4 1 2 4 2 
           
phenobarbital 0 0 0 0 0 1 0 0 1 0 
phenobarbital 24 1 2 1 2 4 2 3 4 3 
           
0 µg/ml 25 2 2 2 4 4 4 4 4 4 
0 µg/ml 28 1 2 1 4 4 4 3 3 3 
0 µg/ml 32 2 2 2 3 4 3 3 4 3 
0 µg/ml 36 2 1 2 4 4 4 3 3 3 
0 µg/ml 48 1 1 1 3 4b b  3 3b 3 3 
           
10 µg/ml 25 1 1 1 4 4 4 3 3 3 
10 µg/ml 28 2a 2 n/a 4a 4 n/a 3a 4 n/a 
10 µg/ml 32 2 2 1 4 4 4 3 3 4 
10 µg/ml 36 2 2a 2a 4 4a 4a 4 3a 3a
10 µg/ml 48 3 3a 2 2 4a 4 2 4a 3 
           
50 µg/ml 25 1 2 1 4 4 3 4 4 3 
50 µg/ml 28 2 1 2 2 4 3 2 4 3 
50 µg/ml 32 1 1 2 2 2 2 2 2 2 
50 µg/ml 36 3 1 2 4 3 4 3 2 3 
50 µg/ml 48 3a 2a 2a 2a 4a 4a 2a 3a 4a
           
100 µg/ml 25 2 2 1 4 2 4 4 2 4 
100 µg/ml 28 2a 2 2 1a 2 3 1a 2 2 
100 µg/ml 32 1 2a 3 1 3a 2 1 2a 2 
100 µg/ml 36 a a a2 3 2 1 3 2 1 2 1 
100 µg/ml 48 2 3 1 0 2 4 0 1 3 
* Lesion scoring: (outermost zone ~10 hepatocytes wide was disregarded) 
 0 < 1% hepatocytes affected 3 21-40% 
1 1-10% 4 41-90% 
 2 11-20% 5 >90% 
 Slides showing marked difference in lesion extent and/or severity as move across the slide 
Surface contamination with yeasts 
n/a No slide 
a 
b   
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Fig. 50.  Mean necrosis hepatic slice lesion scores for slices incubated with carprofen and phenobarbital.  Mean 
necrosis lesion scores (±SE) for slices incubated for 24 hours in phenobarbital (75µg/ml) followed with an additional 
24 hour incubation in carprofen (0, 10, 50 or 100 µg/ml).  Scores are means of three samples per time point. 
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Fig. 51.  Mean vacuolation extent hepatic slice lesion scores for slices incubated with carprofen and phenobarbital.  
Mean vacuolation extent lesion scores (±SE) for slices incubated for 24 hours in phenobarbital (75µg/ml) followed 
with an additional 24 hour incubation in carprofen (0, 10, 50 or 100 µg/ml).  Scores are means of three samples per 
time point.  
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ig. 52.  Mean vacuolation severity hepatic slice lesion scores for slices incubated with carprofen and phenobarbital.  
ean vacuolation severity lesion scores (±SE) for slices incubated for 24 hours in phenobarbital (75µg/ml) followed 
 additional 24 hour incubation in carprofen (0, 10, 50 or 100 µg/ml).  Scores are means of three samples per 
time point. 
 
 
 
differences were seen across time for necrosis (df=6, F-ratio=20.735, p-value=0.000), across 
time (df=6, F-ratio=20.853, p-value=0.000) and among concentrations (df=3, F-ratio=7.703, p-
value=0.000) for vacuolation extent and among concentrations (df=3, F-ratio=10.171, p-
value=0.000) and across time (df=6, F-ratio=29.098, p-value=0.000) for vacuolation severity.  
For necrosis, mean lesion scores at time 0 were lower than at all other time points (Table 46, 
Figure 53).  Twenty-four hour lesion scores were lower than those at 36 and 48 hours.  With 
vacuolation extent, lesion scores were lower for slices incubated in 100 µg/ml media than for 0 
and 10 µg/ml media (Table 47, Figure 54).  Across time, lesion scores for vacuolation extent 
were lower at time 0 than for all other time points (Table 48, Figure 55).  Twenty-four hour 
lesion scores were lower than 25 hour scores.   For vacuolation severity, lesion scores at  0 hour 
e 
0, Figure 57).   
F
M
with an
were lower than at all other time points, and 25 hour lesion scores were higher than those at 32, 
36 and 48 hours (Table 49, Figure 56).  Additionally, for vacuolation severity, mean lesion 
scores for slices incubated in 100 µg/ml media were lower than all other concentrations (Tabl
5
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Table 46.  Time analysis of mean necrosis lesion scores for slices incubated with carprofen and phenobarbital.  
Comparison of necrosis lesion scores (n=12) across time for slices incubated in all concentrations of carprofen.  Slices 
were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additional 24 hour incubation in carprofen.  
Homogeneous groups for necrosis two-way ANOVA for time are represented as letters.  Times with the same letter 
are not significantly different.   
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Fig. 53.  Time analysis for mean necrosis lesion scores for slices incubated with carprofen and phenobarbital.  
Comparison of mean necrosis lesion scores (±SE, n=12) across time for slices incubated in all concentrations of 
carprofen.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additional 24 hour 
incubation in carprofen.  Homogeneous groups for necrosis two-way ANOVA for time are represented as letters.  
Times with the same letter are not significantly different.   
 
 
 
 
 
 
 
 
 
 
mogeneous groups score 
0 a     0.00 
Time 
(hour) Ho
Mean lesion 
24  b    1.33 
25  b c   1.50 
28  b c   1.73 
32  b c   1.75 
36   c   2.00 
48   c   2.00 
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Table. 47.  Concentration analysis for mean vacuolation extent lesion scores for slices incubated with carprofen and 
phenobarbital.  Comparison of mean vacuolation extent lesion scores (n=18) among carprofen concentrations for all 
time points.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additional 24 hour 
cubation in carprofen.  Homogeneous groups for vacuolation extent two-way ANOVA for concentration are 
presented as letters.  Concentrations with the same letter are not significantly different. 
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Fig. 54.  Concentration analysis for mean vacuolation extent lesion scores for slices incubated with carprofen and 
phenobarbital.  Comparison of mean vacuolation extent lesion scores (±SE, n=18) among carprofen concentrations for 
all time points.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additional 24 hour 
incubation in carprofen.  Homogeneous groups for vacuolation extent two-way ANOVA for concentration are 
represented as letters.  Concentrations with the same letter are not significantly different. 
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Table 48.  Tim
phenobarbital.  Comparison 
e analysis of mean vacuolation extent lesion scores for slices incubated with carprofen and 
of mean vacuolation extent lesion scores (n=12) across time for slices incubated in all 
concentrations of carprofen.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additional 
24 hour incubation in carprofen.  Homogeneous groups for vacuolation extent two-way ANOVA for time are 
represented as letters.  Times with the same letter are not significantly different.  
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Fig. 55.  Time analysis of mean vacuolation extent lesion scores for slices incubated with carprofen and phenobarbita
Comparison of mean vacuolation extent lesion scores (±SE, n=12) across time for slices incubated in all 
concentrations of carprofen.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additio
24 hour incubation in carprofen.  Homogeneous groups for vacuolation
sented ters.  Times with e letter a
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Table 49.  Concentration analysis for mean vacuolation severity lesion scores for slices incubated with carprofen and 
phenobarbital.  Comparison of mean vacuolation severity lesion scores (n=18) among carprofen concentrations for all 
time points.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additional 24 hour 
incubation in carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for concentration are 
represented as letters.  Concentrations with the same letter are not significantly different.   
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Fig. 56.  Concentration analysis for mean vacuolation severity lesion scores for slices incubated with carprofen and 
phenobarbital.  Comparison of mean vacuolation severity lesion scores (±SE, n=18) among carprofen concentrations 
for all time points.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an additional 24 hour 
incubation in carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for concentration are 
represented as letters.  Concentrations with the same letter are not significantly different. 
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Homogeneous  
groups 
Mean lesion 
score 
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50 a    2.57 
100  b   1.86 
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Table 50.  Time analysis of mean vacuolation severity lesion scores for slices incubated with carprofen and 
phenobarbital.  Comparison of mean vacuolation severity lesion scores (n=12) across time for slices incubated in all 
concentrations of carprofen.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an ad
24 hour incubation in carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for time are 
represented as letters.  Times with the same letter are not significan
ditional 
tly different.    
 
 
 
 
 
 
 
 
 
 
 
-0.5
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
bc b
0 24 25 28 32 36 48
Time (hour)
M
ea
n 
Le
si
on
 S
co
re
a
bc c c c
 
Fig. 57.  Time analysis of mean vacuolation severity lesion scores for slices incubated with carprofen and 
phenobarbital.  Comparison of mean vacuolation severity lesion scores (±SE, n=12) across time for slices incubated in 
all concentrations of carprofen.  Slices were incubated for 24 hours in phenobarbital (75µg/ml) followed by an 
additional 24 hour incubation in carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for time 
are represented as letters.  Times with the same letter are not significantly different. 
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lower limit of quantification.  Supernatant concentrations (ng/ml) measured for carprofen were 
below the lower limit of quantification for 0 and 10 µg/ml media.   
     The carprofen concentration in ) after slice incubation with cimetidine 
fol cubation with carprofen (Figure 58) w ated for differences among media 
concentrations.  The AUC (hour*µg B wa er than the AUC of peak A at 10 
µg/ml (p-value=0.0020; wit 0 hour p-value=0.032 g/ml (p-value=0.0331; 
without 0 hour p-value>0.05) (Table 51, Figure 59).  T  no differences in AUC of peaks 
for 50 µg/m edia
s media (µg/ml
lowed by in ere evalu
/ml) of peak s high
hout 1) and 100 µ
here were
l m . 
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Fig. 58.  Mean carprofen media concentrations following incubation with cimetidine and carprofen.  Mean 
concentration (µg/ml±SE) of carprofen enantiomers (A or B) in media after incubation for 24 hours with cimetidine 
(1000µM) followed with an additional incubation in carprofen for 1, 4, 8, 12 and 24 hours.  Values are means of nine 
samples per media concentration per time point.  Carprofen concentrations of 0 µg/ml media were below the LOQ. 
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Table 51.  AUC of carprofen in media following incubation with cimetidine and carprofen.  Mean AUC (hour*µg/ml, 
n=3) of carprofen in media (0, 10, 50 or 100 µg/ml) for slices incubated for 24 hours in cimetidine (1000 µM) 
followed by an additional 24 hour incubation in carprofen. 
 
Carprofen and 
cimetidine   Media 
 Carprofen and 
cimetidine 
(without 0 hour) 
  Media 
Concentration 
(µg/ml) Peak 
AUC 
(hour*µg/ml)
 Concentration 
(µg/ml) Peak
AUC 
(hour*µg/ml)
0 A 23.12 0 A 11.56
 B 66.48   B 33.24
10 A 176.47 10 A 164.90
 B 205.47   B 172.17
50 A 819.13 50 A 807.53
 B 833.10   B 799.87
100 A 1583.00 100 A 1571.67
  B 1609.67   B 1576.33
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.  AUC of carprofen in media following incubation with cimetidine and carprofen.  Mean AUC (hour*µg/ml, 
n=3) of carprofen in media (10, 50 or 100 µg/ml) for slices incubated for 24 hours in cimetidine (1000 µM) followed 
Fig. 59
by an additional 24 hour incubation in carprofen.  For each media concentration, peaks were compared for significant 
differences. Within each carprofen media concentration, peaks with the same letter are not significantly different.  For 
100 µg/ml media, no statistical difference was noted (a3*) when 0 hour carprofen concentrations were excluded. 
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     The mean supernatant concentrations for slices incubated in cimetidine (1000 µM) followed 
y carprofen (Figure 60) showed that 0 and 24 hour concentrations were below the lower limit of 
ifferences in peak AUC values were noted for 100 
µg/ml media. 
 
 
 
b
quantification.  For 50 µg/ml media, the AUC (hour*ng/ml) of peak B was higher than peak A 
(p-value=0.0101) (Table 52, Figure 61).  No d
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Fig. 60.  Mean hepatic slice supernatant concentrations of carprofen following incubation with cimetidine and 
carprofen.  Mean concentrations (ng/ml±SE) of carprofen enantiomers (A or B) in hepatic slice supernatant after 
incubation for 24 hours with cimetidine (1000 µM) followed with an additional incubation in carprofen for 1, 4, 8, 12 
and 24 hours.  The values are an average of six samples per media concentration per time point.  Carprofen 
supernatant concentrations for slices incubated in 0 and 10 µg/ml media were below the LOQ. 
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Table 52.  AU
AUC (hour*ng/ml, n=3)
C of carprofen in hepatic slice supernatant following incubation with cimetidine and carprofen.  Mean 
 of carprofen in supernatant of hepatic slices incubated for 24 hours in cimetidine (1000 µM) 
followed by an additional 24 hour incubation in carprofen media (0, 10, 50 and 100 µg/ml). 
 
Carprofen and 
cimetidine   Supernatant 
 Carprofen and 
cimetidine 
(without 0 hour) 
 Supernatant 
Concentration 
(µg/ml) Peak 
AUC 
(hour*ng/ml) 
 Concentration 
(µg/ml) Peak 
AUC 
(hour*ng/ml) 
0 A 0.00 0 A 0.00
 B 0.00 B 0.00
10 A 0.00 10 A 0.00
 B 0.00 B 0.00
50 A 74169.67 50 A 74179.67
 B 105371.00 B 105371.00
100 A 167755.33 A 167758.67100
  B 203131.00B 203131.00
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n with cimetidine and carprofen.  Mean 
pernat o lices incubated for 24 hours in cimetidine (1000 µM) 
llowed on in c 0 and 100 µg/ml). For each media concentration, 
s wer gnificant differences. ofen media concentration, peaks with the same 
A (p<0.05). 
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Fig. 61.  AUC of carprofen in hepatic slice supernatant following incubatio
AUC (hour*ng/ml, n=3) of carprofen in su ant f hepatic s
fo  24 hour incubatiby an additional arprofen media (5
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Potassium 
   Figure 62 shows the potassium concentrations for slices incubated in cimetidine followed by 
incubation with carprofen.  Significant differences across time (df=6, F-ratio=64.516, p-
value=0.000) and concentration (df=3, F-ratio=11.568, p-value=0.000) were noted by two-way 
ANOVA.  ANOVA groups were based on the means of all samples at each time point (n=24) or 
the means of all times for each concentration (n=42).  Zero hour mean potassium concentrations 
were higher than those at all other time points (Table 53, Figure 63).  Forty-eight hour potassium 
concentrations were less than those at 25, 28, 32 and 36 hours.  Among the media 
concentrations, mean potassium concentrations for slices incubated in 10 µg/ml media were 
higher than 0, 50 and 100 µg/ml potassium concentrations (Table 54, Figure 64).  The potassium 
content AUC (hour*µmol/g-L) was also determined for each concentration of carprofen (Table 
55). 
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Fig. 62.  Potassium concentrations for slices incubated with cimetidine and  carprofen.  Potassium concentrations 
(µmol/g-L±SE, mean) in hepatic slice supernatant during 24 hours of incubation cimetidine (1000 µM) followed by an 
additional 24 hour incubation in carprofen (0, 10, 50 and 100 µg/ml).  Potassium concentrations are a mean of six 
samples per time point for each concentration. 
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Table 53.  Time analysis of  potassium concentrations for slices incubated with cimetidine and carprofen.  
Comparison of mean potassium concentrations (µmol/g-L) of all potassium samples (n=24) at each time point for all 
carprofen concentrations.  Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 
hour incubation in carprofen.  Homogeneous groups for potassium two-way ANOVA for time are represented as 
letters.  Times with the same letter are not significantly different. 
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Fig.  63.  Time analysis of potassium concentrations for slices incubated with carprofen and cimetidine.  Comparis
of mean potassium concentrations (µmol/g-L±SE) of all potassium samples (n=24) at each time point for all carpro
concentrations.  Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour 
incubation in carprofen.  Homogeneous groups for potassium two-way ANOVA for time are represented as letters.  
Times with the same letter are not significantly different. 
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Table 54.  Concentration analysis of potassium concentrations for slices incubated with carprofen and cimetid
Comparison of mean potassium concentrations (µmol/g-L, n=42) at all times for each carprofen media concentration.  
Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation in 
carprofen.  Homogeneous groups for potassium two-way ANOVA for concentration are represented as letters.  
Concentrations with the same let
ine.  
ter are not significantly different. 
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Table 55.  Potassium content AUC for slices incubated with carprofen and cimetidine.  Mean AUC (hour*µmol/g-L, 
n=3) of potassium content for slices incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 
hour incubation in media containing 0, 10, 50 and 100 µg/ml carprofen.    
 
Carprofen and 
cimetidine 
Potassium 
Content 
 Carprofen and 
cimetidine 
(without 0 hour)
Potassium 
Content 
Concentration 
(µg/ml) 
AUC 
(hour*µmol/g-L) 
 Concentration 
(µg/ml) 
AUC 
(hour*µmol/g-L)
0 4.101E+06 0 1.638E+06
10 4.461E+06 10 1.998E+06
50 3.985E+06 50 1.522E+06
100 4.047E+06 100 1.585E+06
 
 
ion 
me and among carprofen media 
concentrations.  Two-way ANOVA demonstrated significant differences across time (df=6, F-
ratio=7.833, p-value=0.000).  ANOVA groups were based on the means of all samples at each 
time point (n=24) or the means of all times for each concentration (n=42).  Mean ATP 
concentrations at 0 hour were less than those at 24, 25 and 32 hours (Table 56, Figure 66).  
Concentrations at 24 hours were higher than at 25, 28, 32, 36 and 48 hours.  The ATP content 
AUC (hour*nmol/g) was also determined for each concentration of carprofen (Table 57). 
 
 
ATP 
     Mean ATP concentrations (nmol/g) for slices incubated in cimetidine followed by incubat
 carprofen (Figure 65) were evaluated for differences across tiin
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Fig. 65.  ATP concentrations for slices incubated with carprofen and cimetidine.  ATP concentrations (nmol/g±SE, 
mean) in hepatic slice supernatant during 24 hours of incubation cimetidine (1000 µM) followed by an additional 24 
hour incubation in carprofen (0, 10, 50 and 100 µg/ml).  ATP concentrations are a mean of six samples per time po
for each concentration. 
 
 
 
 
Table 56.  Time analysis of ATP concentrations for slices incubated with carprofen and cimetidine.  Comparison of 
mean ATP concentrations (nmol/g) of all ATP samples (n=24) at each time point for all carprofen concentrations.  
Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation in 
carprofen.  Homogeneous groups for ATP two-way ANOVA for time are represen
are not
ime
nificantly differe
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Fig. 66.   Time analysis of ATP concentrations for slices incubated with carprofen and cimetidine.  Comparison of 
mean ATP concentrations (nmol/g±SE) of all ATP samples (n=24) at each time point for all carprofen concentrations.  
Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation in 
carprofen.  Homogeneous groups for ATP two-way ANOVA for time are represented as letters.  Times with the sam
letter are not significantly different. 
e 
 
 
Table 57.  ATP content AUC for slices incubated with carprofen and cimetidine.  Mean AUC (hour*nmol/g, n=3) of 
ATP content for slices incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation 
in media containing 0, 10, 50 and 100 µg/ml carprofen. 
 
Carprofen and 
cimetidine ATP Content 
 Carprofen and 
cimetidine 
(without 0 hour)
ATP Content
 
Concentration 
(µg/ml) 
AUC 
(hour*nmol/g) 
 Concentration 
(µg/ml) 
AUC 
(hour*nmol/g)
0 11.52 0 5.07
10 11.84 10 5.91
50 10.65 50 4.73
100 10.64 100 4.71
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Histology 
     The hepatic slice lesion scores for slices incubated in cimetidine and carprofen (Table 58, 
Figures 67 through 69) were examined by two-way ANOVA and showed significant differences 
r necrosis, vacuolation extent and vacuolation severity.  For necrosis, mean lesion scores  
   
 
Table 58. atic slic es for  incub d with carprofen and cimetidine.  Lesion scores of hepatic 
slices incubated in cim ti 4 hour wed with incubation in carprofen for and additional 1, 4, 8, 12 and 24 
hours. 
  Lesion scores*
fo
  Hep e lesion scor  slices ate
e dine for 2 s follo
 
  
Media 
Concentration 
Time 
(hour) 
Necrosis 
: extent 
Vacuolation 
: extent 
Vacuolation 
: severity 
           
0 µg/ml 0 0 0 0 0 0 1 0 0 1 
0 µg/ml 24 3 3 1 4 4 4 4 4 3 
           
cimetidine 0 0 0 0 0 0 3 0 0 2 
cimetidine 24 1 1 2 1 1 4 2 2 4 
           
0 µg/ml 25 2 2 1 3 3 4 4 4 4 
0 µg/ml 28 1 1 2 4 4 4 4 4 4 
0 µg/ml 32 2 2 3 4 4 4 4 4 4 
0 µg/ml 36 2 2 4 4 4 4 3 3 3 
0 µg/ml 48 2 2 4 3 3 3 3 3 2 
           
10 µg/ml 25 3 1 3 3 4 4 4 3 4 a a a
10 µg/ml 28 1 1 2 4 4 4 4 4 4 
10 µg/ml 32 2 3a 1 4 4a 5 4 4a 4 
10 µg/ml 36 2 3a 2 4 4a 4 4 4a 3 
10 µg/ml 48 2 3a 3a 3 4a 4a 3 4a 4a
           
50 µg/ml 25 2 3a 2 3 4a 4 3 4a 4 
50 µg/ml 28 3 3 3 4 4 4 4 3 3 
50 µg/ml 32 2a 3 3 4a 3 2 4a 2 2 
50 µg/ml 36 2 3 3 4 3 2 3 2 1 
50 µg/ml 48 2 4 4 3 2 2 3 2 2 
           
100 µg/ml 25 2 3 2 1 4 4 2 3 4 
100 µg/ml 28 1 3 3 4 4 2 3 3 2 
100 µg/ml 32 2 3 3 4 2 2 2 1 1 
100 µg/ml 36 2 4 4 4 2 2 3 1 1 
100 µg/ml 48 2 4 4 1 1 2 2 1 2 
* Lesion scoring: (outermost zone ~10 hepatocytes wide was disregarded) 
 0 < 1% hepatocytes affected 3 21-40% 
1 1-10% 4 41-90% 
 2 11-20% 5 >90% 
a  Slides showing marked difference in lesion extent and/or severity as move across the slide 
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Fig. 67.  Mean necrosis hepatic slice lesion scores for slices incubated with carprofen and cimetidine.  Mean necrosis 
lesion scores (±SE) for slices incubated for 24 hours in cimetidine (1000 µM) followed with an additional 24 hour 
incubation in carprofen (0, 10, 50 or 100 µg/ml).  Scores are means of three samples per time point. 
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Fig. 68.  Mean vacuolation extent hepatic slice lesion scores for slices incubated with carprofen and cimetidine.  Mean 
vacuolation extent lesion scores (±SE) for slices incubated for 24 hours in cimetidine (1000 µM) followed with an 
additional 24 hour incubation in carprofen (0, 10, 50 or 100 µg/ml).  Scores are means of three samples per time point. 
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Fig. 69.  Mean vacuolation severity hepatic slice lesion scores for slices incubated with carprofen and cimetidine.  
Mean vacuolation severity lesion scores (±SE) for slices incubated for 24 hours in cimetidine (1000 µM) followed 
with an additional 24 hour incubation in carprofen (0, 10, 50 or 100 µg/ml).  Scores are means of three samples per 
time point. 
 
 
 
 
across time (df=6, F-ratio=22.6 , p-v lue=0.000) were low  hour than at all other times.  
Tw e l er t n those at 32, 36 an urs; 48 hour scores were 
gure 70).  Mean vacuolation extent lesion scores for time 
f=6, F-ratio=9.893, p-value=0.000) were lower at 0 hour than at 25, 28, 32, 36 and 48 hours 
able 60, Figure 71).  Twenty-four hour scores were lower than 25, 32 and 36 hour scores.  
 
scores for v  severity F- alue=0.000) were lower at 
0 hour than at all other time points (Table 62, Figure 7 olation severity among 
concentrations (df=3, F-ratio=9.780 -value=0.000), mean lesion scores for 100 µg/ml media 
we and 10 µg/ml media, and lesion scores for 50 µg/ml media were less 
an for 10 µg/ml media (Table 63, Figure 74).   
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Among concentrations (df=3, F-ratio=2.903, p-value=0.043), mean vacuolation extent scores
were lower for 100 µg/ml media than for 10 µg/ml media (Table 61, Figure 72).  Mean lesion 
acuolation across time (df=6, ratio=16.976, p-v
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Table 59.  Ti
Comparison of n
me analysis of mean necrosis lesion scores for slices incubated with carprofen and cimetidine.  
ecrosis lesion scores (n=12) across time for slices incubated in all concentrations of carprofen.  Slices 
 
 
were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation in carprofen.  
Homogeneous groups for necrosis two-way ANOVA for time are represented as letters.  Times with the same letter 
are not significantly different.   
 
 
 
 
Time 
(hour) 
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groups 
Mean lesion 
score 
0 a    0.00 
24  b   1.33 
25  b   2.17 
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32   c d 2.42 
36   c d 2.75 
48    d 3.00 
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ig. 70.  Time analysis for mean necrosis lesion scores for slices incubated with carprofen and cimetidine.  
omparison of mean necrosis lesion scores (±SE, n=12) across time for slices incubated in all concentrations of 
rprofen.  Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation 
.  Homogeneous groups for necrosis two-way ANOVA for time are represented as letters.  Times with the 
same letter are not significantly different.   
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Table 60.  Time analysis of mean vacuolation extent lesion scores for slices incubated with carprofen and cimetidine.  
Comparison of vacuolation extent lesion scores (n=12) across time for slices incubated in all concentrations of 
carprofen.  Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation 
in carprofen.  Homogeneous groups for vacuolation extent two-way ANOVA for time are represented as letters.  
Times with the same letter are not significantly different.   
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48  b  2.83 
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Table 61.  Concentration analysis for mean vacuolation extent lesion scores for slices incubated with carprofen an
cimetidine.  Comparison of mean vacuolation extent lesion scores (n=18) among carprofen concentrations for all time
points.  Slices were incubated for 24 hours in cimetidine (1000 µM
d 
 
) followed by an additional 24 hour incubation in 
carprofen.  Homogeneous groups for vacuolation extent two-way ANOVA for concentration are represented as letters.  
Conce ns w er are tly d ent. 
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Fig. 72.  Concentration analysis for mean vacuolation extent lesion scores for slices incubated with carprofen and 
imetidine.  Comparison of mean vacuolation extent lesion scores c (±SE, n=18) among carprofen concentrations for all 
me points.  Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation 
 carprofen.  Homogeneous groups for vacuolation extent two-way ANOVA for concentration are represented as 
tters.  Concentrations with the same letter are not significantly different. 
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Table 62.  Time analysis of mean vacuolation severity lesion scores for slices incubated with carprofen and 
metidine.  Comparison of vacuolation severity lesion scores (n=12) across time for slices incubated in all 
ncentrations of carprofen.  Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 
our incubation in carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for time are 
presented as letters.  Times with the same letter are not significantly different.   
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Fig. 73.  Time analysis of mean vacuolation severity lesion scores for slices incubated with carprofen and cimetidine.  
Comparison of vacuolation severity lesion scores (±SE, n=12) across time for slices incubated in all concentrations of 
carprofen.  Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation 
in carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for time are represented as letters.  
Times with the same letter are not significantly different.  
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Table 63.  Concentration analysis for mean vacuolation severity lesion scores for slices incubated with carprofen and 
metidine.  Comparison of mean vacuolation severity lesion scores (n=18) among carprofen concentrations for all 
me points.  Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour incubation 
 carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for concentration are represented as 
 
 
 
 
 
ci
ti
in
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Fig. 74.  Concentration analysis for mean vacuolation severity lesion scores for slices incubated with carprofen and 
cimetidine.  Comparison of mean vacuolation severity lesion scores (±SE, n=18) among carprofen concentrations for 
all time points.  Slices were incubated for 24 hours in cimetidine (1000 µM) followed by an additional 24 hour 
incubation in carprofen.  Homogeneous groups for vacuolation severity two-way ANOVA for concentration are 
represented as letters.  Concentrations with the same letter are not significantly different. 
 
 
 
Carprofen Treatment Comparisons 
     The relationship among the slice treatments—carprofen alone, carprofen with phenobarbital 
or carprofen with cimetidine—was investigated by examining carprofen concentrations in media 
and supernatant.   
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     The mean media AUC (hour*µg/ml) for 10 µg/ml (Figure 75), 50 µg/ml (Figure 76) and 100 
µg/ml (Figure 77) were examined for peak and treatment differences.  When each peak was 
analyzed and treatments compared by ANOVA, the AUC of peak A media for 50 µg/ml (p-
value=0.0260; without 0 hour p-value>0.05; Figure 76, Table 64) and 100 µg/ml (p-
value=0.0142; without 0 hour p-value=0.0359; Figure 77, Table 65) were different among 
treatments.  In both instances, treatment with carprofen yielded a higher AUC than carprofen 
with cimetidine.  No significant differences were noted among treatments for peak A or peak B 
for 10 µg/ml media or for peak B of 50 and 100 µg/ml media.  In addition, no significant 
differences were noted among treatments for either peak A or B for supernatant AUC values. 
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Fig. 76. ia.  Mean peak A and B AUC (hour*µg/ml, n=3) for 50 µg/ml 
rprofen, carprofen following phenobarbital (75 µg/ml) incubation and carprofen following cimetidine (1000 µM) 
cubation.  For all treatments, peak A or peak B was compared for significant differences. For each peak, treatments 
with the same letter are not significantly different.  For peak A, no statistical differences were noted among treatments 
(A*) when 0 hour concentrations were excluded. 
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Fig. 77.  Mean carprofen AUC for 100 µg/ml media.  Mean peak A and B AUC (hour*µg/ml, n=3) for 100 µg/ml 
carprofen, carprofen following phenobarbital (75 µg/ml) incubation and carprofen following cimetidine (1000 µM) 
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incubation.  For all treatments, peak A or peak B was compared for significant differences. For each peak, treatments 
with the same letter are not significantly different.   
Table 64.  Mean Peak A AUC for 50 µg/ml media.  Mean peak A (hour*µg/ml, n=3) for 50 µg/ml carprofen
carprofen following phenobarbital (75 µg/ml) incubation and carprofen following cimetidine (1000 µM) incubatio
Treatments with the same letter are not significantly different. 
Treatment Homogenous groups Mean Peak A A
, 
n.  
UC 
(hour*µg/ml) 
Carprofen a  988.40 
Carprofen with phenobarbital  a b 854.67 
Carprofen with cimetidine  b 819.13 
 
arprofen following cimetidine (1000 µM) incubation.  
reatments with the same letter are not significantly different. 
Treatment Homogenous groups Mean Peak A AUC 
(hour*µg/ml) 
Carprofen a  1931.67 
 
 
Table 65.  Mean Peak A AUC for 100 µg/ml media.  Mean peak A (hour*µg/ml, n=3) for 100 µg/ml carprofen, 
arprofen following phenobarbital (75 µg/ml) incubation and cc
T
Carprofen with phenobarbital  a b 1690.00 
Carprofen with cimetidine  b 1583.00 
 
 
 
Histology 
     Mean necrosis lesion scores were compared to identify differences among treatments and 
across time for slices incubated in 0 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml carprofen.  For 0 
µg/ml media (Figure 78), a significant time-treatment interaction was noted (df=8, F-
ratio=2.411, p-value=0.039), and a significant treatment effect (df=2, F-ratio=8.644, p-value-
0.001) was found.  Mean necrosis lesion scores for carprofen alone were lower than for 
carprofen with phenobarbital or cimetidine (Table 66, Figure 79). 
 
 119
0 µg/ml
-1.00
-0.50
0.00
0.50
1.00
1.50
3.
1 4 8 12 24
N
ec
ro
si
s 
Le
si
on
 S
e
2.00
2.50co
r
3.00
50
Carprofen
Time (hour)
Carprofen + Phenobarbital
Carprofen + Cimetidine
g/ml carprofen media for slices incubated in carprofen, carprofen with phenobarbital or carprofen with cimetidine.  
ime is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The values are means of 
er treatment per time point. 
 
 
 
 
 
 
 
Table 66.  Mean necrosis lesion score 0 µg/ml treatment analysis.  Comparison of mean necrosis lesion scores for 
slice treatments (n=15) for all time points.  Homogeneous groups for necrosis two-way ANOVA for treatment are 
represented as letters.  Treatments with the same letter are not significantly different.   
 
 
 
 
 
 
 
 
 
 
 
 
Treatment Homogeneous groups 
Mean Lesion 
Score 
carprofen alone a    1.03 
 
 
ig. 78.  Mean necrosis lesion scores among 0 µg/ml carprofen treatments.  Mean necrosis lesion scores (±SE) for 0 F
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carprofen with cimetidine  b   2.13 
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Fig. 79.  Mean necrosis lesion score 0 µg/ml treatment analysis.  Comparison of mean necrosis lesion scores for slice 
treatments (±SE, n=15) for all time points.  Homogeneous groups for necrosis two-way ANOVA for treatment are 
represented as letters.  Treatments with the same letter are not significantly different.   
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     For 10 µg/ml necrosis lesion scores (Figure 80), a significant factor interaction was noted 
(df=8, F-ratio=2.973, p-value=0.015).  A significant time effect (df=4, F-ratio=11.250, p-
han 24 hour 
scores. 
9) 
ted as 
 
 
 
 
 
 
 
 
value=0.000) was found with one hour mean lesion scores less than those at 12 and 24 hours 
(Table 67, Figure 81).  Four and eight hour necrosis lesion scores were lower t
 
 
 
Table 67.  Mean necrosis lesion score 10 µg/ml time analysis.  Comparison of mean necrosis lesion scores (n=
across time for all treatments.  Homogeneous groups for necrosis two-way ANOVA for treatment are represen
letters.  Times with the same letter are not significantly different. 
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Fig.  81.  Mean necrosis lesion score 10 µg/ml time analysis.  Comparison of mean necrosis lesion scores (±SE, n=9) 
across time for all treatments.  Homogeneous groups for necrosis two-way ANOVA for treatment are represented as 
letters.  Times with the same letter are not significantly different. 
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     The mean necrosis lesion scores for 50 µg/ml media (Figure 82) revealed significant time 
(df=4, F-ratio=4.938, p-value=0.004) and treatment (df=2, F-ratio=25.222, p-value=0.000)  
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Fig. 82.  Mean necrosis lesion scores among 50 µg/ml carprofen treatments.  Mean necrosis lesion scores (±SE) for 50 
µg/ml carprofen media for slices incubated in carprofen, carprofen with phenobarbital or carprofen with cimetidine.  
Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The values are means of 
three scores per treatment per time point. 
 
 
 
 
 
 
effects.  With time, one hour necrosis lesion scores were less than 12 and 24 hour scores (Table 
68, Figure 83).  Among treatments, mean necrosis lesion scores for carprofen alone were less 
than those for carprofen with phenobarbital or cimetidine; necrosis scores for carprofen with 
phenobarbital were less than those for carprofen with cimetidine (Table 69, Figure 84).   
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Table 68.  Mean necrosis lesion score 50 µg/ml time analysis.  Comparison of mean necrosis lesion scores (n=9) 
across time for all treatments.  Homogeneous groups for necrosis two-way ANOVA for treatment are represented as
letters.  Times with the same letter are not significantly different.     
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Fig. 83.  Mean necrosis lesion score 50 µg/ml time analysis.  Comparison of mean necrosis lesion scores (±SE, n=9) 
across time for all treatments.  Homogeneous groups for necrosis two-way ANOVA for treatment are represented as 
letters.  Times with the same letter are not significantly different. 
 
 
 
Table 69.  Mean necrosis lesion score 50 µg/ml treatment analysis.  Comparison of mean necrosis lesion scores for 
(n=15) for all time points.  Homogeneous groups for necrosis two-way ANOVA for treatment are 
presented as letters.  Treatments with the same letter are not significantly different.   
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Fig. 84.  Mean necrosis lesion score 50 µ ent aris  of mean necrosis lesion scores for slice 
treatments (±S r all time p eo ros  two-way ANOVA for treatment are 
represented as letters.  Treatments with th etter are n cantly erent.   
 
 
 
   Mean necrosis scores for 100 µg/ml media (Figure 85) were analyzed by two-way ANOVA 
nd significant time (df=4, F-ratio=4.856, p-value=0.004) and treatment (df=2, F-ratio=9.945, p-
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 treated with 
carprofen and cimetidine were higher than those for slices treated with carprofen alone or with 
carprofen and phenobarbital (Table 71, Figure 87). 
 
 
able 70.  Mean necrosis lesion score 100 µg/ml time analysis.  Comparison of mean necrosis lesion scores (n=9) 
ross time for all treatments.  Homogeneous groups for necrosis two-way ANOVA for treatment are represented as 
tters.  Times with the same letter are not significantly different.        
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Fig. 85.  Mean necrosis lesion scores among 100 µg/ml carprofen treatments.  Mean necrosis lesion scores (±
100 µg/ml carprofen media for slices incubated in carprofen, carprofen with phe
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less than those at 12 and 24 hours, and four hour lesion scores were less than those at 12 hours 
(Table 70, Figure 86).  Among treatments, mean necrosis lesion scores for slices
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Fig. 86.  Mean necrosis lesion score 100 µg/ml time analysis.  Comparison of mean necrosis lesion scores (±SE, 
across time for all treatments.  Homogeneous groups for necrosis two-way ANOVA for treatment are repres
n=9) 
ented as 
tters.  Times with the same letter are not significantly different.   
able 71.  Mean necrosis lesion score 100 µg/ml treatment analysis.  Comparison of mean necrosis lesion scores for 
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Fig. 87.  Mean necrosis lesion score 100 µg/ml treatment analysis.  Comparison of mean necrosis lesion scores for 
slice treatments (±SE, n=15) for all time points.  Homogeneous groups for necrosis two-way ANOVA for treatment 
are represented as letters.  Treatments with the same letter are not significantly different.   
 
 
 
 
          Mean vacuolation extent lesion scores were compared to identify differences among 
treatments and across time for slices incubated in 0 µg/ml (Figure 88), 10 µg/ml, 50 µg/ml and 
100 µg/ml carprofen.  No significant differences were found for mean vacuolation extent lesion 
scores for 0 µg/ml media.  For 10 µg/ml media (Figure 89), a significant factor interaction (df=8, 
F-ratio=4.324, p-value=0.002) and significant treatment effect (df=2, F-ratio=27.165, p-
 
 
value=0.000) were noted.  Mean lesion scores for carprofen alone were lower than those for 
carprofen with phenobarbital or cimetidine (Table 72, Figure 90). 
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Fig. 88.  Mean vacuolation extent lesion scores among 0 µg/ml carprofen treatments.  Mean vacuolation extent lesion 
scores (±SE) for 0 µg/ml carprofen media for slices incubated in carprofen, carprofen with phenobarbital or carprofen 
with cimetidine.  Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  Th
values are means of three scores per treatment per time point. 
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Table 72.  Mean vacuola xtent lesion score l treat lysis.  Comparison of mean vacuolation extent 
sion res for slice treatments (n=15) for all time poi  for vacuolation extent two-way 
NOVA for treatment are represented as letters.  Treatments with the same letter are not significantly different.   
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Fig. 90.  Mean vacuolation extent lesion score 10 µg/ml treatment analysis.  Comparison of mean vacuolation extent 
lesion scores for slice treatments (±SE, n=15) for all time points.  Homogeneous groups for vacuolation extent two-
way ANOVA for treatment are represented as letters.  Treatments with the same letter are not significantly different.   
 
 
Treatment Homogeneous groups 
Mean Lesion 
Score 
carprofen alone a    2.57 
carprofen with phenobarbital  b   3.87 
carprofen with cimetidine  b   3.93 
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     Mean lesion scores for vacuolation ex l media (Figure 91) showed a 
significant time effect (df=4, F -way ANOVA.  Eight hour 
mean vacuolation extent lesion scores were lower than one hour lesion scores (Table 73, Figure 
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Fig. 91.  Mean vacuolation extent lesion scores among 50 µg/ml carprofen treatments.  Mean vacuolation extent lesion 
scores (±SE) for 50 µg/ml carprofen media for slices incubated in carprofen, carprofen with phenobarbital or 
carprofen with cimetidine.  Time is the hour incubated in carprofen or post incubation with phenobarbital or 
cimetidine.  The values are means of three scores per treatment per time point. 
 
 
 
 
Table 73.  Mean vacuolation extent lesion score 50 µg/ml time analysis.  Comparison of mean vacuolation extent 
lesion scores (n=9) across time for all treatments.  Homogeneous groups for vacuolation extent two-way ANOVA for 
treatment are represented as letters.  Times with the same letter are not significantly different.  
 
 
 
 
 
 
 
Time 
(hour) 
Homogeneous 
groups 
Mean Lesion 
Score 
1 a    3.67 
4 a b   3.33 
8  b   2.67 
12 a b   3.33 
24 a b   3.00 
 131
 
0
0.5
1
1.5
1 4 8 12 24
Time (hour)
M
ea
n
 
Fig. 92.  Mean vacuolation extent lesion score 50 µg/ml time analysis.  Comparison of mean vacuolation extent les
scores (±SE, n=9) across time for all treatments.  Homogeneous groups for vacuolation extent two-way ANOVA fo
treatment are represented as letters.  Times with the same letter are not significantly different.  
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    The mean vacuolation extent lesion scores for 100 µg/ml carprofen (Figure 93) did not show 
any significant differences across time or among treatments. 
     Mean vacuolation severity lesion scores were compared to identify differences among 
treatments and across time for slices incubated in 0 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml 
carprofen.  For vacuolation severity of 0 µg/ml media (Figure 94), a significant factor interaction 
was noted (df=8, F-ratio=6.814, p-value=0.000); a signification treatment effect (df=2, F-
ratio=12.615, p- value=0.000) was also found. 
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Fig. 93.  Mean vacuolation extent lesion scores among 100 µg/ml carprofen treatments.  Mean vacuolation ex
lesion scores (±SE) for 100 µg/ml carprofen media for slices incubated in carprofen, carprofen with phenobarbita
carprofen with cimetidine.  Time is the hour incubated in carprofen or post incubation with phenobarbital or 
cimetidine.  The values are means of three scores per treatment per time point. 
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g 0 µg/ml carprofen treatments.  Mean vacuolation severity 
lesion scores (±SE) for 0 µg/ml carprofen media for slices incubated in carprofen, carprofen with phenobarbital or 
carprofen with cimetidine.  Time is the hour incubated in carprofen or post incubation with phenobarbital or 
cimetidine.  The values are means of three scores per treatment per time point. 
 
 
 
 
  The mean vacuolation severity lesion scores for carprofen alone were lower than those for 
Fig. 94.  Mean vacuolation severity lesion scores amon
carprofen with phenobarbital or cimetidine (Table 74, Figure 95). 
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Table 74.  Mean vacuolation severity lesion score 0 µg/ml treatment analysis.  Comparison of mean vacuolation 
severity lesion scores for slice treatments (n=15) for all time points.  Homogeneous groups for vacuolation severity 
two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not significantly 
different.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment Homogeneous groups 
Mean Lesion 
Score 
carprofen alone a    2.47 
carprofen with phenobarbital  b   3.27 
carprofen with cimetidine  b   3.53 
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Fig. 95.  Mean vacuolation severity lesion score 0 µg/ml treatment analysis.  Comparison of mean vacuolation 
severity lesion scores for slice treatments (±SE, n=15) for all time points.  Homogeneous groups for vacuolation 
severity two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not 
significantly different.   
 
 
     The mean vacuolation severity lesion scores for 10 µg/ml media (Figure 96) revealed a 
significant factor interaction (df=8, F-ratio=3.239, p-value=0.010), as well as, a significant  
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ig. 96.  Mean vacuolation severity lesion scores among 10 µg/ml carprofen treatments.  Mean vacuolation severity 
sion scores (±SE) for 10 µg/ml carprofen media for slices incubated in carprofen, carprofen with phenobarbital or 
rprofen with cimetidine.  Time is the hour incubated in carprofen or post incubation with phenobarbital or 
cimetidine.  The values are means of three scores per treatment per time point. 
 
 
 
treatment effect (df=2, F-ratio=20.161, p-value=0.000).  Mean vacuolation severity lesion scores 
for carprofen alone were lower than those for carprofen with phenobarbital or cimetidine (Table 
75, Figure 97). 
 
 
 
Table 75.  Mean vacuolation severity lesion score 10 µg/ml treatment analysis.  Comparison of mean vacuolation 
severity lesion scores for slice treatments (n=15) for all time points.  Homogeneous groups for vacuolation severity 
two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not significantly 
different.   
 
 
 
 
 
 
 
 
groups Score 
carprofen alone a    2.27 
F
le
ca
 
 Treatment 
Homogeneous Mean Lesion 
carprofen with phenobarbital  b   3.23 
carprofen with cimetidine  b   3.80 
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Fig. 97.  Mean vacuolation severity lesion score 10 µg/ml treatment analysis.  Comparison of mean vacuolation 
severity lesion scores for slice treatments (±SE, n=15) for all time points.  Homogeneous groups for vacuolation 
severity two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not 
 
   Statistical analysis of the mean vacuolation severity lesion scores for 50 µg/ml media (Figure 
8) demonstrated significant time (df=4, F-ratio=2.780, p-value=0.045) and treatment (df=2, F-
e, eight hour mean vacuolation severity lesion 
significantly different.   
 
 
 
 
  
9
ratio=4.376, p-value=0.022) effects.  Across tim
scores were lower than those at one hour (Table 76, Figure 99).  Among treatments, mean lesion 
scores for carprofen alone were lower than those for carprofen with phenobarbital (Table 77, 
Figure 100). 
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Fig. 98.  Mean vacuolation severity lesion scores among 50 µg/ml carprofen treatments.  Mean vacuolation severity 
lesion scores (±SE) for 50 µg/ml carprofen media for slices incubated in carprofen, carprofen with phenobarbital or 
carprofen with cimetidine.  Time is the hour incubated in carprofen or post incubation with phenobarbital or 
cimetidine.  The values are means of three scores per treatment per time point. 
 
 
 
 
 
 
 
 
 
us Mean Lesion 
Score 
1 a    3.22 
 
 
 
Table 76.  Mean vacuolation severity lesion score 50 µg/ml time analysis.  Comparison of mean vacuolation severity
lesion scores (n=9) across time for all treatments.  Homogeneous groups for vacuolation severity two-way ANOVA 
for treatment are represented as letters.  Times with the same letter are not significantly different. 
 
Time 
(hour) 
Homogeneo
groups 
4 a b   2.44 
a b   2.78 
 8  b   2.22 
b   2.33 12 a 
24 
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ity lesion score 50 µg/ml time analysis.  Comparison of mean vacuolation severity 
time for all treatments.  Homogeneous groups for vacuolation severity two-way 
NOVA for treatment are represented as letters.  Times with the same letter are not significantly different. 
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Table 77.  Mean vacuolation severity lesion score 50 µg/ml treatment analysis.  Comparison of mean vacuolatio
severity lesion scores for slice treatments (n=15) for all time points.  Homogeneous groups for vacuolation severity 
two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not significantly 
different.   
 
 
 
 
 
 
 
 
Treatment Homogeneous groups 
Mean Lesion 
Score 
carprofen alone a    2.13 
carprofen with phenobarbital  b   2.87 
carprofen with cimetidine a b   2.80 
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Fig. 100.  Mean vacuolation severity lesion score 50 µg/ml treatment analysis.  Comparison of mean vacuolation 
severity lesion scores for slice treatments (±SE, n=15) for all time points.  Homogeneous groups for vacuolation 
severity two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not 
significantly different.   
 
 
 
 
, p-value=0.009) was noted for 100 µg/ml      A significant time effect (df=4, F-ratio=4.108
vacuolation severity scores (Figure 101).  One hour mean vacuolation severity lesion scores were 
higher than those at 12 and 24 hours (Table 78, Figure 102). 
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ig. 101.  Mean vacuolation severity lesion scores among 100 µg/ml carprofen treatments.  Mean vacuolation severity 
r 
e is the hour incubated in carprofen or post incubation with phenobarbital or 
metidine.  The values are means of three scores per treatment per time point. 
 
 
 
Table lation severity les  score 100 µg/ml time ana   Comp on  severity 
lesi  across e for all treatments.  Homogeneous groups for vacuolation severity two-way ANOVA 
for t presented as letters.  Times with the same letter are not significantly different.     
 
 
 
 
1
F
lesion scores (±SE) for 100 µg/ml carprofen media for slices incubated in carprofen, carprofen with phenobarbital o
carprofen with cimetidine.  Tim
ci
 
 78.  Mean vacuo
on scores (n=9)
reatment are re
ion lysis. aris of mean vacuolation
 tim
 Time Homogeneous 
s 
Mean Lesion 
Score (hour) group
 a    2.89 
4 a b   1.78 
8 a b   1.56 
12  b   1.67 
24  b   1.67 
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Fig. 102.  Mean vacuolation severity lesion score 100 µg/ml time analysis.  Comparison of mean vacuolation severity
lesion scores (±SE, n=9) across time for all treatments.  Homogeneous groups for
ANOVA for treatment are represented as letters.  Times with the 
 
 vacuolation severity two-way 
same letter are not significantly different. 
 
 
 
 
 
ELISA for Cytochrome P450 Enzymes 
 
     Slices were incubated in media containing no drug or phenobarbital to determine whether 
CYP2B11 enzymes were induced or in media containing no drug or cimetidine to determine 
whether CYP2C21 enzymes were inhibited.  Mean enzyme concentrations were determined for 
CYP2B11 (Table 79) and CYP2C21 (Table 80).  For CYP2B11, no differences were noted 
between 0 and 24 hour concentrations for slices incubated in media with no drug or in media 
ean CYP2C21 concentrations were not different from 0 hour concentrations after 
with 75 µg/ml phenobarbital.  Slices incubated in media containing 150 µg/ml phenobarbital 
showed a 1.2 increase in CYP2B11 concentrations (p-value for paired t-test=0.0115) after 24 
hours of incubation.  Slices incubated in media containing 0, 75 or 150 µg/ml phenobarbital 
show no differences in mean CYP2B11 concentrations between 0 and 48 hours.  Twenty-four 
hour m
incubation in cimetidine. 
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Table 79.  Mean CYP2B11 concentrations.  Mean CYP2B11 concentrations in the hepatic supernatant of slices 
incubated in media containing 0, 75 or 150 µg/ml phenobarbital.  Means are an average of three (0 and 24 hour for 
and 75 µg/ml media) or two (48 hour and 150 µg/ml media) samples. 
Time 
Concentration 
phenobarbital 
(µg/ml) 
Mean CYP2B11 
Concentration 
(pmol/mg protein) 
standard 
deviatio
0 
n 
0 0 0.1109 0.0115 
24 0 0.3496 0.1976 
48 0 0.1706 0.0023 
0 75 0.1276 0.0046 
24 75 0.2534 0.1365 
48 75 0.1098 0.0044 
0 150 0.1026 0.0090 
24 150 0.1249 0.0084 
48 150 0.1774 0.0354 
 
 
 
 
 
Table 80. Mean CYP2C21 concentrations.  Mean CYP2C21 concentrations in hepatic slice supernatant of slices 
incubated in media containing 0 or 1000 µM cimetidine.  Means are an average of four samples per time point per 
concentration. 
Time Concentration cimetidine (µM) 
Mean CYP2C21 
Concentration 
(pmol/mg protein) 
standard 
deviation 
0 0 0.0581 0.0296 
24 0 0.0542 0.0338 
0 1000 0.0471 0.0158 
24 1000 0.0715 0.0201 
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CHAPTER VI 
DISCUSSION AND SUMMARY 
 
Effects of Dynamic Organ Culture Incubation 
     Hepatic slices have been used to study phase I and II biotransformation of various dru
xenobiotics, as well as, their cytotoxicity, genotoxicity and uptake into the slices (Bach et al., 
1996; Gandolfi et al., 1996; Olinga et al., 2001).  Freshly prepared rat hepatic slices remain 
viable for up to 48 hours, and human hepatic slices remain viable for up to 2 to 3 days (Lupp et 
al., 2001; Groneberg et al., 2002).  Some studies have been performed using canine liver slices
but the use of canine tissue slices as a model for studying drug metabolism and hepatotoxicity in
dogs has not been reported.  Because rat and human hepatic slices have shown utility as an in 
gs and 
, 
 
itro model, it was hypothesized that canine hepatic slices would also be a valuable tool for 
investigating drug-induced hepatotoxicity.  Therefore, the major objective of this thesis research 
project was to test the utility of canine hepatic slices as a model for studying the toxicity and 
metabolism of selected drugs, including phenobarbital, primidone, lidocaine and carprofen.   
     Canine hepatic slices incubated in media without drug were evaluated for changes in 
supernatant potassium ion (K+) levels and ATP concentrations and histologic lesions measured 
as necrosis, extent of vacuolation and severity of vacuolation.  Potassium ion concentrations are 
used as the primary general index of hepatic slice viability; they are useful for determining the 
time course of toxicity and the concentration-response relationships of a toxic agent (Azri et al., 
1990).  Fisher et al. (1996a) used potassium ion levels to determine the viability of liver slices 
following cold and cryopreservation, and VandenBranden et al. (1998) used potassium ion 
retention as a measure of viability while studying the catalytic activity of eight cytochrome P450 
isoforms.  ATP concentrations reflect the energy status of hepatic slices following incubation 
with a xenobiotic (Azri et al., 1990).  Obatomi et al. (1998) and Martignoni et al. (2004) used 
changes in ATP content to determine viability of liver slices following exposure to atractyloside 
or testosterone, respectively.  Histologic evaluation can be used to detect injury to specific cell 
populations or slice regions (Azri et al., 1990).  Lupp et al. (2001) and Behrsing et al. (2003) 
employed histopathology to assess liver slice viability.  Martin et al. (2000) used ATP content 
and histology as measures of liver slice viability for fresh and cryopreserved liver slices.  Fisher 
et al. (2001) used potassium ion concentrations, ATP levels and histology to evaluate the 
viability of liver slices of varying thickness under three different incubation systems.   
v
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     Decreases in potassium ion and ATP ere indicators of cellular injury or 
eath.  When potassium concentrations of slices incubated without drug were initially examined, 
sign ges in ATP 
slice
     In iability.  
 
than ic lesion measured 
he 
viab es 
(Lup 002).  Significant histologic changes were noted after 
stud city than 
either potassium ion concentrations or ATP levels.   
 
Hepatic Slice Potassium Content Response to Cooling and Incubation 
tempe hese cells are 
 
follo
in th
     Potassium ion concentrations from canine hepatic slices incubated for 1 and 3 hours in the 
absence of drug were lower than those observed at all other time points; the K+ concentrations 
were increased by 4 hours and were significantly increased by 24 hours (Figure 2).  When the 
l) 
were r incubation for 
lidoca  
potass ).  After incubating slices 
with 0, 10, 50 and 100 µg/ml carprofen, mean potassium levels at 1 hour were significantly 
lower than those at 4 hours (Table 31, Figure33).  While not all of these early decreases were 
concentrations w
d
0 hour time point concentrations were higher than at all other time points, and no other 
ificant declines were seen (Figure 2).  Additionally, no significant chan
concentrations were noted (Figure 3).  Potassium and ATP levels suggest that canine hepatic 
s are viable up to 24 hours. 
creases in hepatic lesion scores are another indication of hepatotoxic damage and v
When hepatic slices were incubated without drug, 0 hour histologic lesion scores were lower
 those observed after incubation for 8, 12 and 24 hours for each histolog
(Figures 4, 5 and 6).  Unlike potassium and ATP levels, the histologic changes indicate that t
ility of canine hepatic slices is much shorter than reported for rat and human hepatic slic
p et al., 2001; Groneberg et al., 2
incubating slices for 8 hours, and these changes may affect the interpretation of drug-induced 
ies.  These results also suggest that histology is a more sensitive measure of toxi
     For isolated liver cells, potassium ion levels decrease when cells are kept at low (4ºC) 
ratures, and the levels subsequently increase to equal or higher levels when t
incubated at 37ºC (Barnabei et al., 1974).  Potassium slice content remains relatively stable
wing an initial recovery period after slicing (Azri et al., 1990).  A similar finding was noted 
is study for canine hepatic slices.   
mean potassium ion concentrations for all phenobarbital concentrations (0, 20, 45 and 75 µg/m
 calculated, the concentrations at 1 hour were lower than those observed afte
6 hours (Table 10, Figure 10).  The potassium ion concentrations of slices incubated with 
ine were lower at 1 hour than at all other time points with a significant increase in
ium ion concentration noted at 24 hours (Table 24, Figure 24
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statistically significant, a pattern was observed.  In these experiments, prior to incubation at 
37ºC, the liver slices were kept at 4ºC.  This pattern of lowered potassium concentrations 
followed by recovery was seen for slices incubated with no drug, phenobarbital, lidocaine and 
cells rted for 
cani n potassium ion concentrations were not 
noted for all experiments, the pattern was consistent for most treatments. 
 
Hepatic Slice Incubation with Phenobarbital 
     The concentrations of phenobarbital in the media were relatively constant over time (Figure 
7).  The initial concentrations in the media were within 10% of expected concentrations 
indicating that the method used for adding drug to the media was successful.  The appearance of 
phenobarbital in the hepatic slice supernatant indicates that phenobarbital penetrated into the 
phen nt of phenobarbital found in the supernatant 
e 
conc  µg/ml 
phen
phenobarbital.   
 75 
µg/m , Figure 11).  
s 
of phe  ions into the 
lices 
incu  
(Tab s for slices incubated with 20 and 45 µg/ml were 
For b ith 75 
     H  with hepatotoxicity 
in dogs (Podell, 1998).  The finding that both potassium and ATP concentrations were lower 
carprofen.  This finding is consistent with experiments using rat liver slices and isolated rat liver 
(McLaughlin, 1973; Barnabei et al., 1974).  This cooling effect has not been repo
ne hepatic slices.  Although significant differences i
slices and diffused into the hepatocytes (Figure 8).  Additionally, as the concentration of 
obarbital in the media increased, the amou
increased.  The retention of phenobarbital in hepatic slices was also concentration-dependent; th
entration of phenobarbital in hepatic slice supernatant of slices incubated with 75
phenobarbital was higher than that of slices treated with 45 µg/ml media (Figure 8).  No 
obarbital was noted in the hepatic slice supernatant of slices treated with 0 or 20 µg/ml 
     The potassium ion concentrations in hepatic slice supernatant for slices incubated with
l phenobarbital were lower than those observed in untreated slices (Table 11
This decrease in potassium ion concentrations indicated that the presence of high concentration
nobarbital caused damage to the liver cells causing them to release potassium
media.  A similar finding was noted for ATP concentrations.  The ATP concentrations for s
bated with 75 µg/ml phenobarbital were significantly lower than in slices that were untreated
le 14, Figure 14).  The ATP concentration
also lower than untreated slices, but the differences were not statistically significant (Table 14).  
oth potassium ions and ATP, the measured concentrations for slices incubated w
µg/ml phenobarbital were the lowest for all concentrations used in this study. 
igh serum concentrations of phenobarbital are thought to be associated
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following slice incubation with 75 µg/ml phenobarbital shows a correlation between results from
lices and in vivo data.  These findings indicate that liver slices may be useful for examining 
otential hepatotoxicity of drugs in dogs.  Using t
 
the s
the p he indices of hepatic slice supernatant 
content of potassium ions and ATP, 75 µg/ml phenobarbital was toxic to canine hepatic slices.  
     Phenobarbital is reported to cause hepatotoxicity in dogs (Dayrell-Hart et al., 1991; Müller et 
al., 2000).  Chronic treatment with phenobarbital has been associated with pathologic hepatic 
bioc
amin se) (Dayrell-Hart et al., 1991; Müller et al., 2000).  Hepatic changes associated 
dividual 
anim se studies dose-dependent changes in 
canine hepatic slice viability measures were found which is similar to the in vivo hepatotoxicity 
associated with phenobarbital. 
 
Hepatic Slice Incubation with Primidone 
     Canine hepatic slices were exposed to primidone to determine the drug metabolizing activity 
of the hepatic slices.  Primidone is metabolized to phenobarbital and phenylethylmalonamide 
(Yeary, 1980).  There was no evidence of primidone metabolism as indicated by the lack of 
quantifiable concentrations of phenobarbital in either the media or hepatic slice supernatant 
     Po  
lower ent with primidone 
incu e were also lower than those for untreated slices, but 
P 
data
pota lices incubated with 20 and 45 µg/ml primidone were 
poss
     P n reported to cause hepatic cirrhosis and increases in alanine 
aminotransferase and alkaline phosphatase in dogs (Bunch et al., 1985; Poffenbarger & Hardy, 
changes—fibrosis, nodular hyperplasia and bile duct proliferation—as well as, serum 
hemical changes—increased serum liver parameters (e.g., alkaline phosphatase, alanine 
otransfera
with phenobarbital are related not only to high serum concentrations but also to an in
al’s response to treatment (Müller et al., 2000).  In the
(Tables 16 and 17). 
tassium ion concentrations for slices incubated with all concentrations of primidone were
 than those for slices incubated without primidone indicating that treatm
caused toxicity (Table 18, Figure 16).  For ATP, mean concentrations of 75 µg/ml primidone 
were lower than those observed for untreated slices (Table 21, Figure 19).  ATP levels for slices 
bated with 20 and 45 µg/ml primidon
the differences were not statistically significant (Table 21).  The potassium ion levels and AT
 are consistent showing that treatment with 75 µg/ml primidone caused toxicity.  The 
ssium ion concentrations for s
statistically lower than concentrations for slices incubated without primidone indicating the 
ibility of toxicity with the other concentrations of primidone.   
rimidone has bee
 147
1985).  Liver toxicity due to primidone is associated with high doses of primidone administered 
chronically (Bunch et al., 1982; Schwartz-Porsche et al., 1985).  The association of primidone 
Resu  
prim
Hep
     L rmine the xenobiotics metabolizing ability of the liver slices.  
Boyes  
and se Breimer, 1997).  
     In h concentration of lidocaine used 
ns 
of lid
µg/m 2 hours were significantly lower than those observed 
conce l 
lidoca g/ml lidocaine, MEGX 
conc
(Fig , and no 
natants.  
Stud
foun
 
Boy
show e rapid 
supe
     Human liver slices have been treated with lidocaine to determine the relationship among the 
metabolites produced (Parker et al., 1996).  MEGX was shown to be one of the metabolites 
with liver disease has caused it to fall out of favor for use in treatment of canine epilepsy.  
lts observed in this study show a dose-dependent in vitro hepatotoxicity associated with
idone which is similar to results observed in vivo. 
 
atic Slice Incubation with Lidocaine 
idocaine was also used to dete
In dogs, lidocaine is metabolized to two active metabolites, MEGX and GX (Keenaghan & 
, 1972; Wilcke et al., 1983) (Figure 103).  Production of MEGX from lidocaine is a rapid
nsitive indicator of hepatic drug metabolizing enzyme activity (Tanaka & 
Lidocaine is metabolized to MEGX in humans by CYP3A4 (Tanaka & Breimer, 1997).   
the media the concentration of lidocaine decreased for eac
(3, 10 and 20 µg/ml) (Figures 20, 21 and 22).  For 10 µg/ml lidocaine, the media concentratio
ocaine were significantly lower after 6 hours compared to 1 hour (Figure 21).  For 3 and 20 
l lidocaine, the concentrations at 1
after 1 hour (Figures 20 and 22).  The metabolite MEGX was produced, and quantifiable 
ntrations were noted for each concentration of lidocaine (3, 10 and 20 µg/ml).  For 3 µg/m
ine, MEGX was detected after 1 hour (Figure 20).  For 10 and 20 µ
was present after 1 hour with concentrations increasing over time (Figures 21 and 22).  MEGX 
entrations were significantly higher by 6 hours for 10 µg/ml and by 8 hours for 20 µg/ml 
ures 20 and 21).  No quantifiable concentrations of GX were found in the media
notable concentrations of lidocaine, MEGX or GX were observed in hepatic slice super
ies using human liver slices have also shown that only negligible amounts of MEGX are 
d in the slices (Olinga et al., 1998). 
     Lidocaine is rapidly metabolized in dogs with a half-life of 45 to 60 minutes (Keenaghan &
es, 1972).  A rapid decrease in plasma concentrations due to rapid clearance has also been 
n when the drug is given by the intraperitoneal route (Wilson et al., 2004).  Th
metabolism of lidocaine may account for the failure to detect its presence in the hepatic slice 
rnatant. 
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produced by human liver slices, and GX concentrations were below the limit of quantification 
ker et al., 1996).  Parker et al. (1996) also found an initial 10 to 20% decrease in media 
trate concentrations indicating the distribution of the sub
(Par
subs strate into the liver tissue.  The 
d 
elim  clearance of lidocaine may be responsible for the non-detectable levels in the 
     W
higher for slices incubated with higher concentrations of lidocaine (Figure 104).  The decreasing 
d 
meta
toxic bation of lidocaine with canine hepatic slices demonstrates the 
d 
by p
 
 
 
 
 
 
 
 
 
experiments of this study are in agreement with those found by Parker et al. (1996).  The rapi
ination and
supernatant, and the decline of lidocaine in the media.   
hen all three concentrations of lidocaine are compared, the MEGX concentrations were 
lidocaine and increasing MEGX concentrations indicate that canine liver slices take up an
bolize lidocaine.  Potassium and ATP concentrations indicated lidocaine did not cause 
ity to the liver slices.  Incu
xenobiotic metabolizing activity of slices and the lack of toxic effects of lidocaine as measure
otassium ion and ATP concentrations in the hepatic slice supernatant. 
Figure 103.  Metabolism of lidocaine.  Lidocaine is metabolized to MEGX by N-deethylation.  A second N-
deethylation produces GX. 
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Cyt
     T  phenobarbital and cimetidine to induce or inhibit cytochrome P450 enzymes in 
the 
     I  been performed in rat liver slices.  The slices were 
incubated for 24 hours in carbogen saturated William’s Medium E containing phenobarbital (100 
µM); based on information from prior experiments, this concentration of phenobarbital induced 
CYP mRNA levels and enzyme activities (Lupp et al., 2001).  Lupp et al. (2001) used a 
semiquantitative immunohistochemistry method for staining slices to determine the location and 
*
04.  Lidocaine and MEGX comparisons among media concentrations.  Lidocaine 
concentrations (ng/ml±SE) in media for slices incubated for 24 hours with 3, 10 and 20 µg/ml lidocaine.  All 
concentrations shown are above the limit of quantification of 50 ng/ml for both lidocaine and MEGX.  Media 
ntrations are an average of two samples per time point.  Time points with an asterisk (*) indicate concentrations
gnificantly different.   
 
ochrome P450 Induction and Inhibition 
he ability of
canine hepatic slices was also investigated.  No induction or inhibition was noted in the slices at 
concentrations used in this study (Tables 79 and 80).   
n vitro induction by phenobarbital has
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induction of CYPs.  With phenobarbital, induction of CYP2B1 and 3A2 was noted, as well a
rplasia of hepatocytes (Lupp et al., 2001).   
henobarbital can induce liver CYPs by multiple mechanisms as shown by the discovery th
s, 
hype
     P at 
higher doses of phenobarbital are required for induction of CYP3A1 mRNA than for CYP2B1 
trigg
the P
1999
rece g (NR) sites (Waxman, 1999; Handschin & Meyer, 2003).  RXR serves as a 
common heterodimerization partner for several orphan nuclear receptors (Waxman, 1999; 
Handschin & Meyer, 2003).  The CAR-RXR heterodimer binds to a hexameric DNA response 
element and activates CYP gene transcription (Waxman, 1999; Handschin & Meyer, 2003).   
a 
num ts and humans (Levine et al., 1998).  
cime
whereas in rats, cimetidine inhibits CYP2C6 and CYP2C11 (Levine et al., 1998).   
com
to th iety of CYP which results in non-specific inhibition of CYP enzymatic activity 
(Fur
Incu  
Carp
d no differences 
were
supernatant of slices incubated in 50 and 100 µg/ml media, the concentrations of carprofen 
creased over time for both enantiomers, and the AUC for peak B AUC was higher than that for 
peak A (Table 30, Figure 31).  Other than an initial decline in potassium ion concentrations (1 
mRNA (Waxman, 1999).  Phenobarbital (PB) and phenobarbital-like inducers induce CYPs by 
ering the cytoplasmic-nuclear translocation of orphan nuclear receptor constitutive 
androstane receptor (CAR) (Waxman, 1999; Handschin & Meyer, 2003).  CAR then binds with 
B-responsive enhancer (PBRE) and confers PB-inducible gene transcription (Waxman, 
).   
     CAR, as a heterodimer with the retinoid X receptor RXR, binds to each of the nuclear 
ptor bindin
     Cimetidine is an H2 receptor antagonist, and this compound inhibits the metabolism of 
ber of xenobiotics in vitro and in vivo in ra
Theophylline, warfarin and lidocaine are examples of drugs whose metabolism is inhibited by 
tidine (Furuta et al., 2001).  In humans, cimetidine inhibits CYP2C9 (Furuta et al., 2001), 
     Cimetidine inhibition of CYPs in vitro displays competitive or mixed 
petitive/noncompetitive enzyme kinetics (Levine et al., 1998).  Cimetidine acts by binding 
e heme mo
(Furuta et al., 2001).  The heme moiety is the oxygen binding site for oxidative metabolism 
uta et al., 2001).    
 
bation with Carprofen, Carprofen with Phenobarbital and Carprofen with Cimetidine
rofen 
     The media concentrations of carprofen were maintained over 24 hours, an
 observed between the enantiomers (Table 29, Figures 28 and 29).  In the hepatic slice 
in
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hour), there were no other significant declines in potassium ion concentration (Table 31, Figure 
conc
in A xtent and 
in 
this crosis and vacuolation 
severity (Tables 37 and 39, Figures 40 and 42).  For necrosis, 0, 1 and 4 hour lesion scores were 
lower than those at 8, 12 and 24 hours (Table 37, Figure 40).  With vacuolation severity, 0, 1 and 
     T
conc effect of time of incubation was noted by 
carp xicity 
in th
Carp
     In
resu edia (Table 40, Figure 
 B 
was 
carp s at 24 
hours, the only other statistically significant decline in potassium ion concentrations occurred at 
48 hours where concentrations were lower than those observed at 24 hours (Table 42, Figure 48).  
lesion .  
nd 
vacuo re is some indication that 
effects 
associ
scores
carpro  
33).  For ATP concentrations, significant decreases were noted at 12 and 24 hours compared to 
entrations at 1, 4 and 8 hours (Table 34, Figure 36).  There were no significant differences 
TP concentrations among the media concentrations.  For necrosis, vacuolation e
vacuolation severity, no significant effects of carprofen were seen at any concentration used 
study.  Significant time differences, however, were noted for ne
4 hour lesion scores were lower than those at 24 hours (Table 39, Figure 42).   
here was no evidence of toxicity caused by carprofen using potassium ion or ATP 
entrations or histologic changes as indicators.  An 
the presence of histologic changes across time for slices incubated in all concentrations of 
rofen (0, 10, 50 and 100 µg/ml).  Treatment with carprofen does not appear to cause to
e hepatic slices.   
 
rofen with Phenobarbital 
cubation of hepatic slices with phenobarbital followed by incubation with carprofen did not 
lt in differences in the concentration of carprofen enantiomers in the m
44).  Similar to incubation with carprofen alone, the hepatic slice supernatant AUC for peak
higher than that for peak A for slices incubated in media containing 50 and 100 µg/ml 
rofen (Table 41, Figure 46).  After an initial decline in potassium ion concentration
No significant differences were noted for ATP concentrations.  The examination of histologic 
s did not reveal consistent differences for the range of carprofen media concentrations
Zero hour lesion scores were lower than all other time points for necrosis, vacuolation extent a
lation severity (Tables 46, 48 and 50, Figures 53, 55 and 57).  The
the length of incubation may be the cause of the histologic changes.  There were no toxic 
ated with the various concentrations of carprofen in the media since the histologic lesion 
 for untreated slices were not lower than those incubated with 10, 50 or 100 µg/ml 
fen (Tables 47 and 49, Figures 54 and 56).  No toxicity appears to be related to hepatic
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slice incubation with phenobarbital and carprofen based on potassium ion and ATP 
concentrations and histologic lesions. 
 
     D ce supernatant were noted for slices incubated with 
med
59), e hepatic slice supernatant peak B AUC for 50 µg/ml carprofen was higher than that 
s at 24 
hours 3).  
When ATP concentrations were compared, concentrations at 24 hours were higher than at all 
ere were 
no si
incre
and
Fig  toxicity was noted for slices incubated with cimetidine and carprofen.  Any toxic 
in 
the m
Treatment Comparisons 
     The only AUC differences noted were for slices incubated with 100 µg/ml carprofen; peak A 
AUC for carprofen was higher than that for slices incubated with cimetidine and carprofen 
(Figure 77, Table 65).  The histologic lesion scores for slices incubated with carprofen for up to 
24 hours were compared with the lesion scores for slices incubated for up to 48 hours with 
ere 
obs
cim profen (Table 81).  The differences may be related to length of incubation 
rather than actual treatment differences.  The hepatotoxicity associated with carprofen is thought 
to be idiosyncratic (MacPhail et al., 1998).  These results support that conclusion since no dose-
related hepatic damage was shown for canine slices incubated with carprofen.   
 
Carprofen with Cimetidine 
ifferences for media and hepatic sli
cimetidine followed by incubation with carprofen (Table 51 and 52, Figure 59 and 61).  The 
ia peak B AUC for 10 µg/ml carprofen was higher than that for peak A (Table 51, Figure 
and th
for peak A (Table 52, Figure 61).  After an initial decline in potassium ion concentration
, there were no significant declines in potassium ion concentrations (Table 53, Figure 6
other time points (Table 56, Figure 66).  After the decline in ATP levels at 25 hours, th
gnificant differences in concentrations (Figure 66).  For histologic lesions, significant 
ases in necrosis were noted across time (Table 59, Figure 70).  No significant changes in 
vacuolation extent lesion scores were noted after 25 hours of incubation (Table 60, Figure 71), 
 for vacuolation severity, no significant lesion changes were noted after 24 hours (Table 62, 
ure 73).  No
differences appear to be related to length of incubation and not the concentration of carprofen 
edia. 
 
phenobarbital and carprofen or cimetidine and carprofen.  In most cases where differences w
erved, incubation with carprofen alone produced lower lesion scores than incubation with 
etidine and car
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Table 81.  Summary of histologic results for treatment comparisons.  Summary of histologic lesion findin
incubated with carprofen (C), carprofen and phenobarbital (PC) and carprofen and cimetidine (CC).  Trea
me letter are not significantly different.  
Carprofen Concentrat
gs for slices 
tments with 
the sa
 
ion Treatment 
0 µg/ml 10 µg/ml 50 µg/ml 100 µg/ml 
C L* ND* L L 
PC H* ND* M L 
N
ec
ro
si
s 
CC H* ND* H H 
C ND L* ND ND 
PC ND H* ND ND 
V
ac
uo
la
tio
n 
ex
te
nt
 
CC ND H* ND ND 
C L* L* L ND 
PC H* H* H ND 
V
ac
uo
l
H ND 
at
io
n 
se
ve
rit
y 
CC H* H* L
 ND no difference * factor interaction  
 L low lesion score M middle lesion score  H  high lesion score 
 
 
 
Table 82.  Summary of experiment results.  Summary of experiment results and findings for canine hepatic slices 
incubated with various drugs. 
 
Toxicity Indicated 
Drug Tested 
Parent 
Compound 
Presence in 
Media 
Parent 
Compound 
Presence in 
Supernatant 
Metabolite 
Presence in 
Media 
Metabolite 
Presence in 
Supernatant K+ ATP Histo 
Phenobarbital √ √ NA NA √ √ NM 
Primidone NM NM X X √ √ NM 
Lidocaine √ X √ X X X NM 
Carprofen √ √ NM NM X X X 
Carprofen with 
phenobarbital √ √ NM NM X X X 
Carprofen with 
cimetidine √ √ NM NM X X X 
 NA not applicable  NM not measured  X not present/no  √  present/yes 
 Histo histology 
    
 
 
 
Summary 
     Tissue slices are a good alternative to in vivo studies since tissue slice experiments require 
fewer animals, are cheaper and the effects of multiple agents can be examined at the same time 
(Azri et al., 1990).  Human and animal tissue slices have been used to gather information to 
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predict what might occur in humans (Fisher et al., 2001).  The application of this technique to 
predict what might happen in dogs has not been reported.   
     The results of these studies have shown the utility of canine hepatic slices as a model for 
studying drug metabolism and toxicity in dogs.  Drug uptake, drug metabolism and toxicity were 
demonstrated using this in vitro technique (Table 82).  Potassium ion and ATP levels were found 
to be less sensitive indicators of hepatic slice viability compared with histologic evaluations.  A 
similar finding was noted for canine liver slices used to test three different incubation systems 
(Fisher et al., 2001).  Additionally, when compared with the potassium ion and ATP 
concentrations of the Fisher et al. (2001) study, the ATP levels of these studies were lower, and 
the potassium ion concentrations were comparable or slightly higher.  In another experiment, 
canine liver slices were used to determine the viability of cold-preserved slices (Fisher et al., 
1996a).  Again, the potassium ion concentrations of these studies were comparable or slightly 
higher than those of the Fisher et al. (1996a) study.   
     Cooling canine liver slices caused a decrease in potassium ion concentrations while 
concentrations recovered during incubation (warming) of the slices.  This cooling effect on 
potassium ion concentrations has not been reported for canine hepatic slices, but has been noted 
in rat liver slices and isolated cells (McLaughlin, 1973; Barnabei et al., 1974). 
     Phenobarbital was used to determine the response of canine hepatic cells to a known 
hepatotoxicant.  Toxicity, as indicated by potassium ion and ATP concentrations, was 
demonstrated for slices incubated in 75 µg/ml media (Figures 11 and 14).  When potassium ion 
and ATP concentrations in slices treated with phenobarbital (20, 45 and 75 µg/ml) were 
compared with control slices, a pattern of lower ATP and KP+ P concentrations was associated with 
the treated slices (Tables 11 and 14).   
     Exposure of hepatic slices to primidone was performed to determine the drug metabolizing 
enzyme activity of the slices.  Unfortunately, no phenobarbital was detected to provide evidence 
of metabolism (Tables 16 and 17).  Toxicity was noted, however, as lowered potassium ion and 
ATP concentrations were observed for slices incubated with 75 µg/ml primidone (Figures 16 and 
19).   
     For both phenobarbital and primidone, the potassium ion concentrations after incubation with 
75 µg/ml were the lowest of all treatments (Tables 11 and 18).  The same was true for ATP 
where treatment with 75 µg/ml phenobarbital or primidone gave the lowest ATP concentrations 
(Table 14 and 21).  In these experiments, incubation of hepatic slices with equal concentrations 
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of primidone and phenobarbital yielded similar results.  A trend of high drug concentrations 
being associated with toxicity was observed since both primidone and phenobarbital were toxic 
to canine hepatic slices at high concentrations.  This is similar to what is seen in vivo (Bunch et 
al., 1985; Poffenbarger & Hardy, 1985; Podell, 1998). 
     Phase I and phase II biotransformation have been demonstrated in canine hepatic slices using 
testosterone as a marker drug for phase I biotransformation and glucuronidation and sulfation of 
7-hydroxycoumarin as indicators of phase II biotransformation (Martignoni et al., 2004).     
In these studies, lidocaine was metabolized to MEGX in canine hepatic slices indicating that the 
CYP enzyme responsible for the biotransformation of lidocaine (CYP3A4 in humans) was 
functional.  Since lidocaine metabolism has been used as a hepatic function test in humans, these 
studies indicate that canine hepatic slices are functional for up to 24 hours.    
     The results of the phenobarbital, primidone and lidocaine studies should be confirmed by 
exposing additional slices to these drugs, and the experiments should be repeated using more 
slices to reduce variability.  The use of additional slices would also help to determine whether 
any of the lower concentrations of phenobarbital or primidone could cause hepatotoxicity.  Since 
histologic evaluation was not performed for slices incubated in phenobarbital, primidone or 
lidocaine, the use of histology for these studies would help determine the presence of other toxic 
changes and confirm the toxicity noted in these studies.  Finally, a more sensitive primidone 
assay would be useful to determine whether canine slices are capable of metabolizing primidone 
to phenobarbital.  Increasing the amount of primidone in the media may also lead to formation of 
higher concentrations of phenobarbital; however, increasing the primidone concentrations may 
enhance the apparent toxic effects.         
     Since induction and inhibition did not occur in the experiments performed, these studies 
should be repeated.  Higher concentrations of phenobarbital and cimetidine could be used to 
induce and inhibit cytochrome P450 enzymes, respectively.  Alternatively, different CYP 
inducers (i.e., rifampin) and inhibitors (i.e., ketoconazole) could also be used. 
     No toxicity was noted for slices incubated with carprofen, with phenobarbital and carprofen 
or with cimetidine and carprofen.  The toxicity associated with carprofen in dogs is unlike that 
associated with phenobarbital and primidone.  Phenobarbital and primidone-induced 
hepatotoxicity is associated with exposure of liver to high serum levels of these drugs while 
carprofen is thought to cause an idiosyncratic hepatotoxicity (MacPhail et al., 1998; Podell, 
1998). 
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     Canine hepatic slices were highly responsive to drugs with established in vivo hepatotoxic 
profiles in dogs.  For drugs with inconsistent or idiosyncratic causes of hepatotoxicity, the use of 
canine hepatic slices has not been predictive in these in vitro slice experiments.  The use of slices 
from breeds that are more sensitive to the toxicity of a drug may be useful for determining the 
utility of canine hepatic slices as a more global in vitro model of hepatotoxicity.  Slices 
incubated in media without drug showed no toxicity over 24 hours based on potassium ion and 
ATP supernatant concentrations whereas significant increases in histologic lesions were noted at 
8, 12 and 24 hours.  Based on the results of these experiments, histologic parameters were more 
sensitive than biochemical measurements for determining the viability of these slices.  Canine 
hepatic slices were found to be a useful model for examining drug metabolism and toxicity for 
up to 24 hours, and current studies are designed to further validate the use of this in vitro model.   
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APPENDIX I 
STOCK SOLUTIONS 
 
Phenobarbital 
Measure 0.1 ml phenobarbital sodium injectable and q.s. to 20.2 ml with prepared media to make a 
phenobarbital solution of concentration 295.074 µg/ml 
 
Primidone 
Measure 0.0502 g powder and q.s. to 20 ml with ethanol to make a 2.51 mg/ml solution 
 
Lidocaine 
Measure 0.5 ml of 2% lidocaine HCl injectable and q.s. with prepared media to 20 ml to make a 405µg/ml 
lidocaine solution 
 
Cimetidine 
Measure 0.513 ml of 150 mg/ml cimetidine injectable and q.s. with prepared media to 305 ml to make a 
solution of 0.2523 mg/ml cimetidine 
 
Diazepam 
Measure 0.1 ml of 5 mg/ml diazepam injectable and q.s to 10 ml with prepared media to make a 50,000 
ng/ml solution 
 
Carprofen 
Racemic – 10,000 µg/ml 
 Measure 0.1 g powder and q.s. to 10 ml with ethanol 
R or S enantiomer – 20,000 µg/ml 
 Measure 0.2 g powder and q.s. to 10 ml with ethanol 
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APPENDIX II 
CHEMICAL STRUCTURES 
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 APPENDIX III 
HEPATIC SLICE WEIGHT TABLE 
 
 
Table A-1.  Hepatic slice weights.  Hepatic slice weights with means and standard deviations (std dev) represent variability across time, among day and between day. 
  2/25/2003 5/1/2003 7/3/2003     
Time 
(hour) 0 µg/ml 
Carp    
10 µg/ml 
Carp      
50 µg/ml 
Carp     
100 µg/ml 0 µg/ml 
Pheno     
20 µg/ml 
Pheno    
45 µg/ml
Pheno    
75 µg/ml
Lido    
3 µg/ml
Lido      
10 µg/ml
Lido      
20 µg/ml 0 µg/ml 
Prim      
20 µg/ml
Prim     
45 µg/ml
Prim     
75 µg/ml  
Means across time for all 
treatments 
1 0.0276 0.0265 0.0364 0.0304 0.0312 0.0278 0.0294 0.0264 0.0283 0.0244 0.0311 0.0249 0.0238 0.0284 0.0228  Time (hour) mean (g) std dev
  0.0299 0.0334 0.0292 0.0366 0.0231 0.0313 0.0320 0.0269 0.0316 0.0222 0.0294 0.0273 0.0258 0.0267 0.0272  0 0.0252 0.0038
3         0.0264 0.0232 0.0228 0.0313 0.0301 0.0230 0.0259 0.0277 0.0213 0.0206 0.0226  1 0.0260 0.0044
          0.0275 0.0300 0.0280 0.0241 0.0263 0.0272 0.0232 0.0195 0.0254 0.0189 0.0273  3 0.0251 0.0035
6              0.0315 0.0264 0.0272 0.0221 0.0279 0.0261 0.0267 0.0297 0.0209 0.0220 0.0255 0.0186 0.0231 0.0207 0.0278 4 0.0229 0.0036
  0.0258 0.0290 0.0225 0.0248 0.0235 0.0249 0.0227 0.0290 0.0249 0.0263 0.0267 0.0228 0.0215 0.0237 0.0265  6 0.0250 0.0030
8              0.0305 0.0236 0.0241 0.0266 0.0260 0.0284 0.0248 0.0295 0.0256 0.0273 0.0226 0.0187 0.0195 0.0175 0.0270 8 0.0236 0.0035
  0.0276 0.0272 0.0283 0.0215 0.0224 0.0225 0.0271 0.0257 0.0227 0.0242 0.0218 0.0184 0.0191 0.0210 0.0200  12 0.0227 0.0033
12               0.0272 0.0252 0.0232 0.0243 0.0257 0.0286 0.0265 0.0223 0.0280 0.0238 0.0249 0.0174 0.0171 0.0171 0.0212 24 0.0234 0.0034
  0.0220 0.0259 0.0325 0.0265 0.0235 0.0237 0.0207 0.0229 0.0237 0.0238 0.0278 0.0171 0.0177 0.0219 0.0186     
24              0.0215 0.0267 0.0280 0.0260 0.0251 0.0271 0.0269 0.0281 0.0222 0.0279 0.0235 0.0183 0.0183 0.0182 0.0180 
  0.0249 0.0280 0.0256 0.0318 0.0229 0.0227 0.0260 0.0261 0.0251 0.0246 0.0225 0.0200 0.0210 0.0162 0.0200  
Mean for all times and 
treatments = 0.0241 
                                    
mean 0.0269 0.0272     0.0277 0.0271 0.0254 0.0264 0.0261 0.0268 0.0258 0.0247 0.0254 0.0209 0.0211 0.0209 0.0233
std dev 0.0034 0.0026     0.0043 0.0046 0.0026 0.0030 0.0031 0.0028 0.0032 0.0020 0.0029 0.0038 0.0029 0.0038 0.0037
Std Dev for all times and 
treatments = 0.0038 
mean 0.0272   0.0258 0.0215    
std dev 0.0037 0.0028 0.0036     
                    
  10/15/2003 10/14/2003 
Time 
(hour) 0 ng/ml 0 ng/ml 0 ng/ml 
Diaz      
100 ng/ml 
Diaz       
250 ng/ml
Diaz       
500 ng/ml
Pheno    
75 µg/ml
Cimet 
1000 µM 0 ng/ml
Diaz    
100 ng/ml
Diaz      
250 ng/ml
Diaz      
500 ng/ml 0 µg/ml 
Carp     
10 µg/ml
Carp     
50 µg/ml
Carp      
100 µg/ml
Carp    
10 
µg/ml 
Carp    
50 
µg/ml 
Carp    
100 
µg/ml 
0 0.0269 0.0261 0.0261 0.0250 0.0226 0.0185 0.0302 0.0227 0.0287 0.0272 0.0226 0.0239 0.0247 0.0329 0.0241 0.0225 0.0283  0.0235 0.0187 
  0.0231 0.0247 0.0275 0.0272 0.0284 0.0243 0.0231 0.0314 0.0267 0.0236 0.0235 0.0305 0.0219 0.0270 0.0209 0.0239 0.0351  0.0175 0.0234 
1 0.0194     0.0273 0.0172 0.0233     0.0257 0.0238 0.0349 0.0198 0.0226 0.0234 0.0230 0.0266 0.0318 0.0256 0.0220 
  0.0266     0.0201 0.0208 0.0192     0.0251 0.0250 0.0217 0.0192 0.0221 0.0271 0.0266 0.0240 0.0241 0.0199 0.0225 
4 0.0216     0.0238 0.0201 0.0235     0.0266 0.0242 0.0255 0.0199 0.0222 0.0302 0.0224 0.0222 0.0231 0.0238 0.0218 
  0.0160     0.0216 0.0284 0.0191     0.0234 0.0178 0.0199 0.0271 0.0208 0.0276 0.0191 0.0246 0.0317 0.0192 0.0210 
8 0.0196     0.0205 0.0240 0.0200     0.0249 0.0260 0.0268 0.0235 0.0235 0.0273 0.0205 0.0187 0.0338 0.0221 0.0196 
  0.0269     0.0217 0.0222 0.0215     0.0257 0.0217 0.0260 0.0261 0.0222 0.0220 0.0230 0.0184 0.0269 0.0230 0.0173 
12 0.0218     0.0218 0.0198 0.0243     0.0271 0.0193 0.0181 0.0250 0.0210 0.0263 0.0222 0.0217 0.0228 0.0233 0.0224 
  0.0197     0.0192 0.0198 0.0229     0.0280 0.0214 0.0235 0.0217 0.0194 0.0195 0.0234 0.0212 0.0250 0.0200 0.0216 
24 0.0253 0.0220 0.0229 0.0227 0.0205 0.0266 0.0267 0.0260 0.0242 0.0212 0.0281 0.0281 0.0224 0.0263 0.0177 0.0222 0.0215   0.0246 0.0220
  0.0243 0.0171 0.0197 0.0192 0.0193 0.0203 0.0223 0.0216 0.0220 0.0281 0.0260 0.0246 0.0232 0.0208 0.0231 0.0231 0.0287  0.0213 0.0196 
                                        
mean 0.0226 0.0225 0.0241 0.0225 0.0219 0.0220 0.0256 0.0254 0.0257 0.0233 0.0247 0.0241 0.0222 0.0259 0.0222 0.0224 0.0277 0.0220 0.0210
std dev 0.0035 0.0040 0.0035 0.0028 0.0035 0.0026 0.0036 0.0044 0.0019 0.0031 0.0043 0.0035 0.0014 0.0039 0.0024 0.0023 0.0046 0.0024 0.0018
mean  0.0228 0.0237 
std dev 0.0033 0.0035 
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 APPENDIX IV  
DIAZEPAM RESULTS 
 
Abbreviation:  Time (h) = Time (hour) 
     Diazepam was used as a drug to determine the drug-metabolizing ability of the hepatic slices.  
The results showed the potential formation of metabolites, but because of assay limitations, the 
metabolite concentrations could not be quantified.  Additionally, there appeared to be a cross-
reactivity of phenobarbital and cimetidine with diazepam in detection.  Another predicament was 
the loss of supernatant samples during preparation for drug analysis.  Because of these issues, the 
diazepam results are presented here.  The author suggests that the diazepam experiment be tried 
again using the concentrations presented here, as well as, higher concentrations.  Also, extension 
of the limits of quantification should be attempted.   
 
 
Chemical Structures 
N
N
Cl
O
H3C
 
Fig. A-8.  Diazepam 
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Fig. A-9.  Temazepam 
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Fig. A-11.  Nordiazepam 
O
Media and supernatant drug concentrations 
     Figures A-12 through A-15 show the concentrations of diazepam and its metabolites, 
oxazepam, temazepam and nordiazepam, in media and supernatant without phenobarbital or 
cimetidine incubation.  Media concentrations are a mean of three samples per time point per 
concentration.  Concentrations of diazepam in 0 ng/ml media were below the lower limit of 
quantification (LOQ). 
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Fig. A-12.  Concentration of diazepam and metabolites in media containing 100 ng/ml diazepam.  Limit of 
quantification for diazepam is 40 ng/ml and for all metabolites is 80 ng/ml. 
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Fig. A-13.  Concentration of diazepam and metabolites in media containing 250 ng/ml diazepam.  Limit of 
quantification for diazepam is 40 ng/ml and for all metabolites is 80 ng/ml. 
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Fig A-14.  Concentration of diazepam and metabolites in media containing 500 ng/ml diazepam.  Limit of 
quantification for diazepam and nordiazepam is 40 ng/ml; for all other metabolites, it is 80 ng/ml. 
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Fig. A-15.  Concentrations of diazepam in media containing 0, 100, 250 and 500 ng/ml diazepam.   Limit 
of quantification for diazepam is 40 ng/ml. 
 
     The concentrations of the diazepam metabolites in the media were below the lower limit of 
quantification (LOQ).  A few samples did have concentrations above the lower LOQ for 
oxazepam and  nordiazepam (Figures A-16 and A-17).   
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Fig. A-16.  Concentrations of oxazepam in media containing 0, 100, 250 and 500 ng/ml diazepam.   Limit 
of quantification for oxazepam is 80 ng/ml. 
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Fig. A-17.  Concentrations of nordiazepam in media containing 0, 100, 250 and 500 ng/ml diazepam.   
Limit of quantification for nordiazepam is 40 ng/ml. 
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ean of three samples per time point per treatment.  Diazepam concentrations in media 
ontaining 0 ng/ml diazepam were below the lower LOQ.   
     Figures A-18 through A-25 show the concentrations of diazepam and its metabolites in media 
with no treatment or following treatment with phenobarbital or cimetidine.  Concentration
m
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Fig. A-18.  Concentration of diazepam in media containing 100 ng/ml diazepam following no treatment or 
treatment with phenobarbital or cimetidine.  The limit of quantification is 40 ng/ml for diazepam. 
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Fig. A-19.  Concentration of oxazepam in media containing 100 ng/ml diazepam following no treatment 
or treatment with phenobarbital or cimetidine.  The limit of quantification is 80 ng/ml. 
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Fig. A-20.  Concenation of diazepam in media containing 250 ng/ml diazepam following no treatment or 
treatment with phenobarbital or cimetidine.  The limit of quantification is 40 ng/ml for diazepam. 
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ig. A-21.  Concentration of oxazepam in media containing 250 ng/ml diazepam following no treatmeF
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Fig. A-22.  Concentration of diazepam in media containing 500 ng/ml diazepam following no treatme
treatment with phenobarbital or cimetidine.  The limit of quantification is 40 ng/ml for diazepam. 
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Fig. A-23.  Concentration of oxazepam in media containing
o
 
 177
0
10
0 10 20 30 40 50
Time (hour)
20
30
4
5
6
7
8
9
0
C
on
ce
0
0
0
0
0
0
10
nt
ra
tio
n 
(n
g/
m
l)
Post phenobarbital
No treatment
Post cimetidine
azepam in media containing 500 ng/ml diazepam following no treatment 
r treatment with phenobarbital or cimetidine.  The limit of quantification is 80 ng/ml. 
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Fig. A- nc ia pam in media containing 500 ng/ml diazepam following no 
treatme a al or cimetidine.  The limit of quantification is 40 ng/ml. 
 
     The hepatic supernatant drug levels were below the limit of quantification for the slices 
exposed to diazepa n 27 show the changes that occurred following 
exposure to phenobarbital nd ci etidine for samples that were above the limit of quantification. 
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Fig. A-26.  He ic upernat t concentration of temazepam.  Slices were incubated in media containing 
100 /ml d am ng no treatment or treatment with phenobarbital or cimetidine.  The limit of 
qua icati 80 g/ml.  Values are an average of two samples per time point per treatment. 
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Fig. A-27.   Hepatic supernatant concentration of temazepam.  Slices were incubated in media containing 
500 ng/ml diazepam following no treatment or treatment with phenobarbital or cimetidine.  The limit of 
quantitation is 80 ng/ml.  Values are an average of two samples per time point per treatment. 
 
 
Potassium 
     Mean potassium values across time and by concentration are shown in Figure A-28.  The 
two-way ANOVA results showed that mean potassium values for time were significantly 
different (df=5, F-ratio=28.442, p-value=0.000).  Concentrations at time 0 were higher than 
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Fig. A-28.  Potassium concentration in hepatic supernatant following incubati n media containing 
r media concentration. 
s at 1 hour were lower than concentrations at 4, 
12  ho  disp ys the homogeneous groups for time.   
 
Table A-2.  g oups for m an potassium values across time. 
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No significant differences were found for concentration (df=3, F-ratio=0.116, p-value=0.950) or 
the time-concentration interaction (df=15, F-ratio=0.808, p-value=0.665). 
     Figure A-29 shows the mean potassium values following incubation with phenobarbital and 
diazepam. Mean potassium values for time 0 were significantly higher than for all other 
concentrations (df=6, F-ratio=19.690, p-value=0.000) (Table A-3).  For concentration (df=
ratio=2.0317, p-value=0.132) and time-concentration interaction (df=18, F-ratio=0.496, p
value=0.938), no significant differences were found. 
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Fig. A-29. Potassium concentration in hepatic supernatant following exposure to phenobarbital and 
diazepam.  Values are an average of two samples per time point per concentration. 
 
 
 
 
Table A-3.  Homogeneous groups for mean potassium value 
 
 
 
 
 
 
 
 
 
 
 
 
    The potassium values following exposure to cimetidine and diazepam are shown in Figure A-
30.  Theean values for potassium are significantly higher at time 0 compared to times 25 through 
48 (df=6, F-ratio=9.841, p-value=0.000) (Table A-4).  Additionally, potassium values at time 48 
are significantly lower than time 24.  No significant differences were found for concentration 
(df=3, F-ratio=0.147, p-valu%=0.931) or the time*concentration interaction (df=18, F-
ratio=1.085, p-value=0.413). 
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Fig ue r slices exposed to diazepam over 24 hours.  Concentrations are a mean of four 
sup ples pe me point d concentration. 
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Fig. A-32. ues r slices ex sed to phen arbital and di epam. 
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Fig. P value r slices exposed to cime ine and diazepam. 
 
 
Tab ogeneo roups for P by time 
 
 
Tab  for ATP by concentration 
 
 
 
 
 
 
ogene roups 
  
A-33.  AT s fo tid
le A-7.  Hom us g AT
 
 
 
 
 
 
 
 
 
 
le A-8. Homogeneous groups
 
Time 
(h) Hom ous g
0 a  
24 a b 
25 a 
  
   
b   
  
c  
c  
 ogeneougroups 
a  
28 a 
32  b 
36   
48   
Medi
concentration
a 
(ng/ml) 
Hom s 
0   
100 
250 
a  
a  
  
 
b 
 
 
500 b  
 185
Histology 
 
Table A-9.  Diazepam Hepa hepatic slices incubated in 
diazepam for up to twenty-four hours.   
  Lesion scores*  
tic Slice Lesion Scores.  Lesion scores of 
  
Media Time Necrosis 
Concentration (hour) : extent 
Vacuolation
: extent 
Vacuolation
: severity Comments 
           
0 ng/ml 0 0 0 0  
0 ng/ml 1 0 0 0  
0 ng/ml 4 1 2 1  
0 ng/ml 8 1 3 1 a 
0 ng/ml 12 1 1 1  
0 ng/ml 24 2 2 2  
      
100 ng/ml 0 0 0 0  
100 ng/ml 1 0 0 0  
100 ng/ml 4 1 2 1  
100 ng/ml 8 1 3 1  
100 ng/ml 12 2 1 1  
100 ng/ml 24 1 1 1  
      
250 ng/ml 0 0 0 0  
250 ng/ml 1 0 2 1  
250 ng/ml 4 0 2 1  
250 ng/ml 8 1 2 1  
250 ng/ml 12 1 2 2 a 
250 ng/ml 24 2 1 1  
      
500 ng/ml 0 0 0 0  
500 ng/ml 1 0 2 1  
500 ng/ml 4 1 2 1  
500 ng/ml 8 1 3 2  
500 ng/ml 12 1 1 1 a 
500 ng/ml 24 1 2 2  
 
* Lesion scoring: (outermost zone ~10 hepatocytes wide was disregarded) 
  1 5 >90% 
a Slides showi rence in lesion extent and/or severity as move across the slide 
 0 < 1% hepatoc9tes affected 3 21-40% 
1 1-10% 4 41-90% 
2 1-20% 
ng marked diffe
 186
Table A-10.  Diazepam 2 Hepatic Slice Lesion Scores.  Lesion scores of hepatic slices incubated in 
iazepam for up to twenty-four hours.   
 
d
    Lesion scores*  
Media Time Necrosis Vacuolation Vacuolation Comments Concentration (hour) : extent : extent : severity 
      
0 ng/ml 0 0 1 1  
0 ng/ml 1 0 0 0  
0 ng/ml 4 1 2 1  
0 ng/ml 8 2 3 2  
0 ng/ml 12 1 4 4  
0 ng/ml 24 2 4 4  
      
100 ng/ml 0 0 1 1  
100 ng/ml 1 0 1 1  
100 ng/ml 4 1 2 1  
1 g/m 2 3 2  00 n l 8 
1 ng/m 1 1 2 1  00 l 2 
1 ng/m 2 2 4 4 a 00 l 4 
      
2 g/ml 0 1 1  50 n  0 
2 g/ml 0 1 1  50 n  1 
250 ng/ml 4 0 3 2  
250 ng/ml 8 1 4 3  
250 ng/ml 12 1 3 1  
250 ng/ml 24 2 4 3  
      
500 ng/ml 0 0 1 1  
500 ng/ml 1 0 2 1  
500 ng/ml 4 1 3 2  
500 ng/ml 8 1 4 3  
500 ng/ml 12 1 3 2  
500 ng/ml 24 1 4 4  
* Lesion scoring: (outermost zone ~10 hepatocytes wide was disregarded) 
 0 < 1% hepatocytes affected 3 21-40% 
1 1-10% 4 41-90% 
 2 11-20% 5 >90% 
a Slides showing marked difference in lesion extent and/or severity as move across the slide 
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Table A-11.  Diazepam and phenobarbital Hepatic Slice Lesion Scores.  Lesion scores of hepatic slices 
incubated in phenobarbital for 24 hours followed by incubation in diazepam for 1, 4, 8, 12 and 24 hours. 
  Lesion scores*  
 
  
Media 
Concentration (hour) 
Necrosis 
: extent 
Vacuolation
: extent 
Vacuolation 
: severity Comments 
Time 
      
0 ng/m 0 0 0 0  l 
0 ng/ml 2 0 0   24 
      
phenobarbital 0 0 0 0  
phenobarbital 24 1 3 3  
      
0 ng/ml 25 1 2 3  
0 ng/ml 28 2 4 4 a 
0 ng/ml 32 2 4 4  
0 ng/ml 36 2 3 3  
0 ng/ml 48 2 3 3 a 
      
100 ng/ml 25 1 3 3  
100 ng/ml 28 3 3 2  
100 ng/ml 32 2 3 2  
100 ng/ml 36 2 4 4  
100 ng/ml 48 2 2 2  
      
250 ng/ml 25 2 2 2  
250 ng/ml 28 3 3 2 a 
250 ng/ml 32 3 4 4  
250 ng/ml 36 3 4 4  
250 ng/ml 48 2 4 4  
      
500 ng/ml 25 2 3 3 a 
500 ng/ml 28 2 4 4 a 
500 ng/ml 32 3 3 2  
500 ng/ml 36 3 4 4  
500 ng/ml 48 2 3 3  
  * Lesion scoring: (outermost zone ~10 hepatocytes wide was disregarded) 
 0 < 1% hepatocytes affected 3 21-40% 
1 1-10% 4 41-90% 
 2 11-20% 5 >90% 
a Slides showing marked difference in lesion extent and/or severity as move across the slide 
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Table A-12.  Diazepam and cimetidine Hepatic Slice Lesion Scores.  Lesion scores of hepatic slices 
incubated in cimetidine for 24 hours followed by incubation in diazepam for 1, 4, 8, 12 and 24 hours. 
  Lesion scores*  
 
  
Media
Concentration 
e 
(hour) 
Necrosis 
: extent 
Vacuolation 
: extent 
Vacuolation 
: severity Comments 
 T mi
      
0 ng/ml 0 0 0   0 
0 ng/ml 4 3 1 2   2
      
cimetidine 0 0 0 0  
cimetidine 24 2 0 0  
      
0 ng/ml 2 2 2   25 
0 ng/ml  2 3 3  28
0 ng/m 3 3 2 a l 32 
0 ng/m 3 3 2 a l 36 
0 ng/m 2 2 2  l 48 
      
1 g/m 2 1 2 a 00 n l 25 
100 ng/ml 28 3 2 2  
100 ng/ml 32 3 2 2  
100 ng/ml 36 2 4 3  
100 ng/ml 48 4 2 2  
      
250 ng/ml 25 2 2 2  
250 ng/ml 28 3 2 2  
250 ng/ml 32 3 2 1  
250 ng/ml 36 4 3 2  
250 ng/ml 48 4 2 2  
      
500 ng/ml 25 3 0 0  
500 ng/ml 28 3 2 2 a 
500 ng/ml 32 3 2 1 a 
500 ng/ml 36 4 3 2 a 
500 ng/ml 48 3 3 3 a 
  * L scoring: (outermost zone ~10 hepatocytes wide was disregarded) 
  fected 3 21-40% 
1 1-10  4 41-90% 
 2 -2 % 5 >90% 
a Slides s i  m rked difference in lesion extent and/or severity as move across the slide 
 
 
 
esion 
0 < 1% hepatocytes af
%
11 0
how ng a
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APPENDIX V 
CARPROFEN SINGLE STUDY DATA 
 
 
Abbreviation:  Time (h) = Time (hour) 
arprofen Single Study Data 
 
C
Media 
     Carprofen A, B and C were used to designate the different racemic studies.  Figure A-34 show3 the 
media concentrations of carprofen A following 1, 3, 6, 8, 12 and 24 hours incubation.  The carprofen 
concentrations of media containing 0 µg/ml carprofen were below the lower limit of quantification. 
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Fig. A-34.  Carprofen A media concentrations.  Concentrations of carprofen enantiomers (peak A and B) in media 
during twenty-four hours of incubation.  Carprofen concentrations are an average of two samples per media 
concentration per time point.   
 
     Two-way ANOVA of carprofen A media concentration3 for time and peak for 10 and 50 revealed no 
 significant differences across time or between peaks.  For 100 µg/ml, concentrations at 3 hours were
greater than those at 6 hours (df=5, F-ratio=3.288, p-value=0.042).   Table A-13 shows the homogeneous 
groups for 100 µg/ml carprofen. 
 
Table A-13.  Carprofen A – 100 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA of time are 
represented as letters.  Time points with the same letter are not significantly different. 
Time 
(h) 
Homogeneous 
groups 
1 a b 
3 a  
6  b 
8 a b 
12 a b 
24 a b 
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Fig. A-35.  Carprofen B media concentrations.  Concentrations of carprofen enantiomers in media following 
incubation for 0, 1, 4, 8, 12 and 24 hours.  The values are means of three samples per media concentration per time 
point. 
 
     Figure A-35 illustrates the concentrations of carprofen in carprofen B media following 0, 1, 4, 8, 12 and 
24 hours incubation.  The two-way ANOVA of carprofen B media concentrations for time and peak 
showed differences across time for media containing 50 (df=5, F-ratio=6.273, p-value=0.01) and 100 
µg/ml (df=5, F-ratio=4.145, p-value=0.007) carprofen.  For 50 µg/ml, media concentrations at 12 hours 
were less than those at 0 and 1 hour, and concentrations at 24 hours were less than those at 1 hour.  Table 
A-14 shows the homogeneous groups for 50 µg/ml carprofen B.  The concentrations for 100 µg/ml 
carprofen B were higher at 0 hour than at 24 hours.  Table A-15 shows the homogeneous groups for time 
for 100 µg/ml carprofen B. 
 
 
Table A-14.  Carprofen B – 50 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA of time are 
represented as letters.  Time points with the same letter are not significantly different. 
 
Time 
(h) Homogeneous groups 
0 a  c 
1 a   
4 a b c 
8 a b c 
12  b  
24  b c 
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Table A-15.  Carprofen B – 100 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA of time are 
represented as letters.  Time points with the same letter are not significantly different. 
 
Time 
(h) 
Homogeneous 
groups 
0 a   
1 a  
 b
 b  
 b
b  
 
ith time and peak as 
t 
b 
4 a   
8 a
12 a   
24  
 
     Figure A-36 shows the concentration of carprofen enantiomers in media following hepatic slice 
incubation in carprofen C media.  The two-way ANOVA for media concentrations w
factors indicated that for 10 µg/ml carprofen C, peak B was higher than peak A (df=1, F-ratio=7.610, p-
value=0.011).  For 50 µg/ml carprofen C, differences were found across time (df=5, F-ratio=4.984, p-
value=0.003) and between the peaks (df=1, F-ratio=5.636, p-value=0.026).  At 1 hour, carprofen 
enantiomer concentrations were higher than those at 8, 12 and 24 hours.  The enantiomer concentrations a
4 hours were higher than those at 12 hours.  Peak A concentrations were higher than peak B 
concentrations.  Table A-16 shows the homogeneous groups for time for 50 µg/ml carprofen C.  For 100 
µg/ml carprofen C, enantiomer concentrations at 24 hours were less than those at 1 hour.  Table A-17 
shows the homogeneous groups for time during incubation with 100 µg/ml carprofen C. 
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Fig. A-36.  Carprofen C media concentrations.  Concentrations of carprofen enantiomers in media following 
incubation for 0, 1, 4, 8, 12 and 24 hours.  The values are means of three samples per media concentration per time 
point. 
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Table A-16.  Carprofen C – 50 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA of time are 
represented as letters.  Time points with the same letter are not significantly different. 
 
Time 
(h) 
Homogeneous 
groups 
0 a b c 
1 a   
  
b c 
 
b
 
b  
4 a b 
8  
12  c 
24   c 
 
 
Table A-17.  Carprofen C – 100 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA of time are 
represented as letters.  Time points with the same letter are not significantly different. 
Time 
(h) 
Homogeneous 
gr pou s 
0 a 
1 a   
 b  
 b  
 b
b  
oncentrations higher than at 1 and 3 hours.  Table A-18 shows the 50 µg/ml carprofen A homogenous 
groups for time.  At 12 hours, slices incubated in 100 µg/ml media had supernatant concentrations higher 
than at 1 and 6 hours.  Concentrations were also higher at 24 hours than at 1 hour.  Table A-19 shows the 
homogeneous groups across time for 100 µg/ml carprofen A media. 
 
4 a
8 a
12 
24  
a   
 
 
Supernatant 
     The concentrations of carprofen enantiomers in hepatic slice supernatant for slices incubated in 
carprofen A media are shown in Figure A-37.  Significant differences were noted across time for 50 (df=5, 
F-ratio=5.550, p-value=0.007) and 100 µg/ml (df=5, F-ratio=6.295, p-value=0.004) media using two-way 
NOVA.  At 6 hours, slices incubated in media containing 50 µg/ml carprofen A had supernatant A
c
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ig. A-37.  Carprofen A supernatant concentrations.  Concentrations of carprofen enantiomers in hepatic slice 
ia 
 of 
d as letters.  Time points with the same letter are not significantly different. 
Time 
(h) Homogeneous groups 
1 a    
F
supernatant following incubation for 1, 3, 6, 8, 12 and 24 hours.  The values are an average of two samples per med
concentration per time point.   
 
 
Table A-18.  Supernatant carprofen A – 50 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA
ime are representet
 
3 a    
6  b   
8 a b   
12 a b   
24 a b   
 
 
Table A-19.  Supernatant carprofen A – 100 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA of 
time are represented as letters.  Time points with the same letter are not significantly different. 
 
Time 
(h) Homogeneous groups 
1 a    
3 a b c  
6 a b   
8 a b c  
12   c  
24  b c  
s of carprofen following incubation in carprofen B.  
ignificant differences in carprofen hepatic slice concentrations were noted with two-way ANOVA across 
time for slices incubated in 50 (df=5, F-ratio=34.086, p-value=0.000) and 100 (df=5, F-ratio=190.018, p-
 
 
     Figure A-38 shows the supernatant concentration
S
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value=0.000) µg/ml media.  For the 50 µg/ml media, supernatant concentrations at 0 hours were less than
those at 4, 8, 12 and 24 hours.  At 1 hour the concentrations were also lower than at 
 
4, 8, 12 and 24 hours.  
At 2 s, the supernatant concentrat ns were higher than at 4 hours.  Table A-20 depicts the 
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Fig. A-38.  Carprofen B supernatant concentrations.   Concentrations of carprofen enantiomers in hepatic slice 
supernatant following incubation for 0, 1, 4, 8, 12 and 24 hours.  The values are an average of two samples p
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Table A-20.  Supernatant carprofen B – 50 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA o
time are represented as letters.  Time points with the same letter are not significantly different. 
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Table A-21.  Supernatant carprofen B – 100 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA of
time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
    
 
  
    Figure A-39 illtrates the concentrations of carprofen in hepatic slice supernatant following incubation 
with carprofen C.  Significant differences in supernatant concentrations were found  
across time and between peaks for slices incubated in 50 (time: df=5, F-ratio=222.991, p-value=0.000; 
peak: df=1, F-ratio=100.711, p-v!lue=0.000) and 100 (time: df=5, F-ratio=173.733, p-value=0.000; peak: 
df=1, F-ratio=18.636, p-value=0.001) µg/ml carprofen C media.  With 50 µg/ml media, supernatant 
concentrations were higher for 4, 8, 12 and 24 hours than at 0 or 1 hour.  Concentrations at 4 hours were 
less than those at 8, 12 and 24 hours, and concentrations at 8 hours were less than those at 24 hours.  With 
100 µg/ml media, supernatant concentrations were higher at 4, 8, 12 and 24 hours than at 0 or 1 hour.  At 4 
hours, supernatant concentrations were less than at 8, 12 and 24 hours; at 24 hours, the concentrations 
were higher than at 8 and 12 hours.  Tables A-22 and A-23 show the homogeneous groups time for 50 and 
100 µg/ml carprofen C, respectively.  For 50 and 100 µg/ml media, the concentrations of peak B in the 
supernatant were higher than those of peak A. 
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Fig. A-39.  Carprofen C supernatant concentrations.   Concentrations of carprofen. enantiomers in hepatic slice 
supernatant following incubation for 0, 1, 4, 8, 12 and 24 hours.  The values are an average of two samples per media 
concentration per time point. 
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Table A-22.  Supernatant carprofen C – 50 µg/ml analysis for time.  Homogeneous groups for two-way ANOVA of 
me are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
Table A- upernat t rof nalysis for time.  Homogeneous groups for two-way ANOVA of 
time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
 
Potassium 
     Figure A-40 shows the supernatant potassium concentrations during 24 hours of incubation with 
carprofen A.  The two-way ANOVA for time and concentration revealed a significant difference across 
time (df=4, F-ratio=3.313, p-value=0.034); however, no significant pairwise differences were found.  The 
pairs that were closest to significance which may have been responsible for the statistical significance 
were the higher 6 hour concentrations compared to 1 hour (p-value=0.064) and 24 hours (p-value=0.088).   
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Fig. A-40.  Carprofen A potassium concentrations.  Potassium concentration in hepatic slice supernatant during 24 
hours of incubation in media containing 0, 10, 50 and 100 µg/ml carprofen.  Potassium concentrations are an average 
of two samples per time point for each concentration.   
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     Figure A-41 depicts the potassium concentrations for slices incubated in carprofen B.  A significant 
difference was detected across time (df=5, F-ratio=16.685, p-value=0.000).  The potassium values at 0 
hour were higher than those at 1, 4, 8, 12 and 24 hours.  At 24 hours, the concentrations were higher than 
at 1 hour.  Table A-24 illustrates the homogeneous groups for time.   
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     Figure A-42 shows the potassium concentrations for slices incubated in carprofen C.  The two-way 
ANOVA for time and concentration revealed a significant did th4hence across time (df=5, F-ratio=29.459, 
p-value=0.000).  The concentrations at 0 hour were higher than those at 1, 4, 8, 12 and 24 hours.  The 
concentrations at 1 hour were less 4han those at 4 and 24 hours.  Table A-25 shows the homogenous 
groups for time. 
 
Time 
(h) Homogeneous groups 
0 a     
Fig. A-41.  Carprofen B potassium concentrations.  Potassium concentration in hepatic slice supernatant during 24 
hours of incubation in media containing 0, 10, 50 and 100 µg/ml carprofen.  Potassium concentrations are an average 
of two samples per time point for each concentration. 
 
Table A-24.  Carprofen B potassium analysis for time.  Homogeneous groups for potassium two-way ANOVA
time are represented as letters.  Times with the same letter are not signif
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12  b c   
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upernatant during 24 
ourof incubation in media containing 0, 10, 50 and 100 µg/ml carprofen.  Potassium concentrations are an average of 
two samples per time point for each concentration. 
 
Table A-25.  Carprofen C potassium analysis for time.  Homogeneous groups for potassium two-way ANOVA for 
time are represented as letters.  Tim%s with the same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
ATP 
     Figure A-43 shows the hepatic slice supernatant concentrations of ATP following incubation in 
carprofen A media for up to 24 hours.  Two-way ANOVA of the concentrations revealed a significant 
factor interaction for time and concentration (df=12, F-ratio=5.840, p-value=0.000).  Because of the 
significant factor interaction, it is difficult to assess the main effects.  There were significant main effects 
for time (df=4, F-ratio=152.493, p-value=0.000) and concentration (df=3, F-ratio=11.420, p-value=0.000), 
Time 
(h) Homogeneous groups 
0 a     
 
Fig. A-42.  Carprofen C potassium concentrations.  Potassium concentration in hepatic slice s
h
1  b    
4   c   
8  b c   
12  b c   
24   c   
and the information is stated in Tables A-26 and A-27. 
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Fig. A  Ca f AT concentrations.  ATP concentration in hepatic slice supernatant during 24 hours of 
incubation in media in g 0, 10, 50 and µg/ml carprofen.  ATP concentrations are an average of two samples 
per time point for each c tra n. 
 
Table A-26.  Carprofen A ATP analysis for  Homogeneous groups for ATP two-way ANOVA for time are 
represented as letters.  Times with the same letter are not significantly different.  ATP concentrations at 1 hour were 
igher than those at 6, 8, 12 and 24 hours.  Concentrations at 6 hours were higher than at 8, 12 and 24 hours.  Eight 
 
Table A-27.  Carprofen A ATP analysis for n.  Homogeneous groups for ATP two-way ANOVA for 
ncen ion are repr ed as letters.  Concentrations with the same letter are not significantly different.  ATP 
oncentrations for 10 µg/ml were higher than those for 0, 50 and 100 µg/ml.  Note:  significant factor interaction 
resent. 
 
 
 
ifferences in ATP concentrations across time (df=5, F-ratio=20.392, p-value= 0.000) and concentration 
(df=3, F-ratio=9.378, p-value=0.000).  For time, concentrations at 0 hour were less than those at 1, 4 and 8 
hours.  At 12 hours the concentrations were less than at 1, 4 and 8 hours.  The same was true for 24 hour 
concentrations as they were lower than those at 1, 4 and 8 hours.  For both 0 and 10 µg/ml, ATP 
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     Figure A-44 represents the concentration of ATP in hepatic slice supernatant following incubation in 
carprofen B media.  The two-way ANOVA for time and concentration demonstrated significant 
d
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concentrations were higher than those at 50 and 100 µg/ml.  Tables A-28 and A-29 display the 
homogeneous groups for time and concentration, respectively. 
 
 
10
12
0
2
4
6tr
at
io
n
8
0 1 4 8 12 24
Time (h)
C
on
ce
n
 (n
M
)
0 µg/ml 
10 µg/ml 
50 µg/ml 
100 µg/ml 
 
Fig. A-44.  Carprofen B ATP concentrations.  ATP concentration in hepatic slice supernatant during 24 hours of 
incubation in media containing 0, 10, 50 and 100 µg/ml carprofen.  ATP concentrations are an average of two samples 
per time point for each concentration. 
 
Table A-28.  Carprofen B ATP analysis for time.  Homogeneous groups for ATP two-way ANOVA for time are 
represented as letters.  Times with the same letter are not significantly different.   
 
 
 
 
 
 
 
 
 
Table A-29.  Carprofen B ATP analysis for concentration.  Homogeneous groups for ATP two-way ANOVA for 
concentration are represented as letters.  Concentrations with the same letter are not significantly different. 
 
 
 
 
 
 
Time 
(h) Homogeneous groups 
0 a     
1  b    
4  b    
8  b    
12 a     
24 a     
Concentration 
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10 a     
50  b    
100  b    
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     Figure A-45 demonstrates the hepatic slice supernatant ATP concentrations following incubation in 
carp  media.  Two-way ANOVA or time and concentration revealed significant diffences across 
time (df=5, F-r 0.0 ).  ATP concentrations at 0 and 24 hours were lower than those at 
1, 4 an hou .  o og o s groups or time are represented in Table A-30. 
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Fig. A-45.  Carprofen C ATP concentrations.  ATP concentration in hepatic slice supernatant during 24 hours /f 
incubation in media containing 0, 10, 50 and 100 µg/ml carprofen.  ATP concentrations are an average of two samples 
per time point for each concentration. 
 
Table A-30.  Carprofen C ATP analysis for time.  Homogeneous groups for ATP two-way ANOVA for time are 
represented as letters.  Times with the same letter are not significantly different.   
 
 
 
 
 
 
 
 
 
 
 
arprofen 
, B and C comparing lesion and concentration, only vacuolation extent for carprofen C revealed a 
significant difference across the media concentrations (df=3, F-ratio=3.736, p-value=0.028).  The 
vacuolation extent lesion scores for 10 µg/ml carprofen C media were lower than those for 0 µg/ml 
carprofen C media (see Table A-31 for homogeneous groups).   
Time 
(h) Homogeneous groups 
0 a     
1  b    
4  b    
8  b    
12 a b    
24 a     
Histology 
     Hepatic slices were examined for extent of necrosis and extent and severity of vacuolation as indicators
of toxicity.  Slices were evaluated on a scale from 0 to 5.  When one-way ANOVAs were run for c
A
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Table A-31.  Carprofen C vacuolation extent analysis for concentration.  Homogeneous groups for vacuolation extent 
one-way ANOVA for concentration are represented as letters.  Concentrations with the same letter are not 
significantly diff
 
 
 
 
 
Carprofen with Phenobarbital Single Study Data 
edia 
or 
10 (df=6, F-ratio=27.735, p-value=0.00 ), 50 (df=6, F-ratio=353.152, p-value=0.000) and 100 (df=6, F-
ratio 05, l c profen A media.  Media concentrations for 10, 50 and 100 µg/ml 
carpro  wer s an at 25, 28, 32, 36 and 48 hours.  Additionally for 50 µg/ml 
media, carpro  con entr tio  were lower at 48 hours than at 25, 32 and 36 hours.  Tables A-32 through 
A-34 trat e ho og neous groups r time for 10, 50 and 100 µg/ml media.   
 
erent.   
M
     Figure A-46 depicts the media concentrations of carprofen A following 24 hours incubation with 
phenobarbital.  The two-way ANOVA for time and peak revealed significant differences across time f
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Fig. A-46.  Carprofen A media concentrations following phenobarbital incubation.  Concentrations of carprofen 
enantiomers in media after incubation for 24 hours with phenobarbital and incubated for an additional 1, 4, 8, 12 and 
24 hours with carprofen A.   The values are means of three samples per media concentration per time point. 
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Table A-32.  10 µg/ml carprofen A with phenobarbital incubation analysis for time.  Homogeneous groups for two-
way ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
rofen A with phenobarbital incubation analysis for time.  Homogeneous groups for two-
way ANOVA of time are represented as lett s.  Time points with the same letter are not significantly different. 
 
 
 
Table A-34.  100 µg/ml carprofen A with phenobarbital incubation analysis for time.  Homogeneous groups for two-
way ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
 
 
     The media concentrations for carprofen B following phenobarbital incubation are shown in Figure A-
47.  Similarly to carprofen A, significant differences were detected among the concentrations for all media 
concentrations.  Zero and 24 hour concentrations for 10, 50 and 100 µg/ml carprofen B media were lower 
than those at 25, 28, 32, 36 and 48 hours.  For 50 µg/ml media, concentrations at 36 hours were lower than 
those at 25 and 28 hours.  Tables A-35 through A-37 delineate the homogeneous groups for time for each 
media concentration. 
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Table A-36.  50 µg/ml carprofen B with phenobarbital incubation analysis for time.  Homogeneous groups for two-
way ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
 
 
µ l 
Fig. A-47.  Carprofen B media concentrations following phenobarbital incubation.  Concentrations of carprofen 
enantiomers in media after incubation for 24 hours with phenobarbital and incubated for an additional 1, 4, 8, 12 and 
24 hours with carprofen B.   The values are means of three samples per media concentration per time point. 
 
Table A-35.  10 µg/ml carprofen B with phenobarbital incubation analysis for time.  Homogeneous groups for two-
way ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
Time 
(h) Homogeneous groups 
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24 a     
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28  b    
32  b    
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48  b    
Time 
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32  b c   
36   c   
48  b c   
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Table A-37.  100 µg/ml carprofen B with phenobarbital incubation analysis for time.  Homogeneous groups for two-
way ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
     Carprofen C media concentrations following phenobarbital incubation are displayed in Figure A-48.  
The two-way ANOVA for time and peak revealed significant differences for time for 10 (df=6, F-
ratio=55.096, p-value=0.000), 50 (df=6, F-ratio=117.041, p-value=0.000) and 100 (df=6, F-ratio=333.296, 
p-value=0.000) µg/ml media.  For these media, carprofen concentrations at 0 and 24 hours were less than 
those at 25, 28, 32, 36 and 48 hours.  Additional differences were noted for 10 and 100 µg/ml media.  
Thirty-two hour carprofen concentrations for 10 µg/ml were lower than those at 25 and 28 hours but 
higher than those at 36 hours.  Twenty-five hour carprofen concentrations for 100 µg/ml media were 
higher than 36 hour concentrations, and 28 hour concentrations were higher than those at 32, 36 and 48 
hours.  Tables A-38 through A-40 show the homogeneous groups for time for carprofen C media.   
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Fig. A rofen  following phenobarbital incubation.  Concentrations of carprofen 
enantiomers in me  a  i atio  for 24 hours with phenobarbital and incubated for an additional 1, 4, 8, 12 and 
24 hours with carprofen C.   Th values are means o ee samples per media concentration per time point.  
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Table A-38.  10 µg/ml carprofen C with phenobarbital incubation analysis for time.  Homogeneous groups for two
way ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
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-
able A-39.  50 µg/ml carprofen C with phenobarbital incubation analysis for time.  Homogeneous groups for two-
A of time are represented as letters.  Time points with the same letter are not significantly different. 
 
Table A-40.  100 µg/ml carprofen C with phenobarbital incubation analysis for time.  Homogeneous groups for two-
way ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
 
 
Supernatant 
     Carprofen A concentrations in hepatic slice supernatant after incubation with phenobarbital are sho7n 
in Figure A-49.  The two-way ANOVA for time and peak revealed significant differences for time and 
peak for slices incubated in 50 (time: df=6, F-ratio=247.024, p-value=0.000; peak: df=1, F=45.692, p-
value=0.000) and 100 (time: df=6, F-ratio=113.798, p-value=0.000; peak: df=1, F=11.493, p-value=0.004) 
µg/ml media.  There was a significant time-peak interaction for 50 µg/ml media; the interaction appears to 
be orderly so examination of main effects is reasonable.  At 0, 24 and 25 hours the supernatant 
concentrations of 50 µg/ml media were lower than those at 28, 32, 36 and 48 hours.  At 28 hours, 
supernatant concentrations were lower than at 32, 36 and 48 hours.  At 32 hours the concentrations were 
r 
rs 
pernatant concentrations of carprofen were lower than at 36 hours.  For both 50 and 100 µg/ml, peak B 
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lower than at 36 and 48 hours, and at 36 hours supernatant concentrations were less than at 48 hours.  Fo
100 µg/ml media, supernatant concentrations at 0 and 24 hours were lower than at 25, 28, 32, 36 and 48 
hours.  At 25 hours, the supernatant concentrations were lower than at 28, 32, 36 and 48 hours; at 28 hou
su
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concentrations were higher than for peak A.  Tables A-41 and A-42 show the homogeneous groups for 
me for 50 and 100 µg/ml media. 
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Fig. A-49.  Carprofen A concentrations in hepatic slice supernatant following phenobarbital incubation.   
Concentrations of carprofen enantiomers in hepatic slice supernatant after incubation for 24 hours with phenobarbital 
and incubated for an additional 1, 4, 8, 12 and 24 hours with carprofen A.  The values are an average of two samples 
per media concentration per time point.   
 
Table A-41.  50 µg/ml carprofen A hepatic slice supernatant with phenobarbital incubation analysis for time.  
Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same letter are 
not significantly different. 
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Table A-42.  100 µg/ml carprofen A hepatic slice supernatant with phenobarbital incubation analysis for time.  
Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same letter are 
not significantly different. 
 
 
 
 
 
 
 
 
 
 
value=0.000) and 100 (time: df=6, F-ratio=229.723, p-value=0.000; peak: df=1, 
-ratio=31.634, p-value=0.000) µg/ml.  As seen with 50 µg/ml carprofen A, there was a significant and 
orderly significant interaction (df=6, F-ratio=10.613, p-value=0.000) between the factors time and peak.  
The concentrations for peak B were higher than those for peak A for 50 and 100 µg/ml media.  For 50 
µg/ml media, carprofen supernatant concentrations at 0 and 24 hours were less than those at 25, 28, 32, 36 
and 48 hours.  At 25 hours, the supernatant concentrations were less than at 28, 32, 36 and 48 hours.   
Twenty-eight hour concentrations were lower than 32, 36 and 48 hour concentrations.  Thirty-two hour 
concentrations were lower than at 36 and 48 hours, and concentrations at 36 hours were less than those at 
48 hours. 
    For 100 µg/ml media, supernatant concentrations of carprofen were lower at 0 and 24 hours than at 25, 
28, 32, 36 and 48 hours.  Twenty-five hour concentrations were lower than 28, 32, 36 and 48 hour 
concentrations; concentrations at 28 hours were lower than at 32, 36 and 48 hours.  Tables A-43 and A-44 
show the homogeneous groups for time for 50 and 100 µg/ml media.   
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     Figure A-50 displays the concentrations of carprofen B in the slice supernatant following incubation in
phenobarbital with additional incubation in carprofen B.  Similar to the results of analysis for supernatant 
concentrations for carprofen A (fig. 34), the supernatant concentrations for carprofen B showed significant
differences across time and between peaks for 50 (time: df=6, F-ratio=407.840, p-value=0.000; peak: 
f=1, F-ratio=133.464), p-d
F
 209
-2000
12000
0
2000
0 24 25 28 32 36 48
4000
00
00
00
Time (h)
nc
en
tr
at
io
n 
(n
g/
m
l)
0 µg/ml - Peak A
0 µg/ml - Peak B
60
80
100
1 g/ l - P ak A0 µ m e
1 g/ l - P ak B0 µ m e
5 g/ l - P ak A0 µ m e
5 g/ l - P ak B0 µ m e
1 g l - eak A00 µ /m P
C
o
1 g l - eak B
h phenobarbital 
d incubated for an additional 1, 4, 8, 12 and 24 hours with carprofen B.  The values are an average of two samples 
er media concentration per time point.   
time.  
Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same letter are 
not significantly di
e 
 
 
      
 
 
 
 
 
 
 
T  Homogeneous groups 
00 µ /m P
Fig. A-50.  Carprofen B concentrations in hepatic slice supernatant following phenobarbital incubation.   
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Table A-43.  50 µg/ml carprofen B hepatic slice supernatant with phenobarbital incubation analysis for 
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Table A-44.  100 µg/ml carprofen B hepatic slice supernatant with phenobarbital incubation analysis for time.  
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     The supernatant concentrations of carprofen C following phenobarbital incubation are illustrated in 
Figure A-51.  Significant differences were noted in the two-way ANOVA of time and peak for 50 (time: 
df=6, F-ratio=115.672, p-value=0.000; peak: df=1, F-ratio=284.134, p-value=0.000) and 100 (time: df=6, 
F-ratio=656.537, p-value=0.000; peak: df=1, F=11.988, p-value=0.004) µg/ml media.  For 50 and 100 
µg/ml media, the significant differences for time and peak were the same as for carprofen B.  
Concentrations of peak B were higher than those of peak and the homogeneous groups were the same as 
seen in tables 60 and 61.  There was also a significant factor interaction (df=6, F-ratio=20.479, p-
value=0.000) for 50 µg/ml carprofen C as there was for 50 µg/ml carprofen B. 
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Fig. A-51.  Carprofen C concentrations in hepatic slice supernatant following phenobarbital incubation.   
Concentrations of carprofen enantiomers in hepatic slice supernatant after incubation for 24 hours with phenobarbital
and incubated for an additional 1, 4, 8, 12 and 24 hours with carprofen C.  The values are an average o
 
f two samples 
er media concentration per time point.   
n in 
arprofen B.  Two-way ANOVA of time and concentrations expressed a significant across time (df=6, F-
io=23.406, p-value=0.000).  Concentrations at 0 hour were higher than those at 24, 25, 28, 32, 36 and 
8 hours; concentrations at 24 hours were higher than those at 25 hours.  Table A-45 depicts the 
p
 
 
Potassium 
     Potassium concentrations for slices incubated in phenobarbital followed by carprofen A are show
Figure A-52.  The two-way ANOVA for time and concentration revealed a significant difference across 
time (df=6, F-ratio=21.184, p-value=0.000) and a significant factor interaction (df=18, F-ratio=3.058, p-
value=0.004).  Because the interaction is disorderly, the main effects can be obscured.   
     Figure A-53 depicts the potassium concentrations of slices incubated in phenobarbital followed by 
c
rat
4
homogeneous groups for time.   
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Table A-45.  Carprofen B with phenobarbital potassium analysis for time.  Homogeneous groups for potassium two-
way ANOVA for time are represented as letters.  Times with the same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
 
 
 
    Potassium concentrations for slices incubated in phenobarbital followed by carprofen C are shown in 
Figure A-54.  Again, two-way ANOVA revealed a significant difference for time (df=6, F-rati13.635, p-
value=0.000).  Concentrations at 0 hour were higher than those for all other hours.  Homogeneous groups 
are shown in Table A-46. 
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Table A-46.  Carprofen C with phenobarbital potassium analysis for time.  Homogeneous groups for potassium two-
way ANOVA for time are represented as letters.  Times with the same letter are not significantly different.   
 
 
 
 
 
 
 
 
  The ATP concentrations for slices incubated in phenobarbital followed by carprofen A are depicted in 
Figu 5.  T  re ealed significant differences across time (df=6, F-ratio=6.435, p-
value 00) t not across m dia conc ntrations.  The ATP concentrations at 0 and 24 hours were higher 
than t  at  ho s. t 25 ho rs, the ATP concentrations were higher than those at 32, 36 and 
48 ho  Ta hows t e homogeneous groups for time. 
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Table A-47.  ATP analysis for time of carprofen A with phenobarbital.  Homogeneous groups for ATP two-way 
NOVA for time are represented as letters.  Times with the same letter are not significantly different.   
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Fig. A-56.  Carprofen B ATP concentrations following phenobarbital incubation.  ATP concentration in hepatic slice 
supernatant after incubation for 24 hours with phenobarbital and incubated for an additional 1, 4, 8, 12 and 24 hours 
with carprofen B.  The values are an average of two samples per media concentration per time point. 
 
 
     Figure A-57 displays the ATP concentrations for slices incubated in phenobarbital followed with 
carprofen C incubation.  Two-way ANOVA revealed no significant differences for time or concentration.   
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Histology 
     For the phenobarbital-carprofen A slices, one-way ANOVA of vacuolation extent revealed a significant 
difference among media concentrations (df=3, F-ratio=4.681. p=0.016).  Slices incubated in media 
containing 100 µg/ml carprofen A had lower lesion scores than those incubated in 0 and 10 µg/ml media.  
A significant difference was also noted for one-way ANOVA of 6acuolation severity (df=3, F-ratio=3.421, 
p-value=0.043).  Lesion scores for slices incubated in 100 µg/ml media were lower than those of 0 µg/ml 
media.  Tables A-48 and A-49 demonstrate the homogeneous groups for vacuolation extent and severity. 
 
 
Table A-48.  Vacuolation extent analysis for concentration of carprofen A with phenobarbital.  Homogeneous groups 
for vacuolation extent one-way ANOVA for concentration are represented as letters.  Concentrations with the same 
letter are not significantly different.   
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Table A-49.  Vacuolation severity analysis for concentration of carprofen A with phenobarbital.  Homogeneous 
groups for vacuolation severity one-way ANOVA for concentration are represented as letters.  Concentrations with the
same letter are not significantly different.   
 
 
 
 
 
 
 
      
     Sim r fin ings were ed f ices incubated in phenobarbital followed by carprofen B.  Significant 
fferences were seen for one-way ANOVA of vacuolation extent (df=3, F-ratio=10.364, p-value=0.000) 
nd vacuolation severity (df=3, F-ratio=6.370, p-value=0.005).  For vacuolation extent, lesion scores 
 the 
homoge us groups for one-way ANO A of vacuolation extent and vacuolation severity. 
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Table A-51.  Va sis for concentration of carprofen B with phenobarbital.  Homogeneous 
groups  vacu ation eve ty o e-way ANOVA for concentration are represented as letters.  Concentrations with the 
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Carprofen with Cimetidine Single Study Data 
Media 
    Media concentrations of carprofen A after incubation with cimetidine followed by carprofen A are 
shown in Figure A-58.  Two-way ANOVA for time and peak revealed significant differences across time
for 10 (df=6, F-ratio=307.422, p=0.000), 50 (df=6, F=2282.393, p-value=0.000) and 100 (df=6, F-
ratio=337.555, p-value=0.000) µg/ml media and between peaks (df=1, F=11.859, p-value=0.0
g/ml media. 
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Fig. A  Ca rofen A media concentrations following cimetidine incubation.  Concentrations of carprofen 
enanti s in e  ter incubation for 2 urs with cimetidine and incubated for an additional 1, 4, 8, 12 and 24 
hours  carp fen A.   The values are means of three samples per media concentration per time point. 
     For 10 µg/ml media, 0 and 24 hour concentrations were lower than those at 25, 28, 32, 36 and 48 hours.  
At 25 hours, carprofen concentrations were higher than at 28 and 36 hours, and 28 hour concentrations 
were less than those at 32 and 48 hours.  Peak B concentrations were higher than those for peak A.  Zero 
and 24 hour carprofen concentrations for 50 µg/ml media were lower than those at 25, 28, 32, 36 and 48 
hours.  Concentrations at 25 hours were higher than at 28, 32, 36 and 48 hours, and 28 hour concentrations 
were higher than those at 32, 36 and 48 hours.  The pairwise differences across time for 100 µg/ml media 
were the same as for 10 µg/ml media.  Tables A-52 through A-54 depict the homogeneous groups for 10, 
50 and 100 µg/ml media. 
 
Table A-52.  10 µg/ml carprofen A with cimetidine incubation analysis for time.  Homogeneous groups for two-way 
ANOVA of time are represented as letters.  Time points with the same letter are not significantly different.  
 
 
 
 
 
 
 
 
 
 
Time 
(h) Homogeneous groups 
0 a     
g/m
-58. rp
omer  m dia af 4 ho
with ro
 
 
24 a     
25  b    
28  b c   
32  b c   
36   c   
48  b    
 218
Table A-53.  50 µg/ml carprofen A with cimetidine incubation analysis for time.  Homogeneous groups for two-way 
ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
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Table A-54.  100 µg/ml carprofen A with cimetidine incubation analysis for time.  Homogeneous groups for 4wo-way 
ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
 
 
      
 
 
 
     Figure A-59 displays the media concentrations of carprofen after incubation with cimetidine followed 
by carprofen B.  The two-way ANOVA for time and peak revealed significant differences for time for 10 
(df=6, F-ratio=60.934, p-value=0.000), 50 (df=6, F-ratio=198.658, p-value=0.000) and 100 (df=6, F-
ratio=139.613, p-value=0.000) µg/ml media.  Ten µg/ml carprofen concentrations at 0 and 24 hours were 
lower than those at 25, 28, 32, 36 and 48 hours.  Concentrations at 28 and 32 hours were less t se at han tho
48 hours.  For 50 and 100 µg/ml media, 0 and 24 hour concentrations were less than 25, 28, 32, 36 and 48 
hour concentrations.  Tables A-55 through A-57 denote the homogeneous groups for each media 
concentration. 
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Fig. A-59.  Carprofen B media concentrations following cimetidine incubation.  Concentrations of carprofen 
enantiomers in media after incubation for 24 hours with cimetidine and incubated for an additional 1, 4, 8, 12 and 24
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Table A-56.  50 µg/ml carprofen B with cimetidine incubation analysis for time.  Homogeneous groups for two-way 
ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
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Table A-57.  100 µg/ml carprofen B with cimetidine incubation analysis for time.  Homogeneous groups for tw
ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
o-way 
 
 
 
      
 
 
     The carprofen C media concentrations for slices incubated in cimetidine followed by carprofen C are 
shown in Figure A-60.  Again, two-way ANOVA showed significant differences across time for 10 (df=6, 
F-ratio=48.922, p-value=0.000), 50 (df=6, F-ratio=241.616, p-value=0.000) and 100 (df=6, F-
ratio=504.113, p-value=0.000) µg/ml media.  Pairwise differences were the same for 10 and 100 µg/ml 
media.  For those media, 0 and 24 hour carprofen concentrations were lower than at 25, 28, 32, 36 and 48 
hours, and 36 hour concentrations were lower than 25 and 48 hour concentrations.  For 50 µg/ml media, 0 
and 24 hour concentrations were lower than 25, 28, 32, 36 and 48 hour concentrations.  Additionally, 25 
hour concentrations were higher than at 32 and 36 hours, and 36 hour concentrations were lower than at 28 
and 48 hours.  Tables A-58 through A-60 illustrate the homogeneous groups for time for each media 
concentration. 
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Fig. A-60.  Carprofen C media concentrations following cimetidine incubation.  Concentrations of carprofen 
enantiomers in media after incubation for 24 hours with cimetidine and incubated for an additional 1, 4, 8, 12 and 24 
hours with carprofen C.   The values are means of three samples per media concentration per time point. 
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Table A-58.  10 µg/ml carprofen C with cimetidine incubation analysis for time.  Homogeneous groups for two-way 
ANOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 geneous groups 
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 the same letter are not significantly different. 
 
.  Homogeneous groups for two-way 
NOVA of time are represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
 
 
Supernatant 
     Carprofen A concentrations in hepatic slice supernatant after cimetidine incubation followed by 
incubation in carprofen A are shown in Figure A-61.  The two-way ANOVA for time and peak revealed a 
significant difference across time for 50 (df=4, F-ratio=49.914, p=0.000) and 100 (df=4, F-ratio=4.807, p-
value=0.020) µg/ml media and between peaks (df=1, F-ratio=40.202, p-value=0.000) for 50 µg/ml media.  
For 50 µg/ml media, carprofen supernatant concentrations at 25 and 28 hours were less than those at 32, 
36 and 48 hours.  The supernatant concentrations at 36 hours were less than those at 48 hours.  Peak B 
concentrations were higher than peak A concentrations.  Supernatant concentrations at 25 hours for 100 
µg/ml media were lower tan 32 and 36 hour concentrations.  Tables A-61 and A-62 show the 
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Table A-62.  100 µg/ml carprofen A hepatic slice supernatant with cimetidine incubation analysis for time.  
Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same letter are 
not significantly different. 
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Table A-61.  50 µg/ml carprofen A hepatic slice supernatant with cimetidine incubation analysis for time.  
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     Figure A-62 displays the supernatant concentrations following cimetidine and carprofen B incubation.  
Significant differences by two-way ANOVA were seen for time (df=4, F-ratio=11.814, p-value=0.001) 
and peak (df=1, F-ratio=6.094, p-value=0.033) for 50 µg/ml media.  Peak B concentrations were higher 
than peak A concentrations.  Twenty-five hour supernatant concentrations were lower than those at 36 and 
48 hours.  Twenty-eight and 32 hour concentrations were lower than 48 hour concentrations.  Table A-63 
shows the homogeneous groups for time for 50 µg/ml media. 
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 Carpr C supe n co c trations owing cimetidine and carprofen C incubation are displayed 
36 
and 48 hour concentrations.  Twenty-eight hour concentrations were less than 32, 36 and 48 hour 
Fig. A-62.  Carprofen B concentrations in hepatic slice supernatant following cimetidine incubation
of carprofen 
an additional 1, 4, 8, 12 and 24 hours with carprofen B.  The values are an average of two samples per media 
concentration per time point. 
 
Table A-63.  50 µg/ml carprofen B hepatic slice supernatant with cimetidine incubation analysis for time.  
omogeneous groups for two-way ANOVA of time are represented as letters.  Time points wH
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 Figure A-63.  Two-way ANOVA for 50 µg/ml media revealed a difference across time (df=4, F-
ratio=4.238, p-value=0.029).  Twenty-five hour supernatant concentrations were less than those at 48 
hours.  For 100 µg/ml media, significant differences were noted for time (df=4, F-ratio=101.804, p-
value=0.000) and peak (df=1, F-ratio=34.549, p-value=0.000).  Supernatant concentrations for peak B 
were higher than those for peak A.  For time, 25 hour supernatant concentrations were less than 28, 32, 
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supernatant concentrations.  Tables A-64 and A-65 show the homogeneous groups for 50 and 100 µg/m
media. 
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Fig. A-63.  Carprofen C concentrations in hepatic slice supernatant following cimetidine incubation.   Concentrations 
of carprofen enantiomers in hepatic slice supernatant after incubation for 24 hours with cimetidine and incubated for 
an additional 1, 4, 8, 12 and 24 hours with carprofen C.  The values are an average of two samples per media 
concentration per time point. 
 
Table A-64.  50 µg/ml carprofen C hepatic slice supernatant with cimetidine incubation analysis for time.  
Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same letter are 
not significantly different.   
 
 
 
 
 
 
 
 
Table A-65.  100 µg/ml carprofen C hepatic slice supernatant with cimetidine incubation analysis for time.  
Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same letter are 
not significantly different. 
 
 
 
 
 
 
 
Time 
(h) Homogeneous groups 
25 a     
28 a b    
32 a b    
36 a b    
48  b    
Time 
(h) Homogeneous groups 
25 a     
28  b    
32   c   
36   c   
48   c   
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Potassium 
     Figure A-64 shows the potassium concentrations for slices incubated in cimetidine followed by 
carprofen A.  Two-way ANOVA revealed a significant difference across time (df=6, F-ratio=62.851, p-
value=0.000) and among concentrations (df=3, F-ratio=3.522, p-value=0.027).  For time, 0 hour potassium 
con re 8, 32, 36 and 48 hour concentrations.  Potassium concentrations 
for 10 edia we  f r 50 µg/ml media.  Tables A-66 and A-67 show the 
homogen s group o e n concentr on. 
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Table A- arprofe A  cimetidine potassium analysis for time.  Homogeneous groups for potassium two-way 
ANOVA for time are represented as letters.  Times with the same letter are not significantly different.   
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Table A-67.  Carprofen A with cimetidine potassium analysis for concentration.  Homogeneous groups for potass
two-way ANOVA for concentration are rep
gnificantly different.   
ium 
resented as letters.  Concentrations with the same letter are not 
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Fig. A-65.  Carprofen B potassium concentrations following cimetidine incubation.  Potassium concentration in 
hepatic slice supernatant after incubation for 24 hours with cimetidine and incubated for an additional 1, 4, 8, 12 and 
24 hours with carprofen B.  The values are an average of two samples per media concentration per time point. 
 
     Figure A-66 shows the potassium concentrations for slices incubated in cimetidine followed by 
carprofen C.  Two-way ANOVA revealed a significant factor interaction for time and concentration 
(df=18, F-ratio=2.154, p-value=0.033).  The disorderly interaction made interpretation of the main effects 
difficult.  There were significant differences for the main effects of time (df=6, F-ratio=70.416, p-
value=0.000) and concentration (df=3, F-ratio=16.191, p-value=0.000). 
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Fig. A-66.  Carp m co  following cimetidine incubation.  Potassium concentration in 
hepati ice s p n t t incuba and incubated for an additional 1, 4, 8, 12 and 
24 hours with a r valu rag  of two samples per media concentration per time point. 
 
ATP 
   ATP concentrations for slices incubated in cimetidine followed by carprofen A are illustrated in Figure 
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Fig. A-67.  Carprofen A ATP concentrations following cimetidine incubation.  ATP concentration in hepatic slice 
supernatant after incubation for 24 hours with cimetidine and incubated for an additional 1, 4, 8, 12 and 24 hours with 
carprofen A.  The values are an average of two samples per media concentration per time point. 
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hour concentrations were less than those at 25, 28, 32, 36 and 48 hours.  ATP concentrations at 25 hours 
ere less than those at 28, 32, 36 and 48 hours; 48 hour concentrations were higher than 36 hour 
ntrations.  Table A-68 delineated the homogeneous groups for time.   
for time.  Homogeneous groups for ATP two-way ANOVA 
for ti .  T th th ame letter are not significantly different.   
     F A-6 lay P co entrations for slices incubated in cimetidine followed by 
carpro  B and c .  No nt d ferences were noted by two-way ANOVA for either 
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Fig. A  Ca rof  T concentr wi  cimetidine incubation.  ATP concentration in hepatic slice 
supern t after incubation 4 ou etidine and incubated for an additional 1, 4, 8, 12 and 24 hours with 
carpro .  T e va e  av age p s per media concentration per time point. 
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Fig. A-69.  Carprofen C ATP concentrations following cimetidine incubation.  ATP concentration in hepatic slice 
supernatant after incubation for 24 hours with cimetidine and incubated for an additional 1, 4, 8, 12 and 24 hours with 
carprofen C.  The values are an average of two samples per media concentration per time point. 
 
Histology  
     One-way ANOVA for vacuolation severity from cimetidine-carprofen A incubation expressed 
significant differences among the concentrations (df=3, F-ratio=7.030, p-value=0.003).  Lesion scores for 
100 µg/ml media were less than those for 0, 10 and 50 µg/ml media.  Table A-69 shows the homogeneous 
groups for vacuolation severity associated with cimetidine-carprofen A incubation. 
 
Table A-69.  Carprofen A with cimetidine vacuolation severity analysis for concentration.  Homogeneous groups for 
vacuolation severity one-way ANOVA for concentration are represented as letters.  Concentrations with the same 
letter are not significantly different.   
 
 
 
 
 
   
 
   One-way ANOVA of hepatic slice lesion scores for necrosis and vacuolation severity from cimetidine-
carprofen B incubation revealed significant differences among concentrations.  For necrosis (df=3, F-
ratio=6.281, p-value=0.005), lesion scores for 0 µg/ml media were less than those for 50 and 100 µg/ml 
media.  The lesion scores for vacuolation severity (df=3, F-ratio=6.907, p-value=0.003) for 100 µg/ml 
media were less than those for 0 and 10 µg/ml media.  Tables A-70 and A-71 depict the homogeneous 
groups for necrosis and vacuolation severity. 
Concentration 
(µg/ml) Homogeneous groups 
0 a     
10 a     
50 a     
100  b    
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Table A-70.  Carprofen B with cimetidine necrosis analysis for concentration.  Homogeneous groups for necrosis one-
way ANOVA for concentration are represented as letters.  Concentrations with the same letter are not significantly 
different.   
 
 
 
 
 
 
 
Table A-71.  Carprofen B with cimetidine vacuolation severity analysis for concentration.  Homogeneous groups for 
vacuolation severity one-way ANOVA for concentration are represented as letters.  Concentrations with the same 
letter are not significantly different.   
 
 
 
 
 
 
 
     Cimetidine-carprofen C hepatic lesion scores showed significant differences for vacuolation extent 
(df=3, F-ratio=5.889, p-value=0.007) and vacuolation severity (df=3, F-ratio=3.719, p-value=0.033) by 
one-way ANOVA.  Lesion scores for vacuolation extent and vacuolation severity were lower for 100 
µg/ml media than for 10 µg/ml media.  Table A-72 shows the homogeneous groups for both vacuolation 
extent and vacuolation severity for cimetidine-carprofen B incubation. 
 
Table A-72.  Carprofen C with cimetidine vacuolation severity and extent analysis for concentration.  Homogeneous 
groups for vacuolation severity and vacuolation extent one-way ANOVA for concentration are represented as letters.  
Concentrations with the same letter are not significantly different.   
 
 
 
 
 
 
 
 
Statistics for Mean Carprofen Data—replaced by AUC in Chapter VI 
Carprofen Media 
     The mean values of carprofen enantiomers in media were measured over twenty-four hours of 
incubation.  No significant differences were found across time or between peaks for 10 µg/ml media.  For 
50 µg/ml media, differences were seen across time (df=5, F-ratio=8.673, p-value=0.000) and between the 
peaks (df=1, F-ratio=6.239, p-value=0.015).  The enantiomer concentrations at 0 hour were more than 
those at 12 hours.  The concentrations at 1 hour were higher than at 8, 12 and 24 hours.  At 4 hours, the 
concentrations were greater than at 12 and 24 hours.  Mean concentrations for peak A (43.269 µg/ml) were 
higher than mean peak B concentrations (39.992 µg/ml).  Four homogeneous groups for time (Table A-73) 
were noted for 50 µg/ml media.  For the averaged 100 µg/ml carprofen media, concentrations were 
significantly different across time (df=5, F-ratio=5.161, p-value=0.000) but not between peaks.  
Concentrations at 0 hour were higher than those at 12 and 24 hours.  At 1 hour the concentrations were 
Concentration 
(µg/ml) Homogeneous groups 
0 a     
10 a b    
50  b    
100  b    
Concentration 
(µg/ml) Homogeneous groups 
0 a     
10 a     
50 a b    
100  b    
Concentration 
(µg/ml) Homogeneous groups 
0 a b    
10 a     
50 a b    
100  b    
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also higher than at 12 and 24 hours.  There were two homogeneous groups for time for the mean 100 
µg/ml carprofen media (Table A-74). 
 
 
Table A-73.  Comparison of mean 50 µg/ml carprofen media concentrations (A and B enantiomers) across time.  
Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same letter are 
not significantly different. 
 
Time 
(h) 
Homogeneous groups Means 
(µg/ml) 
 0 a b c  43.69316 
1 a    48.04358 
4 a b   45.24405 
8  b c d 39.13747 
12    d 36.58165 
24   c d 38.50213 
 
 
Table A-74.  Comparison of mean 100 µg/ml carprofen media concentrations (A and B enantiomers) across time.  
Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same letter are 
not significantly different. 
 
Time 
(h) 
Homogeneous 
groups 
Means 
(µg/ml) 
0 a   87.94843 
1 a   88.29685 
4 a b  83.55151 
8 a b  78.96168 
12  b  73.04642 
24  b  70.55279 
 
 
Carprofen Supernatant 
     For mean carprofen concentrations in hepatic slice supernatant, carprofen concentrations for slices 
incubated in 0 and 10 µg/ml carprofen were below the lower limit of quantification.  The two-way 
ANOVA revealed significant differences across time and between peaks for the supernatant of slices 
incubated in the 50 (time: df=5, F-ratio=150.851, p-value=0.000; peak: df=1, F-ratio=65.558, p-
value=0.000) and 100 µg/ml carprofen media (time: df=5, F-ratio=85.978, p-value=0.000; peak: df=1, F-
ratio=12.384, p-value=0.001).  There was a significant factor interaction for the 50 µg/ml media (df=5, F-
ratio=4.862, p-value=0.001).  The interaction appeared to be orderly indicating that the test on the main 
effects for time and peak could be meaningful.   
     At 4, 8, 12 and 24 hours the supernatant of slices incubated in 50 µg/ml carprofen contained higher 
mean concentrations than at 0 or 1 hour.  The supernatant concentrations at 4 hours were less than those at 
8, 12 and 24 hours, and at 8 hours the supernatant concentrations were less than at 24 hours.  There were 
four homogeneous groups for time (Table A-75), and mean carprofen concentrations for peak B 
(3142.0423 ng/ml) were higher than those for peak A (2101.7894 ng/ml).   
     For slices incubated in 100 µg/ml carprofen media, mean supernatant concentrations at 1, 4, 8, 12 and 
24 hours were higher than those at 0 hour.  At 1 hour, the supernatant concentrations were less than those 
at 4, 8, 12 and 24 hours.  For 4 hours, the supernatant concentrations were lower than at 12 and 24 hours, 
and at 8 hours, the concentrations were lower than at 24 hours.  There were five homogeneous groups time 
for 100 µg/ml carprofen (Table A-76), and the mean concentrations of peak B (8402.3843 ng/ml) in the 
supernatant were higher than those of peak A (6888.1497 ng/ml). 
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Table A-75.  Comparison of mean supernatant carprofen concentrations (A and B enantiomers) across time for 50 
µg/ml media.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the 
same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
 
 
Table A-76.  Comparison of mean supernatant carprofen concentrations (A and B enantiomers) across time for 100 
µg/ml media.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the 
same letter are not significantly different. 
 
 
 
 
 
 
 
 
 
 
 
Carprofen with Phenobarbital Media 
     The two-way ANOVA revealed significant differences across time but not between peaks for 10 µg/ml 
(df=4, F-ratio=6.659, p-value=0.000), 50 µg/ml (df=4, F-ratio=3.668, p-value=0.009) and 100 µg/ml 
carprofen media (df=4, F-ratio=5.753, p-value=0.000).  Twenty-five and 28 hour concentrations for 10 
µg/ml media were higher than 32 and 48 hour concentrations (Table A-77).   
     Two-way ANOVA for time and peak revealed significant differences for 50 µg/ml (time: df=4, F-
ratio=146.985, p-value=0.000; peak: df=1, F-ratio=87.602, p-value=0.000) and 100 µg/ml media (time: 
df=4, F-ratio=80.364, p-value=0.000; peak: df=1, F-ratio=24.365, p-value=0.000).  A significant factor 
interaction (df=4, F-ratio=3.653, p=0.011) was noted for 50 µg/ml media.  For 50 µg/ml media, 25 and 28 
hour concentrations were higher than those at 48 hours (Table A-78).  Media containing 100 µg/ml 
carprofen had higher concentrations at 25 and 28 hours than at 36 and 48 hours (Table A-79).      
 
 Table A-77.  Comparison across time of mean media concentrations for 10 µg/ml carprofen (A and B enantiomers) 
with phenobarbital incubation.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time 
points with the same letter are not significantly different. 
 
 
 
 
 
 
Time 
(h) 
Homogeneous 
groups 
Means 
(ng/ml) 
0 a    -70.4521 
1 a    510.0783 
4  b   2581.3911 
8   c  3598.2027 
12   c d 3949.3921 
24    d 4251.9186 
Time 
(h) 
Homogeneous 
groups 
Means 
(ng/ml) 
0 a     -70.4521 
1  b    2961.8377 
4   c   8477.9331 
8   c d  9308.6271 
12    d  10803.9183 
24     e 12095.3870 
Time 
(h) 
Homogeneous 
groups 
Means 
(µg/ml) 
25 a   8.594 
28 a   8.471 
32  b  6.566 
36 a b  7.736 
48  b  6.887 
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Table A-78.  Comparison across time of mean media concentrations for 50 µg/ml carprofen (A and B enantiomers) 
with phenobarbital incubation.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time 
points with the same letter are not significantly different. 
 
 
 
 
 
 
 
Table A-79.  Comparison across time of mean media concentrations for 100 µg/ml carprofen (A and B enantiomers) 
with phenobarbital incubation.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time 
points with the same letter are not significantly different. 
 
 
 
 
 
  
 
 
 
Carprofen with phenobarbital supernatant 
     Mean supernatant concentrations for 50 µg/ml were lower at 25 hours than at 28, 32, 36, and 48 hours 
(Table A-80).  At 28 hours, concentrations were lower than at 32, 36 and 48 hours.  Thirty-two hour 
concentrations were lower than those at 36 and 48 hours; thirty-six hour concentrations were less than 48 
hour concentrations.  Mean peak B concentrations (2989.12 ng/ml) were higher than those for peak A 
(2069.56 ng/ml).  Supernatant concentrations for 100 µg/ml media at 25 hours were less than those at 28, 
32, 36 and 48 hours; concentrations at 28 hours were less than at 32, 36 and 48 hours (Table A-81).  For 
100 µg/ml media, mean peak B concentrations (7690.740137 ng/ml) were higher than peak A 
concentrations (6247.13528 ng/ml).  Zero and 24 hour concentrations were below the lower limit of 
quantification for all media concentrations.   
 
Table A-80.  Mean 50 µg/ml carprofen A, B and C hepatic slice supernatant with phenobarbital incubation analysis 
for time.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same 
letter are not significantly different. 
 
 
 
 
 
 
 
Time 
(h) 
Homogeneous  
groups 
Means 
(µg/ml) 
25 a   38.569 
28 a   37.789 
32 a b  36.427 
36 a b  34.618 
48  b  32.451 
Time 
(h) 
Homogeneous  
groups 
Means 
(µg/ml) 
25 a   77.020 
28 a   76.808 
32 a b  71.402 
36  b  66.961 
48  b  68.149 
Time 
(h) 
Homogeneous  
groups 
Means 
(ng/ml) 
25 a     607.412 
28  b    1878.299 
32   c   2733.933 
36    d  3458.640 
48     e 3968.394 
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Table A-81.  Mean 100 µg/ml carprofen A, B and C hepatic slice supernatant with phenobarbital incubation analysis 
for time.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same 
letter are not significantly different. 
 
 
 
 
 
 
 
 
 
 
Carprofen with Cimetidine Media 
     Two-way ANOVA for time and peak revealed significant differences across time for 10 µg/ml (df=4, 
F-ratio=5.581, p-value=0.001), 50 µg/ml (df=4, F-ratio=9.368, p-value=0.000) and 100 µg/ml media 
(df=4, F-ratio=7.121, p-value=0.000).  Ten µg/ml media showed media concentrations at 25 hours were 
higher than those at 36 hours (Table A-82).  Forty-eight hour concentrations were higher than at 28 and 36 
hours.  For 50 µg/ml media, 25 hour concentrations were higher than at 32 and 36 hours (Table A-83).  
Thirty-six hour concentrations were lower than at 28 and 48 hours.  The 25 hour concentrations for 100 
µg/ml media were higher than those at 28, 32 and 36 hours (Table A-84).  The 28 hour concentrations 
were lower than the 48 hour concentrations.   
 
Table A-82.  Comparison of mean carprofen concentrations across time for 10 µg/ml media following cimetidine 
incubation.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same 
letter are not significantly different. 
 
 
 
 
 
 
Table A-83.  Comparison of mean carprofen concentrations across time for 50 µg/ml media following cimetidine 
incubation.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same 
letter are not significantly different. 
 
 
 
 
Time 
(h) 
Homogeneous  
groups 
Means 
(ng/ml) 
25 a    2318.528 
28  b   5812.125 
32   c  8575.214 
36   c  9054.678 
48   c  9084.143 
Time 
(h) 
Homogeneous 
groups 
Means 
(µg/ml) 
25 a b   7.758 
28 a  c  6.709 
32 a b c  7.148 
36   c  6.529 
48  b   8.043 
Time 
(h) 
Homogeneous 
groups 
Means 
(µg/ml) 
25 a    38.172 
28 a b   35.992 
32  b c  33.090 
36   c  32.012 
48 a b   35.413 
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Table A-84.  Comparison of mean carprofen concentrations across time for 100 µg/ml media following cimetidine 
incubation.  Homogeneous groups for two-way ANOVA of time are represented as letters.  Time points with the same 
letter are not significantly different. 
 
 
 
 
 
 
 
 
 
Carprofen with Cimetidine Supernatant 
     For 50 and 100 µg/ml, peak B concentrations were higher than peak A concentrations (50: df=1, F-
ratio=5.630, p-value=0.022; 100: df=1, F-ratio=6.236, p-value=0.016).  Supernatant concentrations across 
time were significantly different for 50 µg/ml media (df=4, F-ratio=13.628, p-value=0.000) and 100 µg/ml 
media (df=4, F-ratio=19.533, p-value=0.000).  For 50 µg/ml media, mean 25 hour supernatant 
concentrations were lower than for 32, 36 and 48 hours (Table A-85).  Forty-eight hour concentrations 
were higher than 28, 32 and 36 hour concentrations.  Mean peak B concentrations were 3848.882 ng/ml 
while for peak A concentrations were 2710.508 ng/ml.  For 100 µg/ml media, mean supernatant 
concentrations at 25 hours were lower than those at all other time points (Table A-86).  Twenty-eight hour 
supernatant concentrations were lower than 32, 36 and 48 hour concentrations.  Mean peak B 
concentrations (7728.308 ng/ml) were higher than peak A concentrations (6380.817 ng/ml).   
 
Table A-85.  Comparison across time of mean carprofen concentrations (A and B enantiomers) in hepatic slice 
supernatant for 50 µg/ml media with cimetidine.  Homogeneous groups for two-way ANOVA of time are represented 
as letters.  Time points with the same letter are not significantly different.   
 
 
 
 
 
 
 
 
Table A-86.  Comparison across time of mean carprofen concentrations (A and B enantiomers) in hepatic slice 
supernatant for 100 µg/ml media with cimetidine incubation.  Homogeneous groups for two-way ANOVA of time are 
represented as letters.  Time points with the same letter are not significantly different. 
 
 
 
 
 
 
 
Time 
(h) 
Homogeneous  
groups 
Means 
(µg/ml) 
25 a    72.260 
28  b   62.988 
32  b c  66.438 
36  b c  64.892 
48 a  c  70.626 
Time 
(h) 
Homogeneous 
groups 
Means 
(ng/ml) 
25 a    1009.333 
28 a b   2056.396 
32  b   3391.628 
36  b   3685.621 
48   c  6255.495 
Time 
(h) 
Homogeneous 
groups 
Means 
(ng/ml) 
25 a    2767.895 
28  b   6102.338 
32   c  8730.452 
36   c  8813.921 
48   c  8858.208 
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APPENDIX VI 
CARPROFEN, CARPROFEN WITH PEHNOBARBITAL AND CARPROFEN WITH 
CIMETIDINE 
 
 
Abbreviation:  Time (h) = Time (hour) 
 
This information was replaced by AUC in Chapter VI. 
 
Single Study Media Charts 
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Fig. A-70.  10 µg/ml carprofen A media concentrations alone and after phenobarbital or cimetidine incubation.  Concentrations of 
carprofen enantiomers in media alone and after incubation for 24 hours with phenobarbital or cimetidine.  Time is the hour incubated 
in carprofen or post incubation with phenobarbital or cimetidine.  The values are a mean of three samples per treatment per time 
point. 
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Fig. A-71.  10 µg/ml carprofen B media concentrations alone and after phenobarbital or cimetidine incubation.  Concentrations of 
carprofen enantiomers in media alone and after incubation for 24 hours with phenobarbital or cimetidine.  Time is the hour incubated 
in carprofen or post incubation with phenobarbital or cimetidine.  The values are a mean of three samples per treatment per time 
point. 
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Fig. A-72.  10 µg/ml carprofen C media concentrations alone and after phenobarbital or cimetidine incubation.  Concentrations of 
carprofen enantiomers in media alone and after incubation for 24 hours with phenobarbital or cimetidine.  Time is the hour incubated 
in carprofen or post incubation with phenobarbital or cimetidine.  The values are a mean of three samples per treatment per time 
point. 
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Fig. A-73.  50 µg/ml carprofen A media concentrations alone and after phenobarbital or cimetidine incubation.  Concentrations of 
carprofen enantiomers in media alone and after incubation for 24 hours with phenobarbital or cimetidine.  Time is the hour incubated 
in carprofen or post incubation with phenobarbital or cimetidine.  The values are a mean of three samples per treatment per time 
point. 
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Fig. A-74.  50 µg/ml carprofen B media concentrations alone and after phenobarbital or cimetidine incubation.  Concentrations of 
carprofen enantiomers in media alone and after incubation for 24 hours with phenobarbital or cimetidine.  Time is the hour incubated 
in carprofen or post incubation with phenobarbital or cimetidine.  The values are a mean of three samples per treatment per time 
point. 
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Fig. A-75.  50 µg/ml carprofen C media concentrations alone and after phenobarbital or cimetidine incubation.  Concentrations of 
carprofen enantiomers in media alone and after incubation for 24 hours with phenobarbital or cimetidine.  Time is the hour incubated 
in carprofen or post incubation with phenobarbital or cimetidine.  The values are a mean of three samples per treatment per time 
point. 
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Fig. A-76.  100 µg/ml carprofen A media concentrations alone and after phenobarbital or cimetidine incubation.  Concentrations of 
carprofen enantiomers in media alone and after incubation for 24 hours with phenobarbital or cimetidine.  Time is the hour incubated 
in carprofen or post incubation with phenobarbital or cimetidine.  The values are a mean of three samples per treatment per time 
point. 
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Fig. A-77.  100 µg/ml carprofen B media concentrations alone and after phenobarbital or cimetidine incubation.  Concentrations of 
carprofen enantiomers in media alone and after incubation for 24 hours with phenobarbital or cimetidine.  Time is the hour incubated 
in carprofen or post incubation with phenobarbital or cimetidine.  The values are a mean of three samples per treatment per time 
point. 
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Fig. A-78.  100 µg/ml carprofen C media concentrations alone and after phenobarbital or cimetidine incubation.  Concentrations of 
carprofen enantiomers in media alone and after incubation for 24 hours with phenobarbital or cimetidine.  Time is the hour incubated 
in carprofen or post incubation with phenobarbital or cimetidine.  The values are a mean of three samples per treatment per time 
point. 
 
 241
Single Study Supernatant Charts 
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Fig. A-79.  50 µg/ml carprofen A hepatic slice supernatant concentrations alone and after phenobarbital or cimetidine incubation.  
Concentrations of carprofen enantiomers in supernatant alone and after incubation for 24 hours with phenobarbital or cimetidine.  
Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The values are an average of two 
samples per treatment per time point. 
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Fig. A-80.  50 µg/ml carprofen B hepatic slice supernatant concentrations alone and after phenobarbital or cimetidine incubation.  
Concentrations of carprofen enantiomers in supernatant alone and after incubation for 24 hours with phenobarbital or cimetidine.  
Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The values are an average of two 
samples per treatment per time point. 
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Fig. A-81.  50 µg/ml carprofen C hepatic slice supernatant concentrations alone and after phenobarbital or cimetidine incubation.  
Concentrations of carprofen enantiomers in supernatant alone and after incubation for 24 hours with phenobarbital or cimetidine.  
Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The values are an average of two 
samples per treatment per time point. 
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Fig. A-82.  100 µg/ml carprofen A hepatic slice supernatant concentrations alone and after phenobarbital or cimetidine incubation.  
Concentrations of carprofen enantiomers in supernatant alone and after incubation for 24 hours with phenobarbital or cimetidine.  
Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The values are an average of two 
samples per treatment per time point. 
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Fig. A-83.  100 µg/ml carprofen B hepatic slice supernatant concentrations alone and after phenobarbital or cimetidine incubation.  
Concentrations of carprofen enantiomers in supernatant alone and after incubation for 24 hours with phenobarbital or cimetidine.  
Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The values are an average of two 
samples per treatment per time point. 
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Fig. A-84.  100 µg/ml carprofen C hepatic slice supernatant concentrations alone and after phenobarbital or cimetidine incubation.  
Concentrations of carprofen enantiomers in supernatant alone and after incubation for 24 hours with phenobarbital or cimetidine.  
Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The values are an average of two 
samples per treatment per time point. 
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Charts and Statistics for Treatment Comparisons (Compiled Data) 
 
Treatment Comparisons for 10 µg/ml Media and Supernatant 
   The mean media concentrations for slices incubated in 10 µg/ml carprofen alone or in conjunction with 
phenobarbital or cimetidine (Figure A-85) were compared using two-way ANOVA.  For peak A, 
differences among treatments were noted (df=2, F-ratio=4.455, p-value=0.014).  Media concentrations for 
slice treatments with carprofen and cimetidine were lower than those for slices treated with carprofen 
alone (Table A-87).  The mean supernatant concentrations for slices incubated in 10 µg/ml carprofen 
media alone associated with phenobarbital or cimetidine were all below the lower limit of quantification. 
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Fig. A-85.  Mean media concentrations of carprofen for 10 µg/ml media alone and with phenobarbital or cimetidine incubation.  
Concentrations (µg/ml) of carprofen enantiomers (A or B) in media alone and after incubation for 24 hours with phenobarbital (75 
µg/ml) or cimetidine (1000 µM).  Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The 
values are a mean of nine samples per treatment per time point. 
 
Table A-87.  Comparison among treatments of mean peak A media concentrations of carprofen in 10 µg/ml media for all times.  
Homogeneous groups for peak A two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not 
significantly different.   
 
 
 
 
 
 
 
Treatment Comparisons for 50 µg/ml Media and Supernatant 
    The mean media concentrations of carprofen following slice incubation in 50 µg/ml carprofen media 
alone or in succession with phenobarbital or cimetidine (Figure A-86) were compared for differences.  
Two-way ANOVA by time and treatment revealed significant differences across time and treatment for 
Treatment Homogeneous groups 
Means 
(µg/ml) 
carprofen alone a    8.06005 
carprofen with phenobarbital a b   7.64913 
carprofen with cimetidine  b   7.07692 
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peak A (time: df=4, F-ratio=10.400, p-value=0.000; treatment: df=2, F-ratio=31.131, p-value=0.000) and 
peak B (time: df=4, F-ratio=8.330, p-value=0.000; treatment: df=2, F-ratio=10.409, p-value=0.000).   
     For peak A, media concentrations were higher one and four hours post-incubation than at 8, 12 and 24 
hours post-incubation (Table A-88).  Media concentrations for slices treated with carprofen alone were 
higher than those treated with phenobarbital and cimetidine (Table A-89).  With peak B, concentrations 
one hour post-incubation were higher than those at 8, 12 and 24 hours, and four hour post-incubation 
concentrations were higher than 12 hours (Table A-90).  Among treatments, carprofen concentrations for 
peak B were higher for carprofen alone than for slices treated with phenobarbital or cimetidine (Table  
A-91).   
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Fig. A-86.  Average media concentrations of carprofen for 50 µg/ml media alone and with phenobarbital or cimetidine incubation.  
Concentrations (µg/ml) of carprofen enantiomers (A or B) in media alone and after incubation for 24 hours with phenobarbital (75 
µg/ml) or cimetidine (1000 µM).  Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The 
values are a mean of nine samples per treatment per time point. 
 
 
Table A-88.  Comparison across time of mean peak A media concentrations of carprofen for 50 µg/ml media for all treatments.  
Homogeneous groups for peak A two-way ANOVA for time are represented as letters.  Times with the same letter are not 
significantly different.   
 
 
 
 
 
 
Time 
(h) 
Homogeneous 
groups 
Means 
(µg/ml) 
1 a    42.506 
4 a    39.980 
8  b   36.658 
12  b   35.551 
24  b   35.744 
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Table A-89.  Comparison among treatments of mean peak A media concentrations of carprofen in 50 µg/ml media for all times.  
Homogeneous groups for peak A two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not 
significantly different.   
 
 
 
 
 
 
 
 
 
Table A-90.  Comparison across time of mean peak B concentrations of carprofen for 50 µg/ml media for all treatments.  
Homogeneous groups for peak B two-way ANOVA for time are represented as letters.  Times with the same letter are not 
significantly different.     
 
 
 
 
 
 
 
 
Table A-91.  Comparison among treatments of mean peak B media concentrations of carprofen in 50 µg/ml media for all times.  
Homogeneous groups for peak B two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not 
significantly different.   
 
 
 
 
 
 
      
 
     The average hepatic slice supernatant concentrations for slices incubated in 50 µg/ml media alone or in 
conjunction with phenobarbital or cimetidine (Figure A-87) were determined and compared for 
differences.  Two-way ANOVA revealed significant differences across time and among treatments for 
peak A (time: df=4, F-ratio=32.189, p-value=0.000; treatment: df=2, F-ratio=3.222, p-value=0.000) and 
peak B (time: df=4, F-ratio=37.509, p-value=0.000; treatment: df=2, F-ratio=3.465, p-value=0.036).  For 
peaks A and B, supernatant concentrations at one hour post-incubation were lower than those at 4, 8, 12 
and 24 hours (Table A-92).  Four hour post-incubation concentrations were lower than 8, 12 and 24 hour 
concentrations.  Twenty-four hour concentrations were higher than 8 and 12 hour concentrations.  Among 
treatments, average supernatant concentrations for peak A and peak B were higher in slices incubated in 
carprofen with cimetidine than those incubated in carprofen with phenobarbital (Table A-93).   
 
 
 
 
 
Treatment Homogeneous groups 
Means 
(µg/ml) 
carprofen alone a    43.270 
carprofen with phenobarbital  b   36.599 
carprofen with cimetidine  b   35.118 
Time 
(h) 
Homogeneous 
groups 
Means 
(µg/ml) 
1 a    40.187 
4 a b   37.977 
8  b c  35.554 
12   c  33.089 
24  b c  34.932 
Treatment Homogeneous groups 
Means 
(µg/ml) 
carprofen alone a    39.340 
carprofen with phenobarbital  b   35.343 
carprofen with cimetidine  b   34.754 
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Fig. A-87.  Average hepatic slice supernatant concentrations of carprofen for 50 µg/ml media alone and after phenobarbital or 
cimetidine incubation.  Concentrations (µg/ml) of carprofen enantiomers (A or B) in supernatant alone and after incubation for 24 
hours with phenobarbital (75 µg/ml) or cimetidine (µM).  Time is the hour incubated in carprofen or post incubation with 
phenobarbital or cimetidine.  The values are a mean of six samples per treatment per time point. 
 
 
Table A-92.  Comparison across time of mean peak A and B supernatant concentrations of carprofen for slices incubated in 50 µg/ml 
media for all treatments.  Homogeneous groups for peaks A and B two-way ANOVA for time are represented as letters.  Times with 
the same letter are not significantly different. 
 
 
 
 
 
 
 
 
Table A-93.  Comparison among treatments of mean peak A and B supernatant concentrations of carprofen for slices incubated in 50 
µg/ml media for all times.  Homogeneous groups for peaks A and B two-way ANOVA for treatment are represented as letters.  
Treatments with the same letter are not significantly different.   
 
 
 
 
 
 
 
      
 
Treatment Comparisons for 100 µg/ml Media and Supernatant 
     The average carprofen media concentrations for slices incubated in 100 µg/ml carprofen media alone or 
in combination with phenobarbital or cimetidine (Figure A-88) were compared using two-way ANOVA.  
For peak A, two-way ANOVA indicated significant differences for time (df=4, F-ratio=4.248, p-
value=0.003) and treatment (df=2, F-ratio=22.240, p-value=0.000).  Media concentrations one hour post-
incubation were higher than 12 and 24 hour concentrations (Table A-94).  Among treatments, media 
concentrations for carprofen alone were higher than those treated with phenobarbital or cimetidine (Table 
Time 
(h) 
Homogeneous 
groups 
Peak A Means 
(ng/ml) 
Peak B Means 
(ng/ml) 
1 a    535.999 881.883 
4  b   1732.818 2475.503 
8   c  2647.300 3835.209 
12   c  3037.234 4358.535 
24    d 3968.487 5682.051 
Treatment Homogeneous groups 
Peak A Means 
(ng/ml) 
Peak B Means 
(ng/ml) 
carprofen alone a b  2373.041 3501.911 
carprofen with phenobarbital a   2069.555 2989.116 
carprofen with cimetidine  b  2710.508 3848.882 
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A-95).  Additionally, average media concentrations for slices treated with cimetidine were lower than 
those treated with phenobarbital.  Peak B two-way ANOVA revealed a time-treatment interaction (df=8, 
F-ratio=3.710, p-value=0.001).  There were significant main effects, and the interaction appeared to be 
orderly.  Peak B media concentrations were higher at one hour than at 8, 12 and 24 hours, and four hour 
media concentrations were higher than 12 hour concentrations (Table A-96).  For treatments, peak B 
concentrations for carprofen alone were higher than those for carprofen with phenobarbital or with 
cimetidine (Table A-97).   
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Fig. A-88.  Average media concentrations of carprofen for100 µg/ml media alone and after phenobarbital or cimetidine incubation.  
Concentrations (µg/ml) of carprofen enantiomers (A or B) in media alone and after incubation for 24 hours with phenobarbital (75 
µg/ml) or cimetidine (1000 µM).  Time is the hour incubated in carprofen or post incubation with phenobarbital or cimetidine.  The 
values are a mean of nine samples per treatment per time point. 
 
Table A-94.  Comparison across time of mean peak A media concentrations of carprofen in 100 µg/ml media for all treatments.  
Homogeneous groups for peak A two-way ANOVA for time are represented as letters.  Times with the same letter are not 
significantly different.   
 
 
 
 
 
 
Time 
(h) 
Homogeneous 
groups 
Means 
(ug/ml) 
1 a    80.384 
4 a b   76.802 
8 a b   74.225 
12  b   70.906 
24  b   69.620 
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Table A-95.  Comparison among treatments of mean peak A media concentrations of carprofen in 100 µg/ml media for all times.  
Homogeneous groups for peak A two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not 
significantly different.   
 
 
 
 
 
 
 
 
Table A-96.  Comparison across time of mean peak B media concentrations of carprofen in 100 µg/ml media for all treatments.  
Homogeneous groups for peak B two-way ANOVA for time are represented as letters.  Times with the same letter are not 
significantly different.     
 
 
 
 
 
 
 
 
Table A-97.  Comparison among treatments of mean peak B media concentrations of carprofen in 100 µg/ml media for all times.  
Homogeneous groups for peak B two-way ANOVA for treatment are represented as letters.  Treatments with the same letter are not 
significantly different.   
 
 
 
 
 
 
      
 
     The mean supernatant concentrations for slices incubated in carprofen 100 µg/ml media alone or in 
conjunction with phenobarbital or cimetidine (Figure A-89) were examined for differences.  Two-way 
ANOVA revealed significant differences for peak A and peak B across time (peak A: df=4, F-
ratio=73.088, p-value=0.000; peak B: df=4, F-ratio=49.960, p-value=0.000) and among treatments (peak 
A: df=2, F-ratio=11.504, p-value=0.000; peak B: df=2, F-ratio=7.441, p-value=0.001).  For peaks A and 
B, supernatant concentrations at one hour post-incubation were lower than those at 4, 8, 12 and 24 hours 
(Table A-98).  At 4 hours, peak A and B supernatant concentrations were lower than at 8, 12 and 24 hours.  
Among treatments, peak A and B supernatant concentrations for slices incubated in carprofen alone were 
higher than those for slices incubated with phenobarbital and cimetidine (Table A-99).   
 
 
 
 
 
Treatment Homogeneous groups 
Means 
(µg/ml) 
carprofen alone a    83.363 
carprofen with phenobarbital  b   73.454 
carprofen with cimetidine   c  67.342 
Time 
(h) 
Homogeneous 
groups 
Means 
(µg/ml) 
1 a    77.299 
4 a b   75.080 
8  b c  69.795 
12   c  65.329 
24  b c  69.872 
Treatment Homogeneous groups 
Means 
(µg/ml) 
carprofen alone a    76.795 
carprofen with phenobarbital  b   70.682 
carprofen with cimetidine  b   67.539 
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Fig. A-89.  Average supernatant concentrations of carprofen for slices incubated in 100 µg/ml media alone and after phenobarbital or 
cimetidine incubation.  Concentrations (ng/ml) of carprofen enantiomers in supernatant alone and after incubation for 24 hours with 
phenobarbital (75 µg/ml) or cimetidine (1000 µM).  Time is the hour incubated in carprofen or post incubation with phenobarbital or 
cimetidine.  The values are a mean of six samples per treatment per time point. 
 
 
Table A-98.  Comparison across time of mean peak A and B supernatant concentrations of carprofen in 100 µg/ml media for all 
treatments.  Homogeneous groups for peaks A and B two-way ANOVA for time are represented as letters.  Times with the same 
letter are not significantly different.     
 
 
 
 
 
 
 
 
 
Table A-99.  Comparison among treatments of mean peak A and B supernatant concentrations of carprofen in 100 µg/ml media for 
all times.  Homogeneous groups for peaks A and B two-way ANOVA for treatment are represented as letters.  Treatments with the 
same letter are not significantly different.   
 
 
 
 
 
 
Time 
(h) 
Homogeneous 
groups 
Peak A Means 
(ng/ml) 
Peak B Means 
(ng/ml) 
1 a    2428.702 2936.805 
4  b   5916.870 7223.059 
8   c  7979.768 9763.095 
12   c  8564.749 10550.262 
24   c  9086.225 10938.934 
Treatment Homogeneous groups 
Peak A 
Means 
(ng/ml) 
Peak B 
Means 
(ng/ml) 
carprofen alone a   7757.836 9428.244 
carprofen with phenobarbital  b  6247.135 7690.740 
carprofen with cimetidine  b  6380.817 7728.308 
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APPENDIX VII 
ADDITIONAL CARPROFEN WITH PHENOBARBITAL INCUBATIONS  
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Fig. A-100.  Carprofen A, B and C media concentrations following 48 hour phenobarbital (75 µg/ml) incubation.  Concentrations of 
carprofen enantiomers in media after incubation for 48 hours with 75 µg/ml phenobarbital and incubated for an additional 4, 12 and 
24 hours with carprofen A, B and C.   The values are an average of three samples per carprofen type per time point. 
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Fig. A-101.  Carprofen A, B and C hepatic slice supernatant concentrations following 48 hour phenobarbital (75 µg/ml) incubation.  
Concentrations of carprofen enantiomers in hepatic slice supernatant after incubation for 48 hours with 75 µg/ml phenobarbital and 
incubated for an additional 4, 12 and 24 hours with carprofen A, B and C.   The values are an average of two samples per carprofen 
type per time point. 
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Fig. A-102.  Carprofen A, B and C media concentrations following 24 hour phenobarbital (150 µg/ml) incubation.  Concentrations of 
carprofen enantiomers in media after incubation for 24 hours with 150 µg/ml phenobarbital and incubated for an additional 4, 12 and 
24 hours with carprofen A, B and C.   The values are an average of three samples per carprofen type per time point. 
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Fig. A-103.  Carprofen A, B and C hepatic slice supernatant concentrations following 24 hour phenobarbital (150 µg/ml) incubation.  
Concentrations of carprofen enantiomers in hepatic slice supernatant after incubation for 24 hours with 150 µg/ml phenobarbital and 
incubated for an additional 4, 12 and 24 hours with carprofen A, B and C.   The values are an average of two samples per carprofen 
type per time point. 
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Fig. A-104.  Carprofen A, B and C media concentrations following 48 hour phenobarbital (150 µg/ml) incubation.  Concentrations of 
carprofen enantiomers in media after incubation for 48 hours with 150 µg/ml phenobarbital and incubated for an additional 4, 12 and 
24 hours with carprofen A, B and C.   The values are an average of three samples per carprofen type per time point. 
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Fig. A-105.  Carprofen A, B and C hepatic slice supernatant concentrations following 48 hour phenobarbital (150 µg/ml) incubation.  
Concentrations of carprofen enantiomers in hepatic slice supernatant after incubation for 48 hours with 150 µg/ml phenobarbital and 
incubated for an additional 4, 12 and 24 hours with carprofen A, B and C.   The values are an average of two samples per carprofen 
type per time point. 
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Charts and Statistics for Mean Data 
     The following charts and tables describe the media and supernatant concentrations for slices incubated 
in 75 or 150 µg/ml phenobarbital for 24 or 48 hours and followed by an additional 24 hour incubation in 
media containing 0 or 100 µg/ml carprofen.  Concentrations for media containing 0 µg/ml carprofen and 
associated supernatant samples were all below the lower limit of quantification. 
 
Carprofen and Carprofen with 75 µg/ml Phenobarbital Media 
     The mean media concentrations of carprofen after slice incubation in carprofen for 4, 12 and 24 hours 
or in 75 µg/ml phenobarbital for 24 or 48 hours followed by incubation in 100 µg/ml carprofen media for 
an additional 4, 12 and 24 hours (Figure A-106) were analyzed for time and treatment differences.        
     Two-way ANOVA for peak A revealed a significant factor interaction (df=4, F-ratio=2.822, p-
value=0.032) for time and treatment.  Significant time (df=2, F-ratio=8.483, p-value=0.001) and treatment 
(df=2, F-ratio=5.618, p-value=0.005) effects were noted for mean peak A concentrations.  Mean media 
concentrations at 4 and 12 hours were higher than those at 24 hours (Table A-100).  For treatment, media 
concentrations of carprofen alone were higher than those of media following 24 hour incubation in 
phenobarbital (Table A-101).     
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Fig. A-106.  Mean media concentrations of carprofen alone and following 24 and 48 hour phenobarbital (75 µg/ml) incubation.  
Mean concentrations (µg/ml) of carprofen enantiomers (A or B) in media after incubation in only carprofen or incubated for 24 or 48 
hours with 75 µg/ml phenobarbital and incubated for an additional 4, 12 and 24 hours with carprofen (100 µg/ml).   The values are a 
mean of nine samples per treatment per time point. 
 
 
Table A-100.  Comparison across time of mean peak A media concentrations of carprofen in 100 µg/ml media for all treatments.  
Homogeneous groups for peak A two-way ANOVA for time are represented as letters.  Times with the same letter are not 
significantly different.     
 
 
 
 
 
Time  
post-phenobarbital 
  (h) 
Homogeneous groups Peak A Means (µg/ml) 
4 a    79.332 
12 a    75.861 
24  b   70.712 
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Table A-101.  Comparison among treatments of mean peak A media concentrations of carprofen in 100 µg/ml media incubated for 0, 
24 or 48 hours with 75 µg/ml phenobarbital for all times.  Homogeneous groups for peak A two-way ANOVA for treatment are 
represented as letters.  Treatments with the same letter are not significantly different.   
 
 
 
 
 
 
     A significant factor interaction (df=4, F-ratio=3.083, p-value=0.022) was found for mean peak B 
carprofen media concentrations.  Significant differences were noted for time (df=2, F-ratio=6.286, p-
value=0.003) and for treatment (df=2, F-ratio=5.483, p-value=0.006) for peak B.  Across time, mean 
carprofen concentrations at 4 hours were higher than those at 12 and 24 hours (Table A-102).  Comparison 
of length of phenobarbital incubation revealed that mean carprofen media concentrations following 48 
hour incubation were higher than those after 24 hour incubation (Table A-103).   
 
Table A-102.  Comparison across time of mean peak B media concentrations of carprofen in 100 µg/ml media for all treatments.  
Homogeneous groups for peak B two-way ANOVA for time are represented as letters.  Times with the same letter are not 
significantly different.     
 
 
 
 
 
 
 
Table A-103.  Comparison among treatments of mean peak B media concentrations of carprofen in 100 µg/ml media incubated for 0, 
24 or 48 hours with 75 µg/ml phenobarbital for all times.  Homogeneous groups for peak B two-way ANOVA for treatment are 
represented as letters.  Treatments with the same letter are not significantly different.   
 
 
 
 
 
 
      
 
Carprofen and Carprofen with 75 µg/ml Phenobarbital Supernatant 
     The mean supernatant concentrations for slices incubated in 100 µg/ml carprofen alone or in 75 µg/ml 
phenobarbital for 24 and 48 hours followed by incubation in 100 µg/ml carprofen media for an additional 
4, 12 and 24 hours (Figure A-107) were analyzed for time and treatment differences.  Two-way ANOVA 
for peak A revealed a significant factor interaction (df=4, F-ratio=10.319, p-value=0.000) for time and 
treatment.  Significant time (df=2, F-ratio=18.679, p-value=0.000) and treatment (df=2, F-ratio=6.052, p-
value=0.005) effects were noted for mean peak A concentrations.  Across time, mean concentrations at 4 
hours were lower than those at 12 and 24 hours; 12 hour concentrations were higher than 24 hour 
concentrations (Table A-104).  Among treatments, mean supernatant concentrations for both carprofen 
alone and 48 hour phenobarbital incubation were higher than those for the 24 phenobarbital incubation 
(Table A-105). 
 
 
Length of incubation in 
phenobarbital 
Homogeneous 
groups 
Peak A Means 
(µg/ml) 
0 hours a    78.222 
24 hours  b   71.436 
48 hours a b   76.490 
Time  
post-phenobarbital 
  (h) 
Homogeneous 
groups 
Peak B Means 
(µg/ml) 
4 a    77.686 
12  b   70.431 
24  b   71.529 
Length of incubation in 
phenobarbital 
Homogeneous 
groups 
Peak B 
Means 
(µg/ml) 
0 hours a b   71.787 
24 hours a    69.843 
48 hours  b   77.420 
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Fig. A-107.  Mean hepatic slice supernatant concentrations of carprofen alone and following 24 and 48 hour phenobarbital (75 
µg/ml) incubation.  Mean concentrations (ng/ml) of carprofen enantiomers (A or B) in hepatic slice supernatant after incubation in 
only carprofen or incubated for 24 or 48 hours with 75 µg/ml phenobarbital and incubated for an additional 4, 12 and 24 hours with 
carprofen (100 µg/ml).  The values are a mean of six samples per treatment per time point. 
 
 
Table A-104.  Comparison across time of mean peak A supernatant concentrations of carprofen in 100 µg/ml media for all 
treatments.  Homogeneous groups for peak A two-way ANOVA for time are represented as letters.  Times with the same letter are 
not significantly different.     
 
 
 
 
 
 
 
Table A-105.  Comparison among treatments of mean peak A supernatant concentrations of carprofen in 100 µg/ml media incubated 
for 0, 24 or 48 hours with 75 µg/ml phenobarbital for all times.  Homogeneous groups for peak A two-way ANOVA for treatment are 
represented as letters.  Treatments with the same letter are not significantly different.   
 
 
 
 
 
 
      
     Similar to peak A average supernatant concentrations, a significant factor interaction (df=4, F-
ratio=10.914, p-value=0.000) for time and treatment was found for peak B mean concentrations.  
Additionally, significant time (df=2, F-ratio=18.264, p-value=0.000) and treatment (df=2, F-ratio=6.897, 
p-value=0.003) effects were noted for mean peak B concentrations.   Twelve hour mean supernatant 
concentrations were higher than those at 4 and 24 hours (Table A-106).  Among treatments, mean 
supernatant concentrations for the 24 hour phenobarbital incubation were lower than those for carprofen 
Time  
post-phenobarbital 
  (h) 
Homogeneous 
groups 
Peak A Means 
(ng/ml) 
4 a    6296.522 
12  b   11354.041 
24   c  8344.426 
Length of incubation in 
phenobarbital 
Homogeneous 
groups 
Peak A Means 
(ng/ml) 
0 hours a    9635.661 
24 hours  b   7123.391 
48 hours a    9606.952 
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alone or the 48 hour phenobarbital incubation (Table A-107).  For both peak A and peak B, mean 
supernatant concentrations at 12 hours were higher than those at 4 and 24 hours.  Mean supernatant 
concentrations for carprofen alone and following 48 hour phenobarbital incubation were higher than those 
for the 24 hour incubation.   
 
Table A-106.  Comparison across time of mean peak B supernatant concentrations of carprofen in 100 µg/ml media for all 
treatments.  Homogeneous groups for peak B two-way ANOVA for time are represented as letters.  Times with the same letter are 
not significantly different.     
 
 
 
 
 
 
 
Table A-107.  Comparison among treatments of mean peak B supernatant concentrations of carprofen in 100 µg/ml media incubated 
for 0, 24 or 48 hours with 75 µg/ml phenobarbital for all times.  Homogeneous groups for peak B two-way ANOVA for treatment are 
represented as letters.  Treatments with the same letter are not significantly different.   
 
 
 
 
 
 
 
Carprofen and Carprofen with 150 µg/ml Phenobarbital Media 
     The mean media concentrations of carprofen alone or following incubation for 24 or 48 hours in 150 
µg/ml phenobarbital (Figure A-108) were analyzed for time and treatment differences.  When analyzed by 
two-way ANOVA significant differences were noted for time (df=2, F-ratio=4.647, p-value=0.013) and  
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Fig. A-108.  Mean media concentrations of carprofen alone and following 24 and 48 hour phenobarbital (150 µg/ml) incubation.  
Mean concentrations (µg/ml) of carprofen enantiomers (A or B) in media after incubation in only carprofen or incubated for 24 or 48 
hours with 150 µg/ml phenobarbital and incubated for an additional 4, 12 and 24 hours with carprofen (100 µg/ml).  The values are a 
mean of nine samples per treatment per time point. 
Time  
post-phenobarbital 
  (h) 
Homogeneous groups Peak B Means (ng/ml) 
4 a    7856.020 
12  b   14185.801 
24 a    10534.050 
Length of incubation in 
phenobarbital 
Homogeneous 
groups 
Peak B Means 
(ng/ml) 
0 hours a    11777.784 
24 hours  b   8843.906 
48 hours a    12389.932 
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treatment (df=2, F-ratio=3.964, p-value=0.024) for peak A.  Across time, mean concentrations at 4 hours 
were higher than those at 24 hours (Table A-108).  Among treatments, mean concentrations for the 48 
hour phenobarbital incubation were higher than those for the carprofen only incubation (Table A-109). 
 
Table A-108.  Comparison across time of mean peak A media concentrations of carprofen in 100 µg/ml media for all treatments.  
Homogeneous groups for peak A two-way ANOVA for time are represented as letters.  Times with the same letter are not 
significantly different.     
 
 
 
 
 
 
 
 
Table A-109.  Comparison among treatments of mean peak A media concentrations of carprofen in 100 µg/ml media incubated for 0, 
24 or 48 hours with 150 µg/ml phenobarbital for all times.  Homogeneous groups for peak A two-way ANOVA for treatment are 
represented as letters.  Treatments with the same letter are not significantly different.   
 
 
 
 
 
 
 
     For peak B, a significant factor interaction was noted (df=4, F-ratio=3.145, p-value=0.020).  In 
addition, a significant treatment (df=2, F-ratio=7.622. p-value=0.001) effect was found for mean peak B 
media concentrations of carprofen.  The mean carprofen media concentrations were higher for the 24 hour 
and 48 hour phenobarbital incubations than for the carprofen only incubation (Table A-110). 
 
Table A-110.  Comparison among treatments of mean peak B media concentrations of carprofen in 100 µg/ml media incubated for 0, 
24 or 48 hours with 150 µg/ml phenobarbital for all times.  Homogeneous groups for peak B two-way ANOVA for treatment are 
represented as letters.  Treatments with the same letter are not significantly different.   
 
 
 
 
 
 
      
 
Carprofen and Carprofen with 150 µg/ml Phenobarbital Supernatant 
     The mean supernatant concentrations of carprofen following incubation of slices in carprofen alone or 
following incubation for 24 or 48 hours in 150 µg/ml phenobarbital (Figure A-109) were analyzed for time 
and treatment differences.  For both peak A and peak B, a significant time effect was noted (A: df=2, F-
ratio=58.075, p-value=0.000; B: df=2, F-ratio=62.938, p-value=0.000).  For both peaks, mean supernatant 
concentrations of carprofen at 4 hours were lower than at 12 and 24 hours, and 24 hour concentrations 
were higher than 12 hour concentrations (Table A-111). 
 
Time  
post-phenobarbital 
  (h) 
Homogeneous 
groups 
Peak A Means 
(µg/ml) 
4 a    87.672 
12 a b   83.458 
24  b   78.103 
Length of incubation in 
phenobarbital 
Homogeneous 
groups 
Peak A Means 
(µg/ml) 
0 hours a    78.222 
24 hours a b   82.290 
48 hours  b   87.481 
Length of incubation in 
phenobarbital 
Homogeneous 
groups 
Peak B Means 
(µg/ml) 
0 hours a    71.787 
24 hours  b   84.558 
48 hours  b   84.006 
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Fig. A-109.  Mean hepatic slice supernatant concentrations of carprofen alone and following 24 and 48 hour phenobarbital (150 
µg/ml) incubation.  Mean concentrations (ng/ml) of carprofen enantiomers (A or B) in hepatic slice supernatant after incubation in 
only carprofen or incubated for 24 or 48 hours with 150 µg/ml phenobarbital and incubated for an additional 4, 12 and 24 hours with 
carprofen (100 µg/ml).  The values are a mean of six samples per treatment per time point. 
 
 
Table A-111.  Comparison across time of mean peak A or B supernatant concentrations of carprofen in 100 µg/ml media for all 
treatments.  Homogeneous groups for peaks A and B two-way ANOVA for time are represented as letters.  Times with the same 
letter are not significantly different.     
 
 
 
 
 
 
 
 
   
Time  
post-phenobarbital 
  (h) 
Homogeneous 
groups 
Peak A 
Means 
(ng/ml) 
Peak B 
Means 
(ng/ml) 
4 a    7399.905 9081.241 
12  b   9841.040 12273.708 
24   c  11527.217 14354.917 
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